Message

From: [redacted]

Sent: 8/15/2013 3:21:00 PM

To: Sackler, Mortimer D.A. [redacted] Sackler, Dr Richard [redacted] Sackler, Dame Theresa [redacted] Sackler, David [redacted] Sackler Lefcourt, Ilene [redacted]

CC: Stewart, John H. (US) [redacted] Gasdia, Russell [redacted] Mahony, Edward [redacted] Roncalli, Anthony [redacted]

BCC: Stewart, John H. (US) [redacted]

Subject: Handout Material for US Agenda

Attachments: Identifying OxyContin Growth Opportunities.pptx; AG Brief summary of Purdue-sponsored research v1 - DRAFT 08 08 13.pptx

On behalf of John Stewart, attached please find the following materials related to the US agenda which are being provided as hand-outs at the meeting.

1. AG Brief Summary of Purdue Sponsored Research – [redacted] (for the abuse deterrent agenda item)

2. Identifying OxyContin Growth Opportunities – John Stewart/Russ Gasdia (for the McKinsey agenda item)

Following the meeting [redacted] may provide additional materials as background.

[redacted]

Identifying OxyContin Growth Opportunities

John Stewart & Russ Gasdia

August 15th, 2013

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Context/Objectives

- Understand the underlying factors influencing the OxyContin/opioid business, including:
  - Slowing growth in the LAO market
  - Declining prescriptions for OxyContin
  - Relatively more sudden declines in:
    - ✓Tablets per prescription
    - ✓Prescriptions for 40mg & 80mg strengths
  - Wholesaler/pharmacy opioid policies

Objectives

- Identify actionable items to positively impact sales - both in the short and longer term, specifically in the areas of:
  - Market landscape
  - Access and availability of opioid medications
  - OxyContin messaging and positioning
  - Scientific/medical support of HCPs/salesforce
  - Prescriber segmentation and targeting
  - Salesforce execution of call plans
  - S&P spend levels and allocation between brands

Findings/Observations To-Date

- 40% of zip codes show OxyContin growth
- 47% of OxyContin prescribers increased their prescribing levels
- In Q1 2013, the salesforce reached 21% of OxyContin prescribers, accounting for 54% of OxyContin prescriptions
- OxyContin responds to changes in sales call activity
  - The salesforce made a substantial number of calls on low value prescribers
  - Given relative sales levels, Butrans is receiving a disproportionate share of salesforce effort

Findings/Observations to Date

- Wholesaler and pharmacy chain policies are impacting opioid utilization/prescribing
- Physician awareness and understanding of the new OxyContin formulation and recent label change is inconsistent between specialists and PCPs
- McKinsey's knowledge of the ways other pharma companies operate suggests Purdue should reassess the roles of MSL and HECON Groups - and further drive the salesforce to be more responsive to formulary coverage changes

Actions Underway

- Increase salesforce effort in support of OxyContin
- Revise approach to generation of prescriber target lists
  - Include additional factors
  - Identify specific opportunities
- Increase salesforce adherence to target lists
  - Demonstrate value of this approach to all levels of the salesforce
  - Establish adherence support mechanisms - including compensation
- Modernize/Turbocharge Purdue's overall approach to Salesforce activities

Actions Underway

- Address pharmacy and wholesaler access issues
  - ➢ Task force established within CEAC – Alan Must
    - ✓ Walgreens-specific activities
    - ✓ Consideration of alternative supply mechanisms/routes
    - ✓ Participation in multidisciplinary meetings/solutions

Actions Pending Additional Analyses/Information

- Establish specific sales increase goals from revised prescriber targeting
- Refine reach vs. frequency understanding from analyses of natural pilots and/or proactive testing – reassess optimal salesforce sizing
- Benchmark OxyContin's S&P levels to appropriate reference brands – across several components of the marketing mix.
- Revise communications pertaining to abuse deterrent opioid formulations.

Multiple research projects assessed the burden of opioid abuse and the economic benefits of ADFs*

Project	Topics	Data
The hidden cost to employers of opioid abuse	• Prevalence of diagnosed and undiagnosed abuse • Diversion of prescription opioids (RxOs) • Excess healthcare and indirect costs of abuse to employers	• OptumHealth claims data for commercially-insured diagnosed abusers and matched non-abusers, 1999-2012 • Publicly-available government data (e.g., NSDUH)
The impact of extended-release opioid (ERO) ADFs: a societal perspective	• Changes in ERO utilization following the introduction of the ADF of OxyContin • Changes in rates of abuse and medical costs associated with the introduction of the ADF of OxyContin • Annual medical and indirect cost savings of ADFs in the U.S. • Including analyses of the impact of ERO ADFs in Massachusetts, Ohio, and Oregon	• Truven claims data for commercially-insured, Medicaid, and Medicare-eligible patients with ≥1 RxO claim, 2009-2011 • IMS National Prescription Audit prescription volume data for EROs, 2010-2012 • Publicly-available government data (e.g., NSDUH) • IMS Xponent state-specific prescription volume data for EROs • State-specific government reports, presentations, news articles
Changes in ERO utilization following the introduction of ADFs in the U.S	• Changes in ERO utilization following the introduction of the ADFs of OxyContin and Opana • Including a comparison of rates of abuse between patients switching to an ADF, patients switching to non-ADF EROs, and patients discontinuing EROs	• Truven claims data for commercially-insured patients with ≥1 RxO claim, 2010-2012

*Abuse-deterrent formulations (ADFs) refer to formulations with abuse-deterrent characteristics.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Key messages from Purdue-sponsored research projects

Opioid abuse* imposes substantial costs to society

- The prevalence of diagnosed opioid abuse was 18.6 per 10,000 in 2011 (~3:1 ratio of undiagnosed to diagnosed abuse)
- The annual healthcare costs for patients with diagnosed opioid abuse ($20,343) were more than twice as much compared to similar patients without diagnosed opioid abuse ($9,716)
- For employers in the United States, the cost of opioid abuse is ~$6 per member per month
  - Cost of COPD is ~$3; cost of obesity is ~$4 (male) and ~$6 (female)
- Source of opioids: ~20% of abusers did not have opioid prescription prior to their first diagnosis of abuse
  - Approximately half of these had a family member who had filled an opioid prescription

ADFs of EROs are associated with substantial economic benefits

- ADFs are associated with a ~16% reduction in rates of diagnosed abuse
  - The reduction in abuse after introduction of ADF differed by payer
- In the United States, ADFs yield annual cost savings of ~$1.0 B
- State-level analyses estimated that ADFs yield annual cost savings in Massachusetts (~$26 M), Ohio (~$63 M), and Oregon (~$22 M)

Presence of RxO alternatives that lack abuse-deterrent characteristics undermine the benefits of ADFs

- Compared to chronic users of extended-release oxycodone who switched to the ADF of OxyContin:
  - Those who switched to non-ADF EROs were ~1.9 times more likely to be diagnosed opioid abusers (3.5% vs. 6.7%)
  - Those who discontinued use of EROs but used immediate-release opioids were ~3.2 times more likely to be diagnosed opioid abusers (3.5% vs. 11.3%)
- A similar pattern was observed for the ADF of Opana

*To assure consistency with national statistics, the term "abuse" encompasses opioid abuse and dependence.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Message

From: Roncalli, Anthony [redacted]
Sent: 8/15/2013 5:44:35 PM
To: Sackler, Dr Richard [redacted]
Subject: Fw: Handout Material for US Agenda
Attachments: Identifying OxyContin Growth Opportunities.pptx; AG Brief summary of Purdue-sponsored research v1 - DRAFT 08 08 13.pptx

Redacted

****

Please consider the environment before printing this email. [redacted]

From: [redacted] [mailto: [redacted] @pharma.com]
Sent: Thursday, August 15, 2013 03:21 PM Eastern Standard Time
To: Sackler, Mortimer D.A. < [redacted] @pharma.com>; Sackler, Dr Richard < [redacted] @pharma.com>; Sackler, Dame Theresa < [redacted] @mdsackler.co.uk>; Sackler, David < [redacted] @pharma.com>; Sackler Lefcourt, Ilene < [redacted] @pharma.com>
Cc: Stewart, John H. (US) < [redacted] @pharma.com>; [redacted] < [redacted] @pharma.com> [redacted] < [redacted] @pharma.com>; Gasdia, Russell < [redacted] @pharma.com>; Mahony, Edward < [redacted] @pharma.com>; [redacted]
Subject: Handout Material for US Agenda

On behalf of John Stewart, attached please find the following materials related to the US agenda which are being provided as hand-outs at the meeting.

1. AG Brief Summary of Purdue Sponsored Research – [redacted] (for the abuse deterrent agenda item)

2. Identifying OxyContin Growth Opportunities – John Stewart/Russ Gasdia (for the McKinsey agenda item)

Following the meeting [redacted] may provide additional materials as background.

[redacted]

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please notify me by replying to this message and permanently delete the original and any copy of this e-mail and any printout thereof.

For additional information about Chadbourne & Parke LLP and Chadbourne & Parke (London) LLP, including a list of attorneys, please see our website at http://www.chadbourne.com

Identifying OxyContin Growth Opportunities

John Stewart & Russ Gasdia

August 15th, 2013

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Context/Objectives

- Understand the underlying factors influencing the OxyContin/opioid business, including:
  - ➢ Slowing growth in the LAO market
  - ➢ Declining prescriptions for OxyContin
  - ➢ Relatively more sudden declines in:
    - ✓ Tablets per prescription
    - ✓ Prescriptions for 40mg & 80mg strengths
  - ➢ Wholesaler/pharmacy opioid policies

Objectives

- Identify actionable items to positively impact sales - both in the short and longer term, specifically in the areas of:
  - Market landscape
  - Access and availability of opioid medications
  - OxyContin messaging and positioning
  - Scientific/medical support of HCPs/salesforce
  - Prescriber segmentation and targeting
  - Salesforce execution of call plans
  - S&P spend levels and allocation between brands

Findings/Observations To-Date

- 40% of zip codes show OxyContin growth
- 47% of OxyContin prescribers increased their prescribing levels
- In Q1 2013, the salesforce reached 21% of OxyContin prescribers, accounting for 54% of OxyContin prescriptions
- OxyContin responds to changes in sales call activity
  - The salesforce made a substantial number of calls on low value prescribers
  - Given relative sales levels, Butrans is receiving a disproportionate share of salesforce effort

Findings/Observations to Date

- Wholesaler and pharmacy chain policies are impacting opioid utilization/prescribing
- Physician awareness and understanding of the new OxyContin formulation and recent label change is inconsistent between specialists and PCPs
- McKinsey's knowledge of the ways other pharma companies operate suggests Purdue should reassess the roles of MSL and HECON Groups - and further drive the salesforce to be more responsive to formulary coverage changes

Actions Underway

- Increase salesforce effort in support of OxyContin
- Revise approach to generation of prescriber target lists
  - Include additional factors
  - Identify specific opportunities
- Increase salesforce adherence to target lists
  - Demonstrate value of this approach to all levels of the salesforce
  - Establish adherence support mechanisms - including compensation
- Modernize/Turbocharge Purdue's overall approach to Salesforce activities

Actions Underway

- Address pharmacy and wholesaler access issues
  - ➢Task force established within CEAC – Alan Must
    - ✓Walgreens-specific activities
    - ✓Consideration of alternative supply mechanisms/routes
    - ✓Participation in multidisciplinary meetings/solutions

Actions Pending Additional Analyses/Information

- Establish specific sales increase goals from revised prescriber targeting
- Refine reach vs. frequency understanding from analyses of natural pilots and/or proactive testing – reassess optimal salesforce sizing
- Benchmark OxyContin's S&P levels to appropriate reference brands – across several components of the marketing mix.
- Revise communications pertaining to abuse deterrent opioid formulations.

Multiple research projects assessed the burden of opioid abuse and the economic benefits of ADFs*

Project	Topics	Data
The hidden cost to employers of opioid abuse	• Prevalence of diagnosed and undiagnosed abuse • Diversion of prescription opioids (RxOs) • Excess healthcare and indirect costs of abuse to employers	• OptumHealth claims data for commercially-insured diagnosed abusers and matched non-abusers, 1999-2012 • Publicly-available government data (e.g., NSDUH)
The impact of extended-release opioid (ERO) ADFs: a societal perspective	• Changes in ERO utilization following the introduction of the ADF of OxyContin • Changes in rates of abuse and medical costs associated with the introduction of the ADF of OxyContin • Annual medical and indirect cost savings of ADFs in the U.S. • Including analyses of the impact of ERO ADFs in Massachusetts, Ohio, and Oregon	• Truven claims data for commercially-insured, Medicaid, and Medicare-eligible patients with ≥1 RxO claim, 2009-2011 • IMS National Prescription Audit prescription volume data for EROs, 2010-2012 • Publicly-available government data (e.g., NSDUH) • IMS Xponent state-specific prescription volume data for EROs • State-specific government reports, presentations, news articles
Changes in ERO utilization following the introduction of ADFs in the U.S	• Changes in ERO utilization following the introduction of the ADFs of OxyContin and Opana • Including a comparison of rates of abuse between patients switching to an ADF, patients switching to non-ADF EROs, and patients discontinuing EROs	• Truven claims data for commercially-insured patients with ≥1 RxO claim, 2010-2012

*Abuse-deterrent formulations (ADFs) refer to formulations with abuse-deterrent characteristics.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Key messages from Purdue-sponsored research projects

Opioid abuse* imposes substantial costs to society

- The prevalence of diagnosed opioid abuse was 18.6 per 10,000 in 2011 (~3:1 ratio of undiagnosed to diagnosed abuse)
- The annual healthcare costs for patients with diagnosed opioid abuse ($20,343) were more than twice as much compared to similar patients without diagnosed opioid abuse ($9,716)
- For employers in the United States, the cost of opioid abuse is ~$6 per member per month
  - Cost of COPD is ~$3; cost of obesity is ~$4 (male) and ~$6 (female)
- Source of opioids: ~20% of abusers did not have opioid prescription prior to their first diagnosis of abuse
  - Approximately half of these had a family member who had filled an opioid prescription

ADFs of EROs are associated with substantial economic benefits

- ADFs are associated with a ~16% reduction in rates of diagnosed abuse
  - The reduction in abuse after introduction of ADF differed by payer
- In the United States, ADFs yield annual cost savings of ~$1.0 B
- State-level analyses estimated that ADFs yield annual cost savings in Massachusetts (~$26 M), Ohio (~$63 M), and Oregon (~$22 M)

Presence of RxO alternatives that lack abuse-deterrent characteristics undermine the benefits of ADFs

- Compared to chronic users of extended-release oxycodone who switched to the ADF of OxyContin:
  - Those who switched to non-ADF EROs were ~1.9 times more likely to be diagnosed opioid abusers (3.5% vs. 6.7%)
  - Those who discontinued use of EROs but used immediate-release opioids were ~3.2 times more likely to be diagnosed opioid abusers (3.5% vs. 11.3%)
- A similar pattern was observed for the ADF of Opana

*To assure consistency with national statistics, the term "abuse" encompasses opioid abuse and dependence.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

To: Sackler, Dr Richard[redacted]
Cc: Gasdia, Russell[redacted] Stewart, John H. (US)[redacted]
From: Rosen, David (Sales and Marketing)
Sent: Sat 8/17/2013 12:52:50 PM
Subject: Final - OxyContin Market Events 8-16-13.pptx
Final - OxyContin Market Events 8-16-13.pptx

Hi, Dr. Richard. Here is the updated OxyContin events presentation. We are exploring the impact and potential remediation of many of the more recent events in our work with McKinsey. Please let me know if you have any questions. Have a good weekend.

-David

OxyContin Market Events

8/16/13 – FINAL

FAMR

PURDUE

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

OxyContin Market Events

1.	January 1995	Faulding Pharmaceuticals licenses rights to market Kadian to BMS
2.	**December 1995**	**OxyContin was launched by Purdue Pharma with 256 sales reps**
3.	August 1996	Kadian was launched by Zeneca for Faulding Pharmaceuticals
4.	Q1 1997	Purdue sales force expands to 323 sales reps
5.	Q1 1998	Purdue sales force expands to 422 sales reps
6.	Q1 1999	Purdue sales force expands to 532 sales reps
7.	Q1 2000	Purdue sales force expands to 674 sales reps
8.	January 2000	Time Magazine runs an article about OxyContin abuse & diversion
9.	2000	Purdue sales force expends to 770 sales reps and creates the Hospital Specialty Division (HSD)
10.	Q1 2001	Newsweek and other publications run articles about OxyContin abuse & diversion
11.	March 2001	Barry Meier's first article on OxyContin published in The New York Times
12.	March 2001	New strengths of Kadian launched by Faulding Pharmaceuticals (30 & 60 mg)
13.	April 2001	First OxyContin product liability lawsuit filed
14.	December 2001	Alpharma acquires Faulding, including Kadian
15.	June 2002	Avinza was launched by Ligand
		Redacted
17.	**October 2003**	**Spectracef was launched by Purdue Pharma**
18.	January 2004	First antitrust lawsuits filed
19.	January 2004	1st OxyContin patent decision – Endo wins in district court
20.	April 2004	Teva launches generic OxyContin (80 mg)
21.	June 2004	Purdue sales force contracts to 550 sales reps

FAMR

2 PURDUE

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

OxyContin Market Events

22.	January 2005	Duragesic goes generic
23.	**February 2005**	**Palladone was launched by Purdue Pharma**
24.	June 2005	Ivax and Endo launch generic OER (all strengths)
25.	June 2005	Purdue sales force contracts to 250 sales reps
26.	November 2005	Watson launches (authorized) generic OER (all strengths)
27.	December 2005	Teva and Dava/Impax launch generic OER (all strengths)
28.	January 2006	OxyContin placed on most Medicare Part D plans
29.	**February 2006**	**Purdue Pharma wins Patent appeal**
30.	July 2006	Opana ER launched by Endo
31.	July 2006	Settlement of product liability insurance coverage litigation
32.	**July 2006**	**Purdue Pharma voluntarily removes Palladone from the market**
33.	August 2006	Licensing agreement with Endo & Teva regarding OxyContin patent infringement
34.	October 2006	Agreement in principle to settle WDVA investigation
35.	November 2006	New strengths of Kadian launched by Alpharma (80 mg)
36.	December 2006	First mass settlement of product liability claims
37.	February 2007	Watson (authorized) generic OER ceases production
38.	February 2007	Avinza sold to King Pharmaceuticals from Ligand
39.	April 2007	New strengths of Kadian launched by Alpharma (200 mg)
40.	April 2007	Settlement agreement with Impax
41.	May 2007	Multistate attorney general settlement
42.	May 2007	Announcement of WDVA plea and settlement
43.	July 2007	Court approval of WDVA plea and settlement
44.	August 2007	Filing of next wave of civil litigation (eventually including third party payers, Kentucky Attorney General, class actions, mass actions, individual actions)
45.	September 2007	New strengths of Kadian launched by Alpharma (10 mg)

FAMR

3 PURDUE

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

OxyContin Market Events

46.	**February 2008**	**OxyContin launches three new strengths (15, 30 & 60 mg)**
47.	April 2008	New strengths of Opana ER launched by Endo (7.5, 15 & 30 mg)
	Redacted	
49.	December 2008	Actavis acquires Kadian from Alpharma
50.	December 2008	FDA rejects Remoxy NDA from King Pharmaceuticals
51.	December 2008	OxyContin removed from Humana
52.	Q1 2009	Purdue sales force expends to 350 sales reps
53.	January 2009	OxyContin removed from Humana Medicare Part D
54.	February 2009	New strengths of Avinza launched by King Pharmaceuticals (45 & 75 mg)
55.	**May 2009**	**Ryzolt was launched by Purdue Pharma**
	Redacted	
58.	September 2009	Embeda was launched by King Pharmaceuticals
	Redacted	
61.	Q1 2010	Purdue sales force expends to 400 sales reps
	Redacted	
63.	April 2010	Approval of OxyContin Reformulation
64.	April 2010	Exalgo was launched by Covidien
65.	April 2010	Kadian patent expired
66.	**August 2010**	**OxyContin Reformulation launched by Purdue Pharma**
67.	November 2010	Pfizer to acquire King Pharmaceuticals
68.	November 2010	FDA requests withdrawal of all propoxyphene products (Darvon, Darvocet, and generics containing propoxyphene) due to serious potential heart risks

FAMR

PURDUE

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

OxyContin Market Events

69.	Q1 2011	Purdue sales force expends to 525 sales reps
70.	**January 2011**	**Butrans was launched by Purdue Pharma**
71.	January 2011	OxyContin removed from Caremark (Silverscript) Medicare Part D
72.	January 2011	OxyContin removed from Aetna Medicare Part D
73.	January 2011	OxyContin removed from Wellpoint Medicare Part D
74.	March 2011	Embeda was voluntarily recalled by King Pharmaceuticals because a pre-specified stability requirement was not met during routine testing.
		Redacted
76.	June 2011	FDA rejects Remoxy NDA from Pfizer & King Pharmaceuticals
77.	July 2011	Florida law goes into effect that bars most physicians from dispensing controlled substances from their offices
78.	September 2011	Florida starts state monitoring database that tracks retail sales of controlled substances
79.	September 2011	Nucynta ER was launched by Janssen
80.	November 2011	Kadian generics are available
81.	November 2011	OxyContin added back to Caremark (Silverscript) Medicare Part D
82.	January 2012	Endo Pharmaceuticals temporarily suspends production of several products due to errors in the packaging of the tablets. Products include: Opana (Endo), Opana ER (Endo), Percodan, Endocet, Oxymorphone (Endo), Percocet, Zydone, Endodan, Morphine
83.	January 2012	National Sales Meeting
84.	January 2012	"Individualize the Dose" campaign introduced with refined messages focused specifically on Managed Care coverage and the Savings Card Program
85.	January 2012	OxyContin received 20 primary call details
86.	February 2012	The Regence Group with 1.5M commercial lives moved OxyContin from Tier 3 unrestricted to Tier 3 with a Prior Auth.
87.	March 2012	5% price increase for OxyContin
88.	March 2012	Relay Health eVoucher Program was initiated

FAMR

5 PURDUE

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

OxyContin Market Events

89.	Q3 2012	CVS tells several Florida prescribers it will no longer fill their prescriptions, results in 80 percent drop in oxycodone sales
90.	September 2012	DEA revokes registration for two CVS stories in Sanford, Florida
91.	September 2012	DEA suspends license for Walgreens Jupiter, Florida distribution center
92.	Q4 2012	Walgreen's distribution center in Perrysburg, OH shuts down
93.	Q4 2012	Walgreens: Piloted Good Faith Dispensing (GFD) policy in FL and NV
94.	Q4 2012	Physicians for Responsible Opioid Prescribing (PROP) forms
95.	October 2012	Paused Bi-weekly branded eMail messages for RM program due to OxyContin labeling updates
96.	October 2012	Paused Online Display advertising campaign due to OxyContin labeling updates
97.	December 2012	Resumed Bi-weekly branded email messages for RM program
98.	January 2013	Savings Program (Relay Health/MediMedia Savings Cards) offer increased from up to $70-up to $90, following initial $25 out-of-pocket cost to patient
99.	January 2013	50% call allocation to OxyContin primary details
100.	January 2013	Launch of the Patient Essentials Pack to garner new patient starts where appropriate
101.	January 2013	New journal ad focused on value of and access to OxyContin
102.	January 2013	Increase from 51,000 to 67,000 high potential OxyContin targets in Relationship Marketing program
103.	January 2013	United Healthcare MAPD with 2 million lives removes OxyContin
104.	January 2013	Janssen no longer promotes Nucynta/ER using sales representatives
105.	January 2013	Global launches generic to Opana ER
106.	February 2013	5.5% price increase for OxyContin
107.	**April 2013**	**Labeling updates regarding abuse deterrence studies approved by FDA and original OxyContin extended release tablets were withdrawn from sale for reasons of safety or effectiveness**
108.	April 2013	$11 million CVS Caremark settlement with DOJ
109.	April 2013	Resumed Online Display advertising campaign

Redacted

FAMR

6 PURDUE

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

OxyContin Market Events

111.	May 2013	Walgreens rolls out Good Faith Dispensing Policy to prescribers nationally
112.	May 2013	FDA rules that original formulation of Opana ER was not withdrawn from the market for reasons of safety or effectiveness
113.	June 2013	$80 million Walgreens settlement with DOJ
114.	June 2013	Medicare Part D Journal Ad – featured in Long-Term Care journals
115.	June 2013	Launch of first iPad detailing experience specific to OxyContin – Patient Case Vignettes

FAMR

PURDUE

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY



FAMR

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY



CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY



CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY



CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY



CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY



CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Message

From: Baker, Stuart D. [redacted]

Sent: 8/21/2013 12:03:18 PM

To: Sackler, Dr Raymond R [redacted]; Sackler, Beverly [redacted] Sackler, Dame Theresa [redacted] Sackler Lefcourt, Ilene [redacted] Sackler, Dr Kathe [redacted] Sackler, Jonathan [redacted] Sackler Hunt, Samantha [redacted] Sackler, Mortimer D.A. [redacted] Sackler, David A. [redacted] Boer, Peter [redacted] Boer, Peter [redacted] Lewent, Judy [redacted]; Pickett, Cecil [redacted] Costa, Paulo [redacted] Snyderman, Ralph [redacted]

CC: Sackler, Dr Richard [redacted] Roncalli, Anthony [redacted]

Subject: McKinsey Report Regarding Purdue Pharma L.P.

Attachments: 20130808 Addendum to Board Memo v14.docx

Dear All:

Dr. Richard has arranged a face to face meeting with McKinsey on Friday, August 23, 2013 commencing at 2:00pm to discuss the McKinsey report. This report was included in the Board book for the Thursday, August 15, 2013 meeting. For ease of reference, a copy is attached hereto. Any Directors who would like to attend the meeting can do so. If you would like to attend telephonically, the following are the call in details:

U.S. Participants: **Redacted**

International Participants: **Redacted**

Passcode: **Redacted**

Stuart

This e-mail, and any attachments thereto, is intended only for use by the addressee(s) named herein and may contain legally privileged and/or confidential information. If you are not the intended recipient of this e-mail, you are hereby notified that any dissemination, distribution or copying of this e-mail, and any attachments thereto, is strictly prohibited. If you have received this e-mail in error, please notify me by replying to this message and permanently delete the original and any copy of this e-mail and any printout thereof.

For additional information about Chadbourne & Parke LLP and Chadbourne & Parke (London) LLP, including a list of attorneys, please see our website at http://www.chadbourne.com

CONFIDENTIAL

Memorandum to
John Stewart
Russ Gasdia

From
McKinsey & Company

August 8th, 2013

Identifying granular growth opportunities for OxyContin: Addendum to July 18th and August 5th updates

This addendum highlights two additional findings since our July 18th and August 5th updates and specific actions we believe Purdue should take to begin to increase sales.

1. Prescriber Targeting

Our refined analyses confirm significant opportunity to improve sales through better targeting. We believe the upside is >$100 million in annual sales.

Today Purdue spends as much effort detailing the lesser value prescribers (decile 0-4) as it does on the higher value prescribers (decile 5-10). To put this in perspective, the average prescriber in decile 5-10 writes 25 times as many OxyContin scripts as a prescriber in decile 0-4. In Q1 2013 the majority (52%) of OxyContin primary calls were made to decile 0-4 prescribers. Including the secondary calls, 57% of the primary detail equivalents (PDEs) were made to decile 0-4 prescribers. Best practice in the industry is over 80% of effort on higher value prescribers. (Exhibit 1)

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Exhibit 1: OxyContin calls by market decile



1 PDEs calculated as 1.0 x P1 calls + 0.5 x P2 calls
2 Market decile based on ER-IR market basket as defined by ZS Associates

SOURCE: IMS, Purdue call data

McKinsey & Company | 0

Furthermore, 75% of the decline in OxyContin sales comes from prescribers that Purdue is not calling upon. Two thirds of this decline is from prescribers in deciles 5-10. (Exhibit 2) In addition, the field sales force primary OxyContin calls are running at 65% of goal.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Exhibit 2: OxyContin TRx change at different levels of call activity



Collectively these findings show significant opportunity to improve targeting and also emphasize the upside from improvement as OxyContin's responsiveness to calls appears significant.

2. Retail access

Access to OxyContin for some patients has become quite challenging in specific local markets. This is due to a combination of factors including: regulations, DEA initiatives, PROP, wholesaler initiatives and local pharmacist perceptions.

There is direct evidence of this reduced access through patient calls to Purdue's Medical Information line which have recorded a 300% increase in instances of patients reporting difficulty filling opioid prescriptions, often needing to travel to multiple pharmacies in an attempt to fill their prescription.

There are reports of wholesalers stopping shipments entirely to an increasing number of pharmacies, causing temporary supply disruptions. Although, it appears that pharmacies are able to secure alternative distributors.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00015609

Many wholesalers are also imposing hard quantity limits on orders based on prior purchase levels. This restricts access for new and existing patients, especially in situations when an access challenge arises in a local pharmacy, the wholesaler quantity limits restrict the ability of other local pharmacies to pick up the displaced patients.

While the wholesaler issues are quite visible and real, we believe the daily decisions being made at local pharmacies, while less publicly visible, are in fact creating far greater access issues.

Walgreens, in particular, is having material impact on patients. In April, Walgreens rolled out national opioid dispensing guidelines. These guidelines are quite extensive and include 'flags' for new patients and dose limits which can clearly impact appropriate patient access. (Exhibit 3)

Exhibit 3: Guidelines established by major pharmacy chains for opioid dispensing

Pharmacy chains are implementing guidelines for which patients can fill opioid prescriptions, increasing pharmacists' risk of filling opioid prescriptions...

Common mandatory requirements

- Government ID
- No previous failed attempt to fill the prescription at another pharmacy belonging to same chain
- Clear Prescription Drug Monitoring Program (PDMP) check, in states where available

Additional flags

- Has not previously filled a prescription for the same medicine and dosage at same pharmacy
- Quantity is 120 units or more
- Patient on medication for 6 months or more
- Lives far from the pharmacy
- Prescription not filled on time
- Paid through cash/ credit card rather than insurance

... moreover, pharmacists report increased work and hassle associated with filling opioid prescriptions

- "We kind of discourage [the opioid business]... **it's more headaches than it's worth** for the low profits [and] if you give one patient one prescription [for an opioid], they bring their friends"– *Clinical coordinator at Publix (FL)*
- "Stress load is high- they aren't insuring techs [and] it used to take 10-15 [minutes] to fill a prescription, now it takes a lot longer... Pharmacy also not providing enough support to fill these prescriptions... **80% of the time, they just refuse patients**." – *Clinical coordinator at Publix (FL)*
- "With budget cuts and staffing cuts – we don't have time to handle everything... **it's easier to turn away patients... my personal turn away rate for opioids is about 5%**" – *Former Pharmacy Manager at Walgreens (KY)*

SOURCE: Purdue; Pharmacy expert interviews

McKinsey & Company | 2

Last Modified 6/6/2013 8:56 PM Eastern Standard Time

Printed 8/1/2013 7:22 AM Eastern Standard Time

Separately, as part of their agreement with the DEA, Walgreens eliminated controlled substances from their bonus calculations for pharmacists. Thus individual pharmacists effectively lose money every time they accept the work of fulfilling an opiod prescription. Thus there is a strong dis-incentive for pharmacists to dedicate the extra time needed to maintain patient access to opiods, even independent of the chain's national guidelines on opioid dispensing.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

Deep examination of Purdue's available pharmacy purchasing data shows that Walgreens has reduced its units by 18% in just the last three months. In March – June, the Walgreens reduction alone can account for 50-70% of the total OxyContin decline in units. (Exhibit 4)

Exhibit 4: OxyContin purchasing by pharmacy chain PRELIMINARY - IN VALIDATION



SOURCE: Market Visibility dataset; OMS McKinsey & Company | 3

We have examined multiple zip codes where Walgreens is a major supplier, and the other local pharmacies have not seen offsetting increases in purchases – thus it appears that many of these patients are either going untreated or being forced to find alternatives.

Further, the Walgreens data also shows a significant impact on higher OxyContin dosages. Among Walgreen stores that stock OxyContin 20mg, in the last three months there has been a 21% reduction in the number of stores also purchasing the 80mg. It is also important to note that Walgreen's reduction in the 80mg far exceeds the national trend. Their share of national purchases of the 80mg has fallen by nearly 20%. Thus Walgreens is not simply reflecting lower demand, but apparently taking independent action to further reduce 80mg purchasing.

While Walgreens is currently having the most dramatic impact, there is reason to believe that many of the chains either have implemented (e.g., CVS in 2012) or are considering similar policies. Thus the pharmacy access issue is both urgent and broad.

The magnitude of today's patient access issues underscores the need to: (1) take immediate actions to address issues at pharmacies (e.g., ensure appropriate senior level dialogue with Walgreens, increase patient advocacy efforts); and (2) accelerate exploration of potential

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY
PURDUE-COR-00015611

innovative alternatives such as direct-to-patient mail order which was described in our prior memo.

3. Specific actions to begin to increase Purdue's sales[1]

When combined with prior findings, the scale of change required in Purdue's sales force model is significant. Rather than addressing the pieces individually, we recommend you take actions to 'Turbocharge Purdue's Sales Engine' and optimize across all elements of the winning sales model – from targeting to territories to incentive compensation.

The rationale to for addressing Purdue's sales model holistically is strong. These findings demonstrate the breadth of issues and how they are inter-related. For example, despite the significant value in improving Purdue's targeting, the value cannot be captured unless the field achieves a higher level of adherence to Purdue's call plan.

While the behavioral and process changes described here are significant, and some incremental investments may be required (e.g., additional reps, Sales analytics capabilities), overall the financial investments are moderate relative to the upside sales potential.

Therefore, we recommend Purdue approve five actions immediately:

1. Create a senior leadership team to lead this effort (no more than three executives within and outside sales) and task them to develop a detailed workplan within 30 days.
2. Establish a revenue growth goal (e.g., $150M incremental stretch goal by July 2014) and set monthly progress reviews with CEO and Board.
3. Shift Purdue's sales targeting from decile to workload (industry norm that more precisely defines the value of physicians)
4. Re-balance field effort dramatically toward OxyContin by increasing field force activity where needed and closely measuring changes in sales
5. Mandate field compliance with targets and align the incentive program to match OxyContin prioritization

Our experience with other pharmaceutical companies suggests that such a comprehensive Sales transformation program takes nine months, although positive impact will be seen within 2-3 months. It is critical that Purdue commits to addressing sales as an organizational journey, not an event. Success requires not only the analytic answer, but even more importantly winning the hearts and minds of the sales force and permanently changing how the company operates, from

[1] Recommended actions to address "retail access" will be included in our final report

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

HQ to the field. New capabilities will need to be learned and reinforced on a daily basis. The organizational mindset, behavior and culture will all need to evolve along with journey.

Purdue should start work immediately. Additional analytics are needed (e.g., workload and Champions need to be identified). As mentioned above, a detailed workplan needs to be developed within 30 days. While this effort would be focused on OxyContin, the approach and capabilities built would likely have positive spillover to Butrans and the rest of the portfolio.

While it is challenging to quantify the exact impact of such changes in a dynamic marketplace, we are confident that the value at stake is significant – hundreds of millions, not tens of millions. Analysis done during the prior sales force alignment and our own retrospective analysis both showed over $200M of potential opportunity in a single year, even more in cumulative terms. While this did not take into account the negative landscape drivers such as pharmacy access challenges, it also did not consider the positive drivers such as the recent label change. The substantial size of the opportunity is reassurance that the significant effort required will be well rewarded.

Closing

We emphasized this 'Sales Engine' recommendation because we believe it is fundamental to Purdue's near term and longer term success. We strongly believe that a comprehensive approach is the right answer. Success will require real commitment from Purdue leadership and also significant effort from the organization. This program requires substantial capability building at HQ and in the field. The program office described above will require support of an internal cross-functional working group, likely with executive committee engagement, possibly as co-chairs. Our experience is that these kinds of sales transformations are not easy and require real work but the end result is quite rewarding, both for individuals and for the organization.

Our experience makes clear that one fundamental 'must have' for execution success is strong leadership alignment upfront.

Therefore our recommendation is that Purdue makes a clear go-no go decision to 'Turbocharge the Sales Engine'.

CONFIDENTIAL TREATMENT REQUESTED
NOT FOR CIRCULATION/COMMITTEE MEMBERS AND STAFF ONLY

To: Sackler, Dr Richard[redacted]
Cc: Stewart, John H. (US)[redacted] Gasdia, Russel[redacted]
From: Rosen, David (Sales and Marketing)
Sent: Fri 8/23/2013 9:38:10 AM
Subject: Butrans=10,473; Intermezzo=1,315 (Week ending 8-09-13)
Intermezzo Weekly Report 8-9-2013.xlsx
OxyContin Wkly Report 8-9-13.xlsx
Copy of Butrans Weekly Report 8-9-13.xlsm

Hi, Dr. Richard. Both Butrans and Intermezzo continue their largely flat trend. Overall, Butrans share is increasing but the extended release opioid market continues to soft.

Butrans

Rx Increase from last week (10,240)	2.3%
Share	2.11%
Share last week	2.06%

Intermezzo

Rx Increase from last week (1,316)	-0.1%
Share	0.098%
Share last week	0.097%

-David

David Rosen | Executive Director, Forecasting, Analytics and Market Research | Purdue Pharma | One Stamford Forum Stamford CT 06901|[redacted]@pharma.com |Redacted
Redacted

Produced Natively

	Total					% of Budget Achieved vs. True Rx's		% of TRx		Total Rx		Total NRx		Total RRx		True Rx		Trial Card Redemptions		% Chg vs. Prior Period						
	2012 Budget Rx	2013 Budget Rx	Total Rx	True Rx	Trial Card Redemptions	Weekly True Rx Vs Budget	Cumlative % True Rx vs Budget	True Rx	Trial Card Redemptions	1.75mg Total Rx	3.5mg Total Rx	1.75mg Total Rx	3.5mg Total Rx	1.75mg Total Rx	3.5mg Total Rx	1.75mg True	3.5mg True	1.75mg	3.5mg	Total Rx	1.75mg Total Rx	3.5mg Total Rx	True Rx	1.75mg True Rx	3.5mg True Rx	Trial Card Redemptions
6-Apr-12	69		92	88	4	128.0%	128.0%	96%	4%	53	39	53	39	0	0	50	38	3	1	NA	NA	NA	NA	NA	NA	NA
13-Apr-12	104		410	392	18	376.7%	277.8%	96%	4%	227	183	227	183	0	0	218	174	9	9	345.7%	328.3%	369.2%	345.5%	336.0%	357.9%	350.0%
20-Apr-12	183		468	406	62	221.5%	248.8%	87%	13%	256	212	253	212	3	0	225	181	31	31	14.1%	12.8%	15.8%	3.6%	3.2%	4.0%	244.4%
27-Apr-12	322		461	400	61	124.1%	189.5%	87%	13%	254	207	251	205	3	2	226	174	28	33	-1.5%	-0.8%	-2.4%	-1.5%	0.4%	-3.9%	-1.6%
4-May-12	519		551	466	85	89.8%	146.3%	85%	15%	306	245	306	240	0	5	266	200	40	45	19.5%	20.5%	18.4%	16.5%	17.7%	14.9%	39.3%
11-May-12	924		581	482	99	52.2%	105.3%	83%	17%	329	252	320	242	9	10	279	203	50	49	5.4%	7.5%	2.9%	3.4%	4.9%	1.5%	16.5%
18-May-12	1,171		577	474	103	40.5%	82.3%	82%	18%	303	274	290	249	13	25	249	225	54	49	-0.7%	-7.9%	8.7%	-1.7%	-10.8%	10.8%	4.0%
25-May-12	1,334		644	539	105	40.4%	70.2%	84%	16%	330	314	309	296	21	18	281	258	49	56	11.6%	8.9%	14.6%	13.7%	12.9%	14.7%	1.9%
1-Jun-12	1,423		561	494	67	34.7%	61.8%	88%	12%	295	266	270	245	25	21	256	238	39	28	-12.9%	-10.6%	-15.3%	-8.3%	-8.9%	-7.8%	-36.2%
8-Jun-12	2,153		801	678	123	31.5%	53.9%	85%	15%	409	392	365	346	44	46	339	339	70	53	42.8%	38.6%	47.4%	37.2%	32.4%	42.4%	83.6%
15-Jun-12	2,246		760	657	103	29.2%	48.6%	86%	14%	393	367	362	325	31	42	333	324	60	43	-5.1%	-3.9%	-6.4%	-3.1%	-1.8%	-4.4%	-16.3%
22-Jun-12	2,406		840	720	120	29.9%	45.1%	86%	14%	462	378	426	332	36	46	405	315	57	63	10.5%	17.6%	3.0%	9.6%	21.6%	-2.8%	16.5%
29-Jun-12	2,683		842	728	114	27.1%	42.0%	86%	14%	443	399	395	346	48	53	372	356	71	43	0.2%	-4.1%	5.6%	1.1%	-8.1%	13.0%	-5.0%
6-Jul-12	2,488		715	646	69	26.0%	39.8%	90%	10%	367	348	325	281	42	67	333	313	34	35	-15.1%	-17.2%	-12.8%	-11.3%	-10.5%	-12.1%	-39.5%
13-Jul-12	3,222		904	808	96	25.1%	37.5%	89%	11%	417	487	343	405	74	82	368	440	49	47	26.4%	13.6%	39.9%	25.1%	10.5%	40.6%	39.1%
20-Jul-12	3,606		894	789	105	21.9%	35.3%	88%	12%	451	443	387	358	64	85	403	386	48	57	-1.1%	8.2%	-9.0%	-2.4%	9.5%	-12.3%	9.4%
27-Jul-12	3,926		939	818	121	20.8%	33.3%	87%	13%	458	481	403	398	55	83	391	427	67	54	5.0%	1.6%	8.6%	3.7%	-3.0%	10.6%	15.2%
3-Aug-12	4,452		907	785	122	17.6%	31.2%	87%	13%	461	446	392	367	69	79	393	392	68	54	-3.4%	0.7%	-7.3%	-4.0%	0.5%	-8.2%	0.8%
10-Aug-12	4,679		1,063	954	109	20.4%	29.9%	90%	10%	510	553	458	446	52	107	458	496	52	57	17.2%	10.6%	24.0%	21.5%	16.5%	26.5%	-10.7%
17-Aug-12	4,809		1,094	977	117	20.3%	28.8%	89%	11%	545	549	471	427	74	122	479	498	66	51	2.9%	6.9%	-0.7%	2.4%	4.6%	0.4%	7.3%
24-Aug-12	5,086		1,102	967	135	19.0%	27.8%	88%	12%	547	555	459	444	88	111	466	501	81	54	0.7%	0.4%	1.1%	-1.0%	-2.7%	0.6%	15.4%
31-Aug-12	5,166		1,093	975	118	18.9%	26.9%	89%	11%	539	554	433	426	106	128	479	496	60	58	-0.8%	-1.5%	-0.2%	0.8%	2.8%	-1.0%	-12.6%
7-Sep-12	4,357		974	873	101	20.0%	26.4%	90%	10%	465	509	372	382	93	127	412	461	53	48	-10.9%	-13.7%	-8.1%	-10.5%	-14.0%	-7.1%	-14.4%
14-Sep-12	5,453		1,194	1,078	116	19.8%	25.8%	90%	10%	590	604	489	468	101	136	539	539	51	65	22.6%	26.9%	18.7%	23.5%	30.8%	16.9%	14.9%

Intermezzo® (ZOLPIDEM TARTRATE) sublingual tablet CV
1.75 mg | 3.5 mg

NRx, RRx and TRx by Strength
Distribution of Rxs by Strength
Distribution of NRx, RRx and TRx by Strength
Weekly Growth in Intermezzo TRxs

Data includes retail pharmacy, mail order and LTC channels

Intermezzo New, Refill and Total Prescriptions by Strength

Week #	Week Ending	Total NRx	Total RRx	Total TRx	1.75mg NRx	1.75mg RRx	1.75mg TRx	3.5mg NRx	3.5mg RRx	3.5mg TRx
Week 1*	6-Apr-12	92	0	92	53	0	53	39	0	39
Week 2	13-Apr-12	410	0	410	227	0	227	183	0	183
Week 3	20-Apr-12	465	3	468	253	3	256	212	0	212
Week 4	27-Apr-12	456	5	461	251	3	254	205	2	207
Week 5	4-May-12	546	5	551	306	0	306	240	5	245
Week 6	11-May-12	562	19	581	320	9	329	242	10	252
Week 7	18-May-12	539	38	577	290	13	303	249	25	274
Week 8	25-May-12	605	39	644	309	21	330	296	18	314
Week 9	1-Jun-12	515	46	561	270	25	295	245	21	266
Week 10	8-Jun-12	711	90	801	365	44	409	346	46	392
Week 11	15-Jun-12	687	73	760	362	31	393	325	42	367
Week 12	22-Jun-12	758	82	840	426	36	462	332	46	378
Week 13	29-Jun-12	741	101	842	395	48	443	346	53	399
Week 14	6-Jul-12	606	109	715	325	42	367	281	67	348
Week 15	13-Jul-12	748	156	904	343	74	417	405	82	487
Week 16	20-Jul-12	745	149	894	387	64	451	358	85	443
Week 17	27-Jul-12	801	138	939	403	55	458	398	83	481
Week 18	3-Aug-12	759	148	907	392	69	461	367	79	446
Week 19	10-Aug-12	904	159	1,063	458	52	510	446	107	553
Week 20	17-Aug-12	898	196	1,094	471	74	545	427	122	549
Week 21	24-Aug-12	903	199	1,102	459	88	547	444	111	555
Week 22	31-Aug-12	859	234	1,093	433	106	539	426	128	554
Week 23	7-Sep-12	754	220	974	372	93	465	382	127	509
Week 24	14-Sep-12	957	237	1,194	489	101	590	468	136	604
Week 25	21-Sep-12	972	306	1,278	461	129	590	511	177	688
Week 26	28-Sep-12	1,141	279	1,420	478	124	602	663	155	818
Week 27	5-Oct-12	915	297	1,212	436	128	564	479	169	648
Week 28	12-Oct-12	1,017	267	1,284	485	107	592	532	160	692
Week 29	19-Oct-12	981	288	1,269	452	120	572	529	168	697
Week 30	26-Oct-12	1,026	277	1,303	553	44	597	473	233	706
Week 31	2-Nov-12	997	301	1,298	479	115	594	518	186	704
Week 32	9-Nov-12	1,043	340	1,383	467	151	618	576	189	765
Week 33	16-Nov-12	1,019	328	1,347	506	138	644	513	190	703
Week 34	23-Nov-12	810	299	1,109	369	116	485	441	183	624
Week 35	30-Nov-12	955	353	1,308	466	133	599	489	220	709
Week 36	7-Dec-12	1,046	339	1,385	483	132	615	563	207	770
Week 37	14-Dec-12	1,040	449	1,489	521	188	709	519	261	780
Week 38	21-Dec-12	1,137	397	1,534	537	169	706	600	228	828
Week 39	28-Dec-12	654	341	995	307	144	451	347	197	544
Week 40	4-Jan-13	663	322	985	289	127	416	374	195	569
Week 41	11-Jan-13	916	374	1,290	417	147	564	499	227	726
Week 42	18-Jan-13	1,151	381	1,532	553	144	697	598	237	835
Week 43	25-Jan-13	1,187	340	1,527	625	122	747	562	218	780
Week 44	1-Feb-13	1,417	365	1,782	741	141	882	676	224	900
Week 45	8-Feb-13	1,461	369	1,830	730	126	856	731	243	974
Week 46	15-Feb-13	1,479	408	1,887	779	157	936	700	251	951
Week 47	22-Feb-13	1,493	414	1,907	783	155	938	710	259	969
Week 48	1-Mar-13	1,534	429	1,963	804	177	981	730	252	982
Week 49	8-Mar-13	1,474	474	1,948	744	166	910	730	308	1,038
Week 50	15-Mar-13	1,442	443	1,885	747	176	923	695	267	962
Week 51	22-Mar-13	1,416	523	1,939	739	228	967	677	295	972
Week 52	29-Mar-13	1,401	513	1,914	695	183	878	706	330	1,036
Week 53	5-Apr-13	1,280	449	1,729	692	177	869	588	272	860
Week 54	12-Apr-13	1,367	490	1,857	666	197	863	701	293	994
Week 55	19-Apr-13	1,305	464	1,769	678	189	867	627	275	902
Week 56	26-Apr-13	1,228	520	1,748	594	209	803	634	311	945
Week 57	3-May-13	1,252	538	1,790	640	223	863	612	315	927
Week 58	10-May-13	1,183	511	1,694	554	210	764	629	301	930
Week 59	17-May-13	1,177	518	1,695	571	202	773	606	316	922
Week 60	24-May-13	1,114	495	1,609	538	187	725	576	308	884
Week 61	31-May-13	927	506	1,433	480	175	655	447	331	778
Week 62	7-Jun-13	1,097	486	1,583	503	191	694	594	295	889
Week 63	14-Jun-13	1,066	561	1,627	529	214	743	537	347	884
Week 64	21-Jun-13	1,046	517	1,563	499	204	703	547	313	860
Week 65	28-Jun-13	966	495	1,461	492	180	672	474	315	789
Week 66	5-Jul-13	853	469	1,322	408	186	594	445	283	728
Week 67	12-Jul-13	985	518	1,503	460	196	656	525	322	847
Week 68	19-Jul-13	1,016	517	1,533	477	201	678	539	316	855
Week 69	26-Jul-13	1,017	521	1,538	524	194	718	493	327	820
Week 70	2-Aug-13	989	494	1,483	460	197	657	529	297	826
Week 71	9-Aug-13	965	517	1,482	459	214	673	506	303	809
TOTAL	**2013**	**36,902**	**14,424**	**52,808**	**18,870**	**5,795**	**24,665**	**18,997**	**9,146**	**28,143**
YTD	**2013**	**36,902**	**14,424**	**52,808**	**18,870**	**5,795**	**24,665**	**18,997**	**9,146**	**28,143**

*Includes pre-launch prescriptions

Data includes retail pharmacy, mail order and LTC channels

Distribution of Total Intermezzo Prescriptions by Strength

Week #	Week Ending	Total NRx	Total RRx	Total TRx	1.75mg NRx	1.75mg RRx	1.75mg TRx	3.5mg NRx	3.5mg RRx	3.5mg TRx
Week 1*	6-Apr-12	100.0%	100.0%	100.0%	57.6%	0.0%	57.6%	42.4%	0.0%	42.4%
Week 2	13-Apr-12	100.0%	100.0%	100.0%	55.4%	0.0%	55.4%	44.6%	0.0%	44.6%
Week 3	20-Apr-12	100.0%	100.0%	100.0%	54.4%	100.0%	54.7%	45.6%	0.0%	45.3%
Week 4	27-Apr-12	100.0%	100.0%	100.0%	55.0%	60.0%	55.1%	45.0%	40.0%	44.9%
Week 5	4-May-12	100.0%	100.0%	100.0%	56.0%	0.0%	55.5%	44.0%	100.0%	44.5%
Week 6	11-May-12	100.0%	100.0%	100.0%	56.9%	47.4%	56.6%	43.1%	52.6%	43.4%
Week 7	18-May-12	100.0%	100.0%	100.0%	53.8%	34.2%	52.5%	46.2%	65.8%	47.5%
Week 8	25-May-12	100.0%	100.0%	100.0%	51.1%	53.8%	51.2%	48.9%	46.2%	48.8%
Week 9	1-Jun-12	100.0%	100.0%	100.0%	52.4%	54.3%	52.6%	47.6%	45.7%	47.4%
Week 10	8-Jun-12	100.0%	100.0%	100.0%	51.3%	48.9%	51.1%	48.7%	51.1%	48.9%
Week 11	15-Jun-12	100.0%	100.0%	100.0%	52.7%	42.5%	51.7%	47.3%	57.5%	48.3%
Week 12	22-Jun-12	100.0%	100.0%	100.0%	56.2%	43.9%	55.0%	43.8%	56.1%	45.0%
Week 13	29-Jun-12	100.0%	100.0%	100.0%	53.3%	47.5%	52.6%	46.7%	52.5%	47.4%
Week 14	6-Jul-12	100.0%	100.0%	100.0%	53.6%	38.5%	51.3%	46.4%	61.5%	48.7%
Week 15	13-Jul-12	100.0%	100.0%	100.0%	45.9%	47.4%	46.1%	54.1%	52.6%	53.9%
Week 16	20-Jul-12	100.0%	100.0%	100.0%	51.9%	43.0%	50.4%	48.1%	57.0%	49.6%
Week 17	27-Jul-12	100.0%	100.0%	100.0%	50.3%	39.9%	48.8%	49.7%	60.1%	51.2%
Week 18	3-Aug-12	100.0%	100.0%	100.0%	51.6%	46.6%	50.8%	48.4%	53.4%	49.2%
Week 19	10-Aug-12	100.0%	100.0%	100.0%	50.7%	32.7%	48.0%	49.3%	67.3%	52.0%
Week 20	17-Aug-12	100.0%	100.0%	100.0%	52.4%	37.8%	49.8%	47.6%	62.2%	50.2%
Week 21	24-Aug-12	100.0%	100.0%	100.0%	50.8%	44.2%	49.6%	49.2%	55.8%	50.4%
Week 22	31-Aug-12	100.0%	100.0%	100.0%	50.4%	45.3%	49.3%	49.6%	54.7%	50.7%
Week 23	7-Sep-12	100.0%	100.0%	100.0%	49.3%	42.3%	47.7%	50.7%	57.7%	52.3%
Week 24	14-Sep-12	100.0%	100.0%	100.0%	51.1%	42.6%	49.4%	48.9%	57.4%	50.6%
Week 25	21-Sep-12	100.0%	100.0%	100.0%	47.4%	42.2%	46.2%	52.6%	57.8%	53.8%
Week 26	28-Sep-12	100.0%	100.0%	100.0%	41.9%	44.4%	42.4%	58.1%	55.6%	57.6%
Week 27	5-Oct-12	100.0%	100.0%	100.0%	47.7%	43.1%	46.5%	52.3%	56.9%	53.5%
Week 28	12-Oct-12	100.0%	100.0%	100.0%	47.7%	40.1%	46.1%	52.3%	59.9%	53.9%
Week 29	19-Oct-12	100.0%	100.0%	100.0%	46.1%	41.7%	45.1%	53.9%	58.3%	54.9%
Week 30	26-Oct-12	100.0%	100.0%	100.0%	53.9%	15.9%	45.8%	46.1%	84.1%	54.2%
Week 31	2-Nov-12	100.0%	100.0%	100.0%	48.0%	38.2%	45.8%	52.0%	61.8%	54.2%
Week 32	9-Nov-12	100.0%	100.0%	100.0%	44.8%	44.4%	44.7%	55.2%	55.6%	55.3%
Week 33	16-Nov-12	100.0%	100.0%	100.0%	49.7%	42.1%	47.8%	50.3%	57.9%	52.2%
Week 34	23-Nov-12	100.0%	100.0%	100.0%	45.6%	38.8%	43.7%	54.4%	61.2%	56.3%
Week 35	30-Nov-12	100.0%	100.0%	100.0%	48.8%	37.7%	45.8%	51.2%	62.3%	54.2%
Week 36	7-Dec-12	100.0%	100.0%	100.0%	46.2%	38.9%	44.4%	53.8%	61.1%	55.6%
Week 37	14-Dec-12	100.0%	100.0%	100.0%	50.1%	41.9%	47.6%	49.9%	58.1%	52.4%
Week 38	21-Dec-12	100.0%	100.0%	100.0%	47.2%	42.6%	46.0%	52.8%	57.4%	54.0%
Week 39	28-Dec-12	100.0%	100.0%	100.0%	46.9%	42.2%	45.3%	53.1%	57.8%	54.7%
Week 40	4-Jan-13	100.0%	100.0%	100.0%	43.6%	39.4%	42.2%	56.4%	60.6%	57.8%
Week 41	11-Jan-13	100.0%	100.0%	100.0%	45.5%	39.3%	43.7%	54.5%	60.7%	56.3%
Week 42	18-Jan-13	100.0%	100.0%	100.0%	48.0%	37.8%	45.5%	52.0%	62.2%	54.5%
Week 43	25-Jan-13	100.0%	100.0%	100.0%	52.7%	35.9%	48.9%	47.3%	64.1%	51.1%
Week 44	1-Feb-13	100.0%	100.0%	100.0%	52.3%	38.6%	49.5%	47.7%	61.4%	50.5%
Week 45	8-Feb-13	100.0%	100.0%	100.0%	50.0%	34.1%	46.8%	50.0%	65.9%	53.2%
Week 46	15-Feb-13	100.0%	100.0%	100.0%	52.7%	38.5%	49.6%	47.3%	61.5%	50.4%
Week 47	22-Feb-13	100.0%	100.0%	100.0%	52.4%	37.4%	49.2%	47.6%	62.6%	50.8%
Week 48	1-Mar-13	100.0%	100.0%	100.0%	52.4%	41.3%	50.0%	47.6%	58.7%	50.0%
Week 49	8-Mar-13	100.0%	100.0%	100.0%	50.5%	35.0%	46.7%	49.5%	65.0%	53.3%
Week 50	15-Mar-13	100.0%	100.0%	100.0%	51.8%	39.7%	49.0%	48.2%	60.3%	51.0%
Week 51	22-Mar-13	100.0%	100.0%	100.0%	52.2%	43.6%	49.9%	47.8%	56.4%	50.1%
Week 52	29-Mar-13	100.0%	100.0%	100.0%	49.6%	35.7%	45.9%	50.4%	64.3%	54.1%
Week 53	5-Apr-13	100.0%	100.0%	100.0%	54.1%	39.4%	50.3%	45.9%	60.6%	49.7%
Week 54	12-Apr-13	100.0%	100.0%	100.0%	48.7%	40.2%	46.5%	51.3%	59.8%	53.5%
Week 55	19-Apr-13	100.0%	100.0%	100.0%	52.0%	40.7%	49.0%	48.0%	59.3%	51.0%
Week 56	26-Apr-13	100.0%	100.0%	100.0%	48.4%	40.2%	45.9%	51.6%	59.8%	54.1%
Week 57	3-May-13	100.0%	100.0%	100.0%	51.1%	41.4%	48.2%	48.9%	58.6%	51.8%
Week 58	10-May-13	100.0%	100.0%	100.0%	46.8%	41.1%	45.1%	53.2%	58.9%	54.9%
Week 59	17-May-13	100.0%	100.0%	100.0%	48.5%	39.0%	45.6%	51.5%	61.0%	54.4%
Week 60	24-May-13	100.0%	100.0%	100.0%	48.3%	37.8%	45.1%	51.7%	62.2%	54.9%
Week 61	31-May-13	100.0%	100.0%	100.0%	51.8%	34.6%	45.7%	48.2%	65.4%	54.3%
Week 62	7-Jun-13	100.0%	100.0%	100.0%	45.9%	39.3%	43.8%	54.1%	60.7%	56.2%
Week 63	14-Jun-13	100.0%	100.0%	100.0%	49.6%	38.1%	45.7%	50.4%	61.9%	54.3%
Week 64	21-Jun-13	100.0%	100.0%	100.0%	47.7%	39.5%	45.0%	52.3%	60.5%	55.0%
Week 65	28-Jun-13	100.0%	100.0%	100.0%	50.9%	36.4%	46.0%	49.1%	63.6%	54.0%
Week 66	5-Jul-13	100.0%	100.0%	100.0%	47.8%	39.7%	44.9%	52.2%	60.3%	55.1%
Week 67	12-Jul-13	100.0%	100.0%	100.0%	46.7%	37.8%	43.6%	53.3%	62.2%	56.4%
Week 68	19-Jul-13	100.0%	100.0%	100.0%	46.9%	38.9%	44.2%	53.1%	61.1%	55.8%
Week 69	26-Jul-13	100.0%	100.0%	100.0%	51.5%	37.2%	46.7%	48.5%	62.8%	53.3%
Week 70	2-Aug-13	100.0%	100.0%	100.0%	46.5%	39.9%	44.3%	53.5%	60.1%	55.7%
Week 71	9-Aug-13	100.0%	100.0%	100.0%	47.6%	41.4%	45.4%	52.4%	58.6%	54.6%
TOTAL	**2013**	**100.0%**	**100.0%**	**100.0%**	**51.1%**	**40.2%**	**46.7%**	**51.5%**	**63.4%**	**53.3%**
YTD	**2013**	**102.6%**	**103.6%**	**100.0%**	**51.1%**	**40.2%**	**46.7%**	**51.5%**	**63.4%**	**53.3%**

Distribution of Intermezzo New, Refill and Total Prescriptions by Strength

Week #	Week Ending	Total NRx	Total RRx	Total TRx	1.75mg NRx	1.75mg RRx	1.75mg TRx	3.5mg NRx	3.5mg RRx	3.5mg TRx
Week 1*	6-Apr-12	100.0%	0.0%	100.0%	100.0%	0.0%	100.0%	100.0%	0.0%	100.0%
Week 2	13-Apr-12	100.0%	0.0%	100.0%	100.0%	0.0%	100.0%	100.0%	0.0%	100.0%
Week 3	20-Apr-12	99.4%	0.6%	100.0%	98.8%	1.2%	100.0%	100.0%	0.0%	100.0%
Week 4	27-Apr-12	98.9%	1.1%	100.0%	98.8%	1.2%	100.0%	99.0%	1.0%	100.0%
Week 5	4-May-12	99.1%	0.9%	100.0%	100.0%	0.0%	100.0%	98.0%	2.0%	100.0%
Week 6	11-May-12	96.7%	3.3%	100.0%	97.3%	2.7%	100.0%	96.0%	4.0%	100.0%
Week 7	18-May-12	93.4%	6.6%	100.0%	95.7%	4.3%	100.0%	90.9%	9.1%	100.0%
Week 8	25-May-12	93.9%	6.1%	100.0%	93.6%	6.4%	100.0%	94.3%	5.7%	100.0%
Week 9	1-Jun-12	91.8%	8.2%	100.0%	91.5%	8.5%	100.0%	92.1%	7.9%	100.0%
Week 10	8-Jun-12	88.8%	11.2%	100.0%	89.2%	10.8%	100.0%	88.3%	11.7%	100.0%
Week 11	15-Jun-12	90.4%	9.6%	100.0%	92.1%	7.9%	100.0%	88.6%	11.4%	100.0%
Week 12	22-Jun-12	90.2%	9.8%	100.0%	92.2%	7.8%	100.0%	87.8%	12.2%	100.0%
Week 13	29-Jun-12	88.0%	12.0%	100.0%	89.2%	10.8%	100.0%	86.7%	13.3%	100.0%
Week 14	6-Jul-12	84.8%	15.2%	100.0%	88.6%	11.4%	100.0%	80.7%	19.3%	100.0%
Week 15	13-Jul-12	82.7%	17.3%	100.0%	82.3%	17.7%	100.0%	83.2%	16.8%	100.0%
Week 16	20-Jul-12	83.3%	16.7%	100.0%	85.8%	14.2%	100.0%	80.8%	19.2%	100.0%
Week 17	27-Jul-12	85.3%	14.7%	100.0%	88.0%	12.0%	100.0%	82.7%	17.3%	100.0%
Week 18	3-Aug-12	83.7%	16.3%	100.0%	85.0%	15.0%	100.0%	82.3%	17.7%	100.0%
Week 19	10-Aug-12	85.0%	15.0%	100.0%	89.8%	10.2%	100.0%	80.7%	19.3%	100.0%
Week 20	17-Aug-12	82.1%	17.9%	100.0%	86.4%	13.6%	100.0%	77.8%	22.2%	100.0%
Week 21	24-Aug-12	81.9%	18.1%	100.0%	83.9%	16.1%	100.0%	80.0%	20.0%	100.0%
Week 22	31-Aug-12	78.6%	21.4%	100.0%	80.3%	19.7%	100.0%	76.9%	23.1%	100.0%
Week 23	7-Sep-12	77.4%	22.6%	100.0%	80.0%	20.0%	100.0%	75.0%	25.0%	100.0%
Week 24	14-Sep-12	80.2%	19.8%	100.0%	82.9%	17.1%	100.0%	77.5%	22.5%	100.0%
Week 25	21-Sep-12	76.1%	23.9%	100.0%	78.1%	21.9%	100.0%	74.3%	25.7%	100.0%
Week 26	28-Sep-12	80.4%	19.6%	100.0%	79.4%	20.6%	100.0%	81.1%	18.9%	100.0%
Week 27	5-Oct-12	75.5%	24.5%	100.0%	77.3%	22.7%	100.0%	73.9%	26.1%	100.0%
Week 28	12-Oct-12	79.2%	20.8%	100.0%	81.9%	18.1%	100.0%	76.9%	23.1%	100.0%
Week 29	19-Oct-12	77.3%	22.7%	100.0%	79.0%	21.0%	100.0%	75.9%	24.1%	100.0%
Week 30	26-Oct-12	78.7%	21.3%	100.0%	92.6%	7.4%	100.0%	67.0%	33.0%	100.0%
Week 31	2-Nov-12	76.8%	23.2%	100.0%	80.6%	19.4%	100.0%	73.6%	26.4%	100.0%
Week 32	9-Nov-12	75.4%	24.6%	100.0%	75.6%	24.4%	100.0%	75.3%	24.7%	100.0%
Week 33	16-Nov-12	75.6%	24.4%	100.0%	78.6%	21.4%	100.0%	73.0%	27.0%	100.0%
Week 34	23-Nov-12	73.0%	27.0%	100.0%	76.1%	23.9%	100.0%	70.7%	29.3%	100.0%
Week 35	30-Nov-12	73.0%	27.0%	100.0%	77.8%	22.2%	100.0%	69.0%	31.0%	100.0%
Week 36	7-Dec-12	75.5%	24.5%	100.0%	78.5%	21.5%	100.0%	73.1%	26.9%	100.0%
Week 37	14-Dec-12	69.8%	30.2%	100.0%	73.5%	26.5%	100.0%	66.5%	33.5%	100.0%
Week 38	21-Dec-12	74.1%	25.9%	100.0%	76.1%	23.9%	100.0%	72.5%	27.5%	100.0%
Week 39	28-Dec-12	65.7%	34.3%	100.0%	68.1%	31.9%	100.0%	63.8%	36.2%	100.0%
Week 40	4-Jan-13	67.3%	32.7%	100.0%	69.5%	30.5%	100.0%	65.7%	34.3%	100.0%
Week 41	11-Jan-13	71.0%	29.0%	100.0%	73.9%	26.1%	100.0%	68.7%	31.3%	100.0%
Week 42	18-Jan-13	75.1%	24.9%	100.0%	79.3%	20.7%	100.0%	71.6%	28.4%	100.0%
Week 43	25-Jan-13	77.7%	22.3%	100.0%	83.7%	16.3%	100.0%	72.1%	27.9%	100.0%
Week 44	1-Feb-13	79.5%	20.5%	100.0%	84.0%	16.0%	100.0%	75.1%	24.9%	100.0%
Week 45	8-Feb-13	79.8%	20.2%	100.0%	85.3%	14.7%	100.0%	75.1%	24.9%	100.0%
Week 46	15-Feb-13	78.4%	21.6%	100.0%	83.2%	16.8%	100.0%	73.6%	26.4%	100.0%
Week 47	22-Feb-13	78.3%	21.7%	100.0%	83.5%	16.5%	100.0%	73.3%	26.7%	100.0%
Week 48	1-Mar-13	78.1%	21.9%	100.0%	82.0%	18.0%	100.0%	74.3%	25.7%	100.0%
Week 49	8-Mar-13	75.7%	24.3%	100.0%	81.8%	18.2%	100.0%	70.3%	29.7%	100.0%
Week 50	15-Mar-13	76.5%	23.5%	100.0%	80.9%	19.1%	100.0%	72.2%	27.8%	100.0%
Week 51	22-Mar-13	73.0%	27.0%	100.0%	76.4%	23.6%	100.0%	69.7%	30.3%	100.0%
Week 52	29-Mar-13	73.2%	26.8%	100.0%	79.2%	20.8%	100.0%	68.1%	31.9%	100.0%
Week 53	5-Apr-13	74.0%	26.0%	100.0%	79.6%	20.4%	100.0%	68.4%	31.6%	100.0%
Week 54	12-Apr-13	73.6%	26.4%	100.0%	77.2%	22.8%	100.0%	70.5%	29.5%	100.0%
Week 55	19-Apr-13	73.8%	26.2%	100.0%	78.2%	21.8%	100.0%	69.5%	30.5%	100.0%
Week 56	26-Apr-13	70.3%	29.7%	100.0%	74.0%	26.0%	100.0%	67.1%	32.9%	100.0%
Week 57	3-May-13	69.9%	30.1%	100.0%	74.2%	25.8%	100.0%	66.0%	34.0%	100.0%
Week 58	10-May-13	69.8%	30.2%	100.0%	72.5%	27.5%	100.0%	67.6%	32.4%	100.0%
Week 59	17-May-13	69.4%	30.6%	100.0%	73.9%	26.1%	100.0%	65.7%	34.3%	100.0%
Week 60	24-May-13	69.2%	30.8%	100.0%	74.2%	25.8%	100.0%	65.2%	34.8%	100.0%
Week 61	31-May-13	64.7%	35.3%	100.0%	73.3%	26.7%	100.0%	57.5%	42.5%	100.0%
Week 62	7-Jun-13	69.3%	30.7%	100.0%	72.5%	27.5%	100.0%	66.8%	33.2%	100.0%
Week 63	14-Jun-13	65.5%	34.5%	100.0%	71.2%	28.8%	100.0%	60.7%	39.3%	100.0%
Week 64	21-Jun-13	66.9%	33.1%	100.0%	71.0%	29.0%	100.0%	63.6%	36.4%	100.0%
Week 65	28-Jun-13	66.1%	33.9%	100.0%	73.2%	26.8%	100.0%	60.1%	39.9%	100.0%
Week 66	5-Jul-13	64.5%	35.5%	100.0%	68.7%	31.3%	100.0%	61.1%	38.9%	100.0%
Week 67	12-Jul-13	65.5%	34.5%	100.0%	70.1%	29.9%	100.0%	62.0%	38.0%	100.0%
Week 68	19-Jul-13	66.3%	33.7%	100.0%	70.4%	29.6%	100.0%	63.0%	37.0%	100.0%
Week 69	26-Jul-13	66.1%	33.9%	100.0%	73.0%	27.0%	100.0%	60.1%	39.9%	100.0%
Week 70	2-Aug-13	66.7%	33.3%	100.0%	70.0%	30.0%	100.0%	64.0%	36.0%	100.0%
Week 71	9-Aug-13	65.1%	34.9%	100.0%	68.2%	31.8%	100.0%	62.5%	37.5%	100.0%
TOTAL	**2013**	**69.9%**	**27.3%**	**100.0%**	**76.5%**	**23.5%**	**100.0%**	**67.5%**	**32.5%**	**100.0%**
YTD	**2013**	**69.9%**	**27.3%**	**100.0%**	**76.5%**	**23.5%**	**100.0%**	**67.5%**	**32.5%**	**100.0%**

Weekly Growth in Intermezzo New, Refill and Total Prescriptions by Strength

Week #	Week Ending	Total NRx	Total RRx	Total TRx	1.75mg NRx	1.75mg RRx	1.75mg TRx	3.5mg NRx	3.5mg RRx	3.5mg TRx
Week 1*	6-Apr-12	NA	NA	NA	NA	NA	NA	NA	NA	NA
Week 2	13-Apr-12	345.7%	NA	345.7%	328.3%	NA	328.3%	369.2%	NA	369.2%
Week 3	20-Apr-12	13.4%	NA	14.1%	11.5%	NA	12.8%	15.8%	NA	15.8%
Week 4	27-Apr-12	-1.9%	66.7%	-1.5%	-0.8%	0.0%	-0.8%	-3.3%	NA	-2.4%
Week 5	4-May-12	19.7%	0.0%	19.5%	21.9%	-100.0%	20.5%	17.1%	150.0%	18.4%
Week 6	11-May-12	2.9%	280.0%	5.4%	4.6%	NA	7.5%	0.8%	100.0%	2.9%
Week 7	18-May-12	-4.1%	100.0%	-0.7%	-9.4%	44.4%	-7.9%	2.9%	150.0%	8.7%
Week 8	25-May-12	12.2%	2.6%	11.6%	6.6%	61.5%	8.9%	18.9%	-28.0%	14.6%
Week 9	1-Jun-12	-14.9%	17.9%	-12.9%	-12.6%	19.0%	-10.6%	-17.2%	16.7%	-15.3%
Week 10	8-Jun-12	38.1%


Intermezzo True Rx's (Source: IMS NPA/McKesson) 2013
TRXs (absolute)
8,000
7,000
6,000
5,000
4,000
3,000
2,000
1,000
-
6-Apr-12
20-Apr-12
4-May-12
18-May-12
1-Jun-12
15-Jun-12
29-Jun-12
13-Jul-12
27-Jul-12
10-Aug-12
24-Aug-12
7-Sep-12
21-Sep-12
5-Oct-12
19-Oct-12
2-Nov-12
16-Nov-12
30-Nov-12
14-Dec-12
28-Dec-12
11-Jan-13
25-Jan-13
8-Feb-13
22-Feb-13
8-Mar-13
22-Mar-13
5-Apr-13
19-Apr-13
3-May-13
17-May-13
31-May-13
14-Jun-13
28-Jun-13
12-Jul-13
26-Jul-13
9-Aug-13
23-Aug-13
Total Rx
True Rx
2013 Budget


Intermezzo True Rx's (Source: IMS NPA/McKesson)
2012
TRXs (absolute)
10,000
9,000
8,000
7,000
6,000
5,000
4,000
3,000
2,000
1,000
-
6-Apr-12
6-May-12
6-Jun-12
6-Jul-12
6-Aug-12
6-Sep-12
6-Oct-12
6-Nov-12
6-Dec-12
6-Jan-13
2012
Budget Rx
Total Rx


Total TRx, True Rx and Trial Card Redemptions (Source: IMS NPA/McKesson)
TRx (Absolute)
8,000
7,000
6,000
5,000
4,000
3,000
2,000
1,000
-
6-Apr-12
20-Apr-12
4-May-12
18-May-12
1-Jun-12
15-Jun-12
29-Jun-12
13-Jul-12
27-Jul-12
10-Aug-12
24-Aug-12
7-Sep-12
21-Sep-12
5-Oct-12
19-Oct-12
2-Nov-12
16-Nov-12
30-Nov-12
14-Dec-12
28-Dec-12
11-Jan-13
25-Jan-13
8-Feb-13
22-Feb-13
8-Mar-13
22-Mar-13
5-Apr-13
19-Apr-13
3-May-13
17-May-13
31-May-13
14-Jun-13
28-Jun-13
12-Jul-13
26-Jul-13
9-Aug-13
23-Aug-13
Total Rx
True Rx
Trial Card Redemptions
2013 Budget Rx


True Rx vs. Trial Card Redemptions (Source: IMS NPA/McKesson)
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
14-Sep-12
21-Sep-12
28-Sep-12
5-Oct-12
12-Oct-12
19-Oct-12
26-Oct-12
2-Nov-12
9-Nov-12
16-Nov-12
23-Nov-12
30-Nov-12
7-Dec-12
14-Dec-12
21-Dec-12
28-Dec-12
4-Jan-13
11-Jan-13
18-Jan-13
25-Jan-13
1-Feb-13
8-Feb-13
15-Feb-13
22-Feb-13
1-Mar-13
8-Mar-13
15-Mar-13
22-Mar-13
29-Mar-13
5-Apr-13
12-Apr-13
19-Apr-13
26-Apr-13
3-May-13
10-May-13
17-May-13
24-May-13
31-May-13
7-Jun-13
14-Jun-13
21-Jun-13
28-Jun-13
5-Jul-13
12-Jul-13
19-Jul-13
26-Jul-13
2-Aug-13
9-Aug-13
16-Aug-13
True Rx
Trial Card Redemptions

Intermezzo Total Rxs by Dosage Strength
Week ending August 9, 2013
(Source: IMS NPA)




Intermezzo Total NRx vs. Total RRx
Week ending August 9, 2013
(Source: IMS NPA)
RRx, 34.9%
NRx, 65.1%


Intermezzo Total Rx Share of Insomnia
0.160%
0.140%
0.120%
0.100%
0.080%
0.060%
0.040%
0.020%
0.000%
0.066%
0.080%
0.080%
0.080%
0.077%
0.072%
0.084%
0.092%
0.090%
0.083%
0.093%
0.091%
0.094%
0.094%
0.098%
0.097%
0.092%
0.088%
0.094%
0.105%
0.106%
0.085%
0.073%
0.087%
0.108%
0.116%
0.127%
0.128%
0.13
3-Aug-12
10-Aug-12
17-Aug-12
24-Aug-12
31-Aug-12
7-Sep-12
14-Sep-12
21-Sep-12
28-Sep-12
5-Oct-12
12-Oct-12
19-Oct-12
26-Oct-12
2-Nov-12
9-Nov-12
16-Nov-12
23-Nov-12
30-Nov-12
7-Dec-12
14-Dec-12
21-Dec-12
28-Dec-12
4-Jan-13
11-Jan-13
18-Jan-13
25-Jan-13
1-Feb-13
Share of Mar


Intermezzo True Rx Share of Insomnia Ma
0.140%
0.120%
0.100%
0.080%
0.060%
0.040%
0.020%
0.000%
0.057%
0.072%
0.071%
0.070%
0.069%
0.064%
0.076%
0.082%
0 082%
0.074%
0.086%
0.083%
0.085%
0.086%
0 090%
0.088%
0.085%
0.082%
0 086%
0.097%
0.099%
0 081%
0 068%
0.082%
0.097%
0.103%
0.112%
0.112%
0.1
3-Aug-12
10-Aug-12
17-Aug-12
24-Aug-12
31-Aug-12
7-Sep-12
14-Sep-12
21-Sep-12
28-Sep-12
5-Oct-12
12-Oct-12
19-Oct-12
26-Oct-12
2-Nov-12
9-Nov-12
16-Nov-12
23-Nov-12
30-Nov-12
7-Dec-12
14-Dec-12
21-Dec-12
28-Dec-12
4-Jan-13
11-Jan-13
18-Jan-13
25-Jan-13
1-Feb-13
Share of Ma

Source: IMS NPA Data
Data includes retail pharmacy, mail order and LTC channels
Numbers are absolute

	23-Mar-12	30-Mar-12	6-Apr-12	13-Apr-12
Total Market TRx	1,370,896	1,384,239	1,432,279	1,369,297
Intermezzo Total	-	0	92	410
Intermezzo True			88	392
Share of Market (Total TRx)			**0.006%**	**0.030%**
Share of Market (True TRx)			**0.006%**	**0.029%**

20-Apr-12	27-Apr-12	4-May-12	11-May-12	18-May-12	25-May-12
1,375,370	1,382,029	1,465,269	1,372,778	1,358,917	1,377,379
468	461	551	581	577	644
406	400	466	482	474	539
0.034%	**0.033%**	**0.038%**	**0.042%**	**0.042%**	**0.047%**
0.030%	**0.029%**	**0.032%**	**0.035%**	**0.035%**	**0.039%**

1-Jun-12	8-Jun-12	15-Jun-12	22-Jun-12	29-Jun-12	6-Jul-12	13-Jul-12
1,308,074	1,406,687	1,355,575	1,354,480	1,386,497	1,324,286	1,403,405
561	801	760	840	842	715	904
494	678	657	720	728	646	808
0.043%	**0.057%**	**0.056%**	**0.062%**	**0.061%**	**0.054%**	**0.064%**
0.038%	**0.048%**	**0.048%**	**0.053%**	**0.053%**	**0.049%**	**0.058%**

20-Jul-12	27-Jul-12	3-Aug-12	10-Aug-12	17-Aug-12	24-Aug-12
1,369,334	1,324,286	1,369,334	1,324,286	1,369,334	1,377,799
894	939	907	1,063	1,094	1,102
789	818	785	954	977	967
0.065%	**0.071%**	**0.066%**	**0.080%**	**0.080%**	**0.080%**
0.058%	**0.062%**	**0.057%**	**0.072%**	**0.071%**	**0.070%**

31-Aug-12	7-Sep-12	14-Sep-12	21-Sep-12	28-Sep-12
1,415,168	1,359,788	1,416,839	1,394,006	1,407,414
1,093	974	1,194	1,278	1,265
975	873	1,078	1,144	1,158
0.077%	**0.072%**	**0.084%**	**0.092%**	**0.090%**
0.069%	**0.064%**	**0.076%**	**0.082%**	**0.082%**

5-Oct-12	12-Oct-12	19-Oct-12	26-Oct-12	2-Nov-12
1,461,046	1,385,829	1,391,512	1,389,095	1,378,667
1,212	1,284	1,269	1,303	1,298
1,086	1,187	1,150	1,179	1,183
0.083%	**0.093%**	**0.091%**	**0.094%**	**0.094%**
0.074%	**0.086%**	**0.083%**	**0.085%**	**0.086%**

9-Nov-12	16-Nov-12	23-Nov-12	30-Nov-12	7-Dec-12
1,409,855	1,391,492	1,208,449	1,482,181	1,470,840
1,383	1,347	1,109	1,308	1,385
1,270	1,221	1,026	1,208	1,264
0.098%	**0.097%**	**0.092%**	**0.088%**	**0.094%**
0.090%	**0.088%**	**0.085%**	**0.082%**	**0.086%**

14-Dec-12	21-Dec-12	28-Dec-12	4-Jan-13	11-Jan-13
1,417,828	1,444,247	1,170,577	1,356,237	1,475,389
1,489	1,534	995	985	1,290
1,377	1,430	943	918	1,205
0.105%	**0.106%**	**0.085%**	**0.073%**	**0.087%**
0.097%	**0.099%**	**0.081%**	**0.068%**	**0.082%**

18-Jan-13	25-Jan-13	1-Feb-13	8-Feb-13	15-Feb-13
1,422,268	1,317,001	1,399,365	1,435,241	1,378,842
1,532	1,527	1,782	1,830	1,887
1,377	1,354	1,568	1,606	1,638
0.108%	**0.116%**	**0.127%**	**0.128%**	**0.137%**
0.097%	**0.103%**	**0.112%**	**0.112%**	**0.119%**

22-Feb-13	1-Mar-13	8-Mar-13	15-Mar-13	22-Mar-13
1,334,165	1,439,081	1,454,057	1,390,065	1,372,433
1,907	1,963	1,948	1,885	1,939
1,631	1,664	1,675	1,602	1,665
0.143%	**0.136%**	**0.134%**	**0.136%**	**0.141%**
0.122%	**0.116%**	**0.115%**	**0.115%**	**0.121%**

29-Mar-13	5-Apr-13	12-Apr-13	19-Apr-13	26-Apr-13
1,341,216	1,403,587	1,369,962	1,344,785	1,348,514
1,914	1,729	1,857	1,769	1,748
1,632	1,492	1,627	1,559	1,497
0.143%	**0.123%**	**0.136%**	**0.132%**	**0.130%**
0.122%	**0.106%**	**0.119%**	**0.116%**	**0.111%**

3-May-13	10-May-13	17-May-13	24-May-13	31-May-13
1,420,123	1,369,002	1,338,281	1,353,362	1,263,602
1,790	1,694	1,695	1,609	1,433
1,569	1,507	1,528	1,445	1,302
0.126%	**0.124%**	**0.127%**	**0.119%**	**0.113%**
0.110%	**0.110%**	**0.114%**	**0.107%**	**0.103%**

7-Jun-13	14-Jun-13	21-Jun-13	28-Jun-13	5-Jul-13
1,416,696	1,345,466	1,329,143	1,324,936	1,295,506
1,583	1,627	1,563	1,461	1,322
1,419	1,499	1,414	1,325	1,201
0.112%	**0.121%**	**0.118%**	**0.110%**	**0.102%**
0.100%	**0.111%**	**0.106%**	**0.100%**	**0.093%**

12-Jul-13	19-Jul-13	26-Jul-13	2-Aug-13	9-Aug-13
1,391,722	1,335,269	1,325,989	1,350,570	1,345,158
1,503	1,533	1,538	1,483	1,482
1,362	1,427	1,393	1,316	1,315
0.108%	**0.115%**	**0.116%**	**0.110%**	**0.110%**
0.098%	**0.107%**	**0.105%**	**0.097%**	**0.098%**

1/1 Week Growth
-0.4%
-0.1%
-0.1%

Intermezzo Total Rxs for the week ending			
Strength	NRx	RRx	TRxs
1.75mg	459	214	673
3.5mg	506	303	809
Total	965	517	1,482

Distribution of Total New versus Refill Rxs for Intermezzo			
Strength	NRx	RRx	TRxs
1.75mg	68.2%	31.8%	100.0%
3.5mg	62.5%	37.5%	100.0%
Total	65.1%	34.9%	100.0%

Distribution of Intermezzo Total Rxs by Strength			
Strength	NRx	RRx	TRx
1.75mg	47.6%	41.4%	45.4%
3.5mg	52.4%	58.6%	54.6%
Total	100.0%	100.0%	100.0%

August 9, 2013	
Trial Card Redemptions	"True" Rx
92	581
75	734
167	**1,315**

Intermezzo®
(ZOLPIDEM TARTRATE) sublingual tablet IV
1.75 mg | 3.5 mg

Data includes retail pharmacy, mail order and LT

	Total					% of Budget Achieved vs. True Rx's	
	2012 Budget Rx	2013 Mid-Year Update Forecast	Total Rx	True Rx		Weekly True Rx Vs Budget	Cumlative % True Rx vs Budget
6-Apr-12			92				
13-Apr-12			410				
20-Apr-12			468				
27-Apr-12			461				
4-May-12			551				
11-May-12			581				
18-May-12			577				
25-May-12			644				
1-Jun-12			561				
8-Jun-12			801				
15-Jun-12			760				
22-Jun-12			840				
29-Jun-12			842				
6-Jul-12			715				
13-Jul-12			904				
20-Jul-12			894				
27-Jul-12			939				
3-Aug-12			907				
10-Aug-12			1,063				
17-Aug-12			1,094				
24-Aug-12			1,102				
31-Aug-12			1,093				
7-Sep-12			974				
14-Sep-12			1,194				
21-Sep-12			1,278				
28-Sep-12			1,265				
5-Oct-12			1,212				
12-Oct-12			1,284				
19-Oct-12			1,269				
26-Oct-12			1,303				
2-Nov-12			1,298				
9-Nov-12			1,383				
16-Nov-12			1,347				
23-Nov-12			1,109				
30-Nov-12			1,308				

7-Dec-12			1,385				
14-Dec-12			1,489				
21-Dec-12			1,534				
28-Dec-12			995				
4-Jan-13		918	985	918		100.0%	100.0%
11-Jan-13		1,205	1,290	1,205		100.0%	100.0%
18-Jan-13		1,377	1,532	1,377		100.0%	100.0%
25-Jan-13		1,354	1,527	1,354		100.0%	100.0%
1-Feb-13		1,568	1,782	1,568		100.0%	100.0%
8-Feb-13		1,606	1,830	1,606		100.0%	100.0%
15-Feb-13		1,638	1,887	1,638		100.0%	100.0%
22-Feb-13		1,631	1,907	1,631		100.0%	100.0%
1-Mar-13		1,664	1,963	1,664		100.0%	100.0%
8-Mar-13		1,675	1,948	1,675		100.0%	100.0%
15-Mar-13		1,602	1,885	1,602		100.0%	100.0%
22-Mar-13		1,665	1,939	1,665		100.0%	100.0%
29-Mar-13		1,632	1,914	1,632		100.0%	100.0%
5-Apr-13		1,492	1,729	1,492		100.0%	100.0%
12-Apr-13		1,627	1,857	1,627		100.0%	100.0%
19-Apr-13		1,559	1,769	1,559		100.0%	100.0%
26-Apr-13		1,497	1,748	1,497		100.0%	100.0%
3-May-13		1,569	1,790	1,569		100.0%	100.0%
10-May-13		1,507	1,694	1,507		100.0%	100.0%
17-May-13		1,528	1,695	1,528		100.0%	100.0%
24-May-13		1,445	1,609	1,445		100.0%	100.0%
31-May-13		1,302	1,433	1,302		100.0%	100.0%
7-Jun-13		1,500	1,583	1,419		94.6%	99.8%
14-Jun-13		1,433	1,627	1,499		104.6%	100.0%
21-Jun-13		1,422	1,563	1,414		99.5%	99.9%
28-Jun-13		1,410	1,461	1,325		94.0%	99.7%
5-Jul-13		1,399	1,322	1,201		85.9%	99.2%
12-Jul-13		1,387	1,503	1,362		98.2%	99.2%
19-Jul-13		1,376	1,533	1,427		103.7%	99.3%
26-Jul-13		1,365	1,538	1,393		102.1%	99.4%
2-Aug-13		1,354	1,483	1,316		97.2%	99.4%
9-Aug-13		1,343	1,482	1,315		97.9%	99.3%
16-Aug-13		1,332					
23-Aug-13		1,321					
30-Aug-13		1,310					
6-Sep-13		1,299					
13-Sep-13		1,289					
20-Sep-13		1,278					
27-Sep-13		1,268					
4-Oct-13		1,258					
11-Oct-13		1,247					
18-Oct-13		1,237					
25-Oct-13		1,227					

1-Nov-13	1,217					
8-Nov-13	1,207					
15-Nov-13	1,198					
22-Nov-13	1,188					
29-Nov-13	1,178					
6-Dec-13	1,169					
13-Dec-13	1,159					
20-Dec-13	1,150					
27-Dec-13	1,140					

TC channels

% of TRx			
True Rx	**Trial Card Redemptions**	**True Rx**	**Trial Cards**
0%	0%	-	-
0%	0%	-	-
0%	0%	-	-
0%	0%	-	-
0%	0%	-	-
0%	0%	-	-
0%	0%	-	-
0%	0%	-	-
0%	0%	-	-
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		
0%	0%		

0%	0%		
0%	0%		
0%	0%		
0%	0%		
93%	0%		
93%	0%		
90%	0%		
89%	0%		
88%	0%		
88%	0%		
87%	0%		
86%	0%		
85%	0%		
86%	0%		
85%	0%		
86%	0%		
85%	0%		
86%	0%		
88%	0%		
88%	0%		
86%	0%		
88%	0%		
89%	0%		
90%	0%		
90%	0%		
91%	0%		
90%	0%		
92%	0%		
90%	0%		
91%	0%		
91%	0%		
91%	0%		
93%	0%		
91%	0%		
89%	0%		
89%	0%		


Intermezzo True Rx's (Source: IMS NP
TRXs (absolute)
2,500
2,000
1,500
1,000
500
-
6-Apr-12
20-Apr-12
4-May-12
18-May-12
1-Jun-12
15-Jun-12
29-Jun-12
13-Jul-12
27-Jul-12
10-Aug-12
24-Aug-12
7-Sep-12
21-Sep-12
5-Oct-12
19-Oct-12
2-Nov-12
16-Nov-12
30-Nov-12
14-Dec-12
28-Dec-12
11-Jan-13

A/McKesson) 2013
Total Rx
True Rx
2013 Mid-Year Update Forecast
8-Feb-13
22-Feb-13
8-Mar-13
22-Mar-13
5-Apr-13
19-Apr-13
3-May-13
17-May-13
31-May-13
14-Jun-13
28-Jun-13
12-Jul-13
26-Jul-13
9-Aug-13
23-Aug-13

Produced Natively

OxyContin Weekly TRx - Original Formulation and Reformulation

Source: IMS Health NPA

Retail Pharmacies, mail order and LTC

Numbers Are Absolute

notes:

		11-Jun-10	18-Jun-10	25-Jun-10	2-Jul-10
OxyContin	**Total**	128,530	129,279	131,627	140,649
	10MG	20,900	21,669	22,239	23,049
	15MG	2,689	2,602	2,715	2,874
	20MG	28,398	28,011	28,836	31,277
	30MG	10,274	10,551	10,354	11,062
	40MG	29,131	29,274	30,068	32,789
	60MG	9,650	9,844	9,622	10,348
	80MG	27,488	27,328	27,793	29,250
Generic OER	**Total**	33,210	32,501	32,204	33,775
	10MG	9,079	8,604	8,310	8,726
	20MG	12,743	12,749	12,646	12,981
	40MG	7,008	6,878	7,005	7,459
	80MG	4,380	4,270	4,243	4,609
Total OER	**Total**	161,740	161,780	163,831	174,424
	10MG	29,979	30,273	30,549	31,775
	15MG	2,689	2,602	2,715	2,874
	20MG	41,141	40,760	41,482	44,258
	30MG	10,274	10,551	10,354	11,062
	40MG	36,139	36,152	37,073	40,248
	60MG	9,650	9,844	9,622	10,348
	80MG	31,868	31,598	32,036	33,859

the data below was updated on 2/15/13 as part of change in reporting from retail pharmacies only to retail pharmacies, mail order and LTC. Older OxyContin data will not have all 3 channels as IMS did not begin tracking these until well after OxyContin launched

9-Jul-10	16-Jul-10	23-Jul-10	30-Jul-10	6-Aug-10	13-Aug-10	20-Aug-10	27-Aug-10
125,462	133,822	133,627	131,880	134,357	132,266	134,878	133,091
21,109	22,981	22,783	22,890	22,558	22,560	22,605	22,678
2,702	2,790	2,724	2,808	2,780	2,753	2,695	2,902
27,786	29,917	29,733	29,518	29,945	29,409	30,746	30,977
10,063	10,725	10,540	10,523	10,722	10,810	10,896	10,466
28,057	29,519	29,807	29,486	29,810	28,567	29,602	29,254
9,601	10,050	9,942	9,671	10,114	10,138	10,139	10,045
26,144	27,840	28,098	26,984	28,428	28,029	28,195	26,769
29,122	30,577	30,968	29,723	30,265	29,775	29,408	27,986
7,205	7,639	7,634	7,292	7,281	7,181	6,986	6,941
11,302	11,755	11,937	11,428	11,490	11,407	10,893	9,861
6,470	6,809	7,039	6,745	7,078	6,788	7,084	6,785
4,145	4,374	4,358	4,258	4,416	4,399	4,445	4,399
154,584	164,399	164,595	161,603	164,622	162,041	164,286	161,077
28,314	30,620	30,417	30,182	29,839	29,741	29,591	29,619
2,702	2,790	2,724	2,808	2,780	2,753	2,695	2,902
39,088	41,672	41,670	40,946	41,435	40,816	41,639	40,838
10,063	10,725	10,540	10,523	10,722	10,810	10,896	10,466
34,527	36,328	36,846	36,231	36,888	35,355	36,686	36,039
9,601	10,050	9,942	9,671	10,114	10,138	10,139	10,045
30,289	32,214	32,456	31,242	32,844	32,428	32,640	31,168

3-Sep-10	10-Sep-10	17-Sep-10	24-Sep-10	1-Oct-10	8-Oct-10	15-Oct-10
141,169	124,754	135,893	129,425	133,297	128,212	128,616
23,977	21,794	23,930	23,708	24,274	23,939	24,310
3,121	2,769	3,020	2,800	3,134	2,988	2,893
33,480	30,411	33,476	32,159	33,860	33,054	33,810
11,424	10,179	11,308	10,774	11,064	10,879	10,990
31,078	26,620	29,020	27,518	28,143	26,424	26,143
10,814	9,828	10,396	9,954	10,447	10,024	9,918
27,275	23,153	24,743	22,512	22,375	20,904	20,552
28,560	24,500	27,616	28,171	28,574	27,499	26,923
7,043	6,055	6,603	6,750	6,604	6,446	5,856
9,293	7,348	8,728	8,720	8,339	7,296	6,484
7,345	6,491	7,222	7,292	7,699	7,737	8,011
4,879	4,606	5,063	5,409	5,932	6,020	6,572
169,729	149,254	163,509	157,596	161,871	155,711	155,539
31,020	27,849	30,533	30,458	30,878	30,385	30,166
3,121	2,769	3,020	2,800	3,134	2,988	2,893
42,773	37,759	42,204	40,879	42,199	40,350	40,294
11,424	10,179	11,308	10,774	11,064	10,879	10,990
38,423	33,111	36,242	34,810	35,842	34,161	34,154
10,814	9,828	10,396	9,954	10,447	10,024	9,918
32,154	27,759	29,806	27,921	28,307	26,924	27,124

22-Oct-10	29-Oct-10	5-Nov-10	12-Nov-10	19-Nov-10	26-Nov-10	3-Dec-10	10-Dec-10
128,059	127,622	130,619	130,132	134,808	116,890	142,371	132,687
24,950	25,222	26,143	26,513	27,687	23,447	27,965	27,477
3,042	2,892	3,042	2,983	3,012	2,726	3,278	3,051
33,695	34,448	35,145	34,663	35,581	31,196	37,879	35,095
10,847	10,495	10,676	10,673	10,876	9,391	11,649	10,767
26,126	26,040	27,173	27,400	28,942	25,635	31,691	28,560
9,757	9,525	9,716	9,533	9,874	8,537	10,399	9,510
19,642	19,000	18,724	18,367	18,836	15,958	19,510	18,227
25,704	23,276	21,529	19,321	18,957	15,757	18,261	15,659
5,119	4,302	3,693	3,178	3,059	2,423	2,645	2,204
6,024	5,144	4,897	4,433	4,370	3,484	4,278	3,595
7,732	7,001	5,978	4,577	4,067	3,186	3,426	2,786
6,829	6,829	6,961	7,133	7,461	6,664	7,912	7,074
153,763	150,898	152,148	149,453	153,765	132,647	160,632	148,346
30,069	29,524	29,836	29,691	30,746	25,870	30,610	29,681
3,042	2,892	3,042	2,983	3,012	2,726	3,278	3,051
39,719	39,592	40,042	39,096	39,951	34,680	42,157	38,690
10,847	10,495	10,676	10,673	10,876	9,391	11,649	10,767
33,858	33,041	33,151	31,977	33,009	28,821	35,117	31,346
9,757	9,525	9,716	9,533	9,874	8,537	10,399	9,510
26,471	25,829	25,685	25,500	26,297	22,622	27,422	25,301

17-Dec-10	24-Dec-10	31-Dec-10	7-Jan-11	14-Jan-11	21-Jan-11	28-Jan-11
135,753	129,843	113,101	134,976	130,378	127,466	121,941
28,407	27,439	23,452	27,567	27,181	27,431	26,218
3,044	2,892	2,581	3,125	2,986	2,963	2,913
35,533	34,714	29,291	35,502	34,019	33,496	32,085
10,799	10,408	9,274	11,149	10,736	10,255	9,720
29,516	27,042	23,248	27,583	25,880	24,853	23,601
9,414	9,262	8,141	9,745	9,326	8,988	8,333
19,040	18,086	17,114	20,305	20,250	19,480	19,071
14,238	13,782	12,427	13,489	12,377	11,744	10,024
1,665	1,476	1,178	1,143	974	1,006	928
3,676	3,351	2,880	3,565	3,273	3,172	2,907
2,562	3,527	4,109	4,637	4,784	4,946	4,410
6,335	5,428	4,260	4,144	3,346	2,620	1,779
149,991	143,625	125,528	148,465	142,755	139,210	131,965
30,072	28,915	24,630	28,710	28,155	28,437	27,146
3,044	2,892	2,581	3,125	2,986	2,963	2,913
39,209	38,065	32,171	39,067	37,292	36,668	34,992
10,799	10,408	9,274	11,149	10,736	10,255	9,720
32,078	30,569	27,357	32,220	30,664	29,799	28,011
9,414	9,262	8,141	9,745	9,326	8,988	8,333
25,375	23,514	21,374	24,449	23,596	22,100	20,850

4-Feb-11	11-Feb-11	18-Feb-11	25-Feb-11	4-Mar-11	11-Mar-11	18-Mar-11	25-Mar-11
131,418	132,743	129,597	124,030	144,839	132,372	126,421	124,996
27,359	28,076	27,450	25,995	28,804	27,569	26,286	26,368
3,054	3,117	3,108	3,010	3,314	3,116	2,844	2,889
33,707	34,570	33,726	32,427	37,890	34,704	33,241	32,998
10,743	10,563	10,562	9,898	11,629	10,588	10,115	9,991
26,130	26,037	25,722	25,009	30,008	26,733	26,005	25,511
9,199	9,239	9,083	8,484	10,061	9,130	8,755	8,496
21,226	21,141	19,946	19,207	23,133	20,532	19,175	18,743
9,770	8,873	7,430	6,282	5,960	4,844	4,290	3,754
899	802	723	658	682	622	560	488
3,050	2,779	2,375	1,969	1,707	1,380	1,101	859
4,280	3,965	3,343	2,843	2,797	2,175	2,013	1,893
1,541	1,327	989	812	774	667	616	514
141,188	141,616	137,027	130,312	150,799	137,216	130,711	128,750
28,258	28,878	28,173	26,653	29,486	28,191	26,846	26,856
3,054	3,117	3,108	3,010	3,314	3,116	2,844	2,889
36,757	37,349	36,101	34,396	39,597	36,084	34,342	33,857
10,743	10,563	10,562	9,898	11,629	10,588	10,115	9,991
30,410	30,002	29,065	27,852	32,805	28,908	28,018	27,404
9,199	9,239	9,083	8,484	10,061	9,130	8,755	8,496
22,767	22,468	20,935	20,019	23,907	21,199	19,791	19,257

1-Apr-11	8-Apr-11	15-Apr-11	22-Apr-11	29-Apr-11	6-May-11	13-May-11
127,947	131,416	126,107	123,106	125,855	134,758	124,730
25,999	26,920	26,486	25,724	26,052	26,976	25,903
2,975	3,076	3,052	2,964	3,042	3,154	3,028
33,707	34,637	33,185	32,785	33,260	35,802	33,201
10,220	10,590	10,316	9,934	10,006	10,915	10,182
26,360	26,853	25,596	25,226	25,665	27,613	25,313
8,772	9,215	8,999	8,445	8,758	9,670	8,642
19,914	20,125	18,473	18,028	19,072	20,628	18,461
3,491	3,427	3,287	3,062	2,896	2,959	2,854
445	431	458	420	388	371	376
750	691	592	525	472	457	427
1,838	1,870	1,791	1,710	1,714	1,801	1,700
458	435	446	407	322	330	351
131,438	134,843	129,394	126,168	128,751	137,717	127,584
26,444	27,351	26,944	26,144	26,440	27,347	26,279
2,975	3,076	3,052	2,964	3,042	3,154	3,028
34,457	35,328	33,777	33,310	33,732	36,259	33,628
10,220	10,590	10,316	9,934	10,006	10,915	10,182
28,198	28,723	27,387	26,936	27,379	29,414	27,013
8,772	9,215	8,999	8,445	8,758	9,670	8,642
20,372	20,560	18,919	18,435	19,394	20,958	18,812

20-May-11	27-May-11	3-Jun-11	10-Jun-11	17-Jun-11	24-Jun-11	1-Jul-11
123,166	128,700	120,695	125,321	123,140	124,430	131,965
25,804	26,764	24,175	26,090	25,752	25,756	26,776
3,006	3,061	2,842	3,074	3,050	2,991	3,160
32,613	33,990	31,701	33,117	32,826	32,617	35,184
10,053	10,407	9,958	10,301	10,233	10,293	11,014
25,048	26,070	24,967	25,279	24,760	25,288	26,387
8,564	9,122	8,602	8,880	8,460	8,896	9,423
18,078	19,286	18,450	18,580	18,059	18,589	20,021
2,595	2,723	2,485	2,504	2,466	2,467	2,642
327	337	276	256	272	246	261
382	407	345	345	324	300	320
1,599	1,708	1,609	1,671	1,608	1,671	1,783
287	271	255	232	262	250	278
125,761	131,423	123,180	127,825	125,606	126,897	134,607
26,131	27,101	24,451	26,346	26,024	26,002	27,037
3,006	3,061	2,842	3,074	3,050	2,991	3,160
32,995	34,397	32,046	33,462	33,150	32,917	35,504
10,053	10,407	9,958	10,301	10,233	10,293	11,014
26,647	27,778	26,576	26,950	26,368	26,959	28,170
8,564	9,122	8,602	8,880	8,460	8,896	9,423
18,365	19,557	18,705	18,812	18,321	18,839	20,299

8-Jul-11	15-Jul-11	22-Jul-11	29-Jul-11	5-Aug-11	12-Aug-11	19-Aug-11
115,918	123,433	122,406	122,673	121,965	120,721	122,134
23,375	25,477	25,092	25,513	24,932	24,760	24,963
2,924	3,089	3,088	2,944	3,073	3,010	3,174
30,589	32,817	32,473	31,894	32,066	31,819	31,968
9,766	10,441	10,091	10,189	10,295	10,140	10,385
23,718	24,752	24,919	25,179	25,196	24,802	25,097
8,281	8,798	8,525	8,755	8,719	8,623	8,641
17,265	18,059	18,218	18,199	17,684	17,567	17,906
2,257	2,248	1,728	1,418	1,165	1,004	934
245	256	188	195	216	187	166
273	294	241	256	200	206	218
1,486	1,425	1,046	726	497	393	305
253	273	253	241	252	218	245
118,175	125,681	124,134	124,091	123,130	121,725	123,068
23,620	25,733	25,280	25,708	25,148	24,947	25,129
2,924	3,089	3,088	2,944	3,073	3,010	3,174
30,862	33,111	32,714	32,150	32,266	32,025	32,186
9,766	10,441	10,091	10,189	10,295	10,140	10,385
25,204	26,177	25,965	25,905	25,693	25,195	25,402
8,281	8,798	8,525	8,755	8,719	8,623	8,641
17,518	18,332	18,471	18,440	17,936	17,785	18,151

26-Aug-11	2-Sep-11	9-Sep-11	16-Sep-11	23-Sep-11	30-Sep-11	7-Oct-11
122,485	123,844	113,128	123,744	121,768	123,112	122,675
25,056	25,649	22,679	25,600	25,315	25,531	25,173
3,144	2,989	2,919	3,178	3,121	3,173	3,230
31,881	32,467	29,616	32,268	31,633	32,218	32,005
10,331	10,239	9,634	10,415	10,237	10,480	10,386
25,350	25,499	23,338	25,367	24,928	25,082	25,214
8,772	8,875	8,099	8,733	8,654	8,822	8,825
17,951	18,126	16,843	18,183	17,880	17,806	17,842
875	761	593	567	482	437	456
154	159	142	164	162	148	149
208	209	204	164	117	104	83
277	217	125	108	85	73	72
236	176	122	131	118	112	152
123,360	124,605	113,721	124,311	122,250	123,549	123,131
25,210	25,808	22,821	25,764	25,477	25,679	25,322
3,144	2,989	2,919	3,178	3,121	3,173	3,230
32,089	32,676	29,820	32,432	31,750	32,322	32,088
10,331	10,239	9,634	10,415	10,237	10,480	10,386
25,627	25,716	23,463	25,475	25,013	25,155	25,286
8,772	8,875	8,099	8,733	8,654	8,822	8,825
18,187	18,302	16,965	18,314	17,998	17,918	17,994

14-Oct-11	21-Oct-11	28-Oct-11	4-Nov-11	11-Nov-11	18-Nov-11	25-Nov-11	2-Dec-11
121,674	120,636	120,531	120,202	120,752	122,501	108,042	129,086
25,182	25,253	25,300	25,314	25,302	25,776	22,486	26,481
3,150	3,163	3,143	3,109	3,177	3,278	2,899	3,251
31,677	31,346	31,483	31,178	31,529	31,779	28,017	33,356
10,382	10,222	10,340	10,417	10,255	10,541	9,246	11,315
24,779	24,444	24,446	24,252	24,246	24,618	21,864	26,379
8,634	8,580	8,761	8,568	8,639	8,952	7,876	9,465
17,870	17,628	17,058	17,364	17,604	17,557	15,654	18,839
422	420	426	394	332	340	307	338
171	146	166	148	135	140	110	144
104	117	93	119	101	112	105	95
64	73	72	67	46	48	55	60
83	84	95	60	50	40	37	39
122,096	121,056	120,957	120,596	121,084	122,841	108,349	129,424
25,353	25,399	25,466	25,462	25,437	25,916	22,596	26,625
3,150	3,163	3,143	3,109	3,177	3,278	2,899	3,251
31,781	31,463	31,576	31,297	31,630	31,891	28,122	33,451
10,382	10,222	10,340	10,417	10,255	10,541	9,246	11,315
24,843	24,517	24,518	24,319	24,292	24,666	21,919	26,439
8,634	8,580	8,761	8,568	8,639	8,952	7,876	9,465
17,953	17,712	17,153	17,424	17,654	17,597	15,691	18,878

9-Dec-11	16-Dec-11	23-Dec-11	30-Dec-11	6-Jan-12	13-Jan-12	20-Jan-12
121,912	124,001	125,651	105,269	115,681	121,679	118,251
25,722	26,431	26,774	21,386	23,413	25,422	24,657
3,338	3,378	3,332	2,757	3,181	3,323	3,275
31,760	31,757	32,674	27,251	30,028	31,200	30,546
10,557	10,790	10,741	9,248	10,274	10,686	10,528
24,313	24,853	25,292	21,455	23,382	24,667	23,720
8,662	9,102	9,080	7,741	8,527	8,821	8,660
17,560	17,690	17,758	15,431	16,876	17,560	16,865
294	306	287	272	278	256	244
122	154	120	113	105	132	115
98	96	85	81	102	65	68
42	34	50	50	43	37	42
32	22	32	28	28	22	19
122,206	124,307	125,938	105,541	115,959	121,935	118,495
25,844	26,585	26,894	21,499	23,518	25,554	24,772
3,338	3,378	3,332	2,757	3,181	3,323	3,275
31,858	31,853	32,759	27,332	30,130	31,265	30,614
10,557	10,790	10,741	9,248	10,274	10,686	10,528
24,355	24,887	25,342	21,505	23,425	24,704	23,762
8,662	9,102	9,080	7,741	8,527	8,821	8,660
17,592	17,712	17,790	15,459	16,904	17,582	16,884

27-Jan-12	3-Feb-12	10-Feb-12	17-Feb-12	24-Feb-12	2-Mar-12	9-Mar-12	16-Mar-12
113,353	120,538	120,353	117,713	114,520	127,414	123,719	119,029
24,317	25,318	25,339	24,539	24,320	26,245	25,819	25,038
3,165	3,227	3,349	3,308	3,182	3,453	3,404	3,416
29,447	31,100	30,832	30,339	29,474	32,682	31,516	30,350
10,002	10,602	10,646	10,254	10,272	11,277	10,982	10,724
22,374	24,012	24,017	23,621	22,660	25,519	24,714	23,867
8,192	8,907	8,745	8,771	8,308	9,681	9,222	8,802
15,856	17,372	17,425	16,881	16,304	18,557	18,062	16,832
271	242	245	205	203	197	187	199
137	97	112	103	85	95	83	89
79	89	74	59	58	60	63	51
41	40	35	22	43	33	21	37
14	16	24	21	17	9	20	22
113,624	120,780	120,598	117,918	114,723	127,611	123,906	119,228
24,454	25,415	25,451	24,642	24,405	26,340	25,902	25,127
3,165	3,227	3,349	3,308	3,182	3,453	3,404	3,416
29,526	31,189	30,906	30,398	29,532	32,742	31,579	30,401
10,002	10,602	10,646	10,254	10,272	11,277	10,982	10,724
22,415	24,052	24,052	23,643	22,703	25,552	24,735	23,904
8,192	8,907	8,745	8,771	8,308	9,681	9,222	8,802
15,870	17,388	17,449	16,902	16,321	18,566	18,082	16,854

23-Mar-12	30-Mar-12	6-Apr-12	13-Apr-12	20-Apr-12	27-Apr-12	4-May-12
115,694	117,693	123,178	117,383	117,663	119,123	126,344
24,587	24,510	25,298	24,741	24,631	25,096	25,823
3,222	3,293	3,456	3,396	3,479	3,337	3,655
29,821	30,389	31,676	30,161	30,298	30,562	32,072
10,438	10,692	11,134	10,693	10,968	11,218	11,808
22,869	23,292	24,654	23,285	23,106	23,307	25,335
8,554	8,955	9,248	8,737	8,813	9,005	9,673
16,203	16,562	17,712	16,370	16,368	16,598	17,978
178	191	180	174	163	149	161
72	80	74	82	65	73	70
48	69	56	35	56	25	40
37	22	29	24	31	35	35
21	20	21	33	11	16	16
115,872	117,884	123,358	117,557	117,826	119,272	126,505
24,659	24,590	25,372	24,823	24,696	25,169	25,893
3,222	3,293	3,456	3,396	3,479	3,337	3,655
29,869	30,458	31,732	30,196	30,354	30,587	32,112
10,438	10,692	11,134	10,693	10,968	11,218	11,808
22,906	23,314	24,683	23,309	23,137	23,342	25,370
8,554	8,955	9,248	8,737	8,813	9,005	9,673
16,224	16,582	17,733	16,403	16,379	16,614	17,994

11-May-12	18-May-12	25-May-12	1-Jun-12	8-Jun-12	15-Jun-12	22-Jun-12
118,056	118,182	122,070	112,484	121,604	117,421	118,726
24,694	24,597	25,260	22,598	25,358	24,612	24,878
3,424	3,510	3,553	3,295	3,662	3,523	3,529
30,482	30,679	31,327	28,725	31,199	30,356	30,061
10,904	11,136	11,668	10,623	11,382	11,231	11,293
23,186	23,106	23,735	22,444	24,047	22,908	23,175
8,827	8,939	9,356	8,707	9,117	8,888	9,219
16,539	16,215	17,171	16,092	16,839	15,903	16,571
142	150	141	143	173	149	152
63	59	64	65	79	78	73
43	56	32	44	40	37	48
22	25	28	24	27	21	19
14	10	17	10	27	13	12
118,198	118,332	122,211	112,627	121,777	117,570	118,878
24,757	24,656	25,324	22,663	25,437	24,690	24,951
3,424	3,510	3,553	3,295	3,662	3,523	3,529
30,525	30,735	31,359	28,769	31,239	30,393	30,109
10,904	11,136	11,668	10,623	11,382	11,231	11,293
23,208	23,131	23,763	22,468	24,074	22,929	23,194
8,827	8,939	9,356	8,707	9,117	8,888	9,219
16,553	16,225	17,188	16,102	16,866	15,916	16,583

29-Jun-12	6-Jul-12	13-Jul-12	20-Jul-12	27-Jul-12	3-Aug-12	10-Aug-12
119,243	116,154	119,139	118,784	116,567	117,416	115,928
24,839	22,927	24,571	24,474	24,189	24,085	23,942
3,479	3,470	3,697	3,597	3,561	3,628	3,559
30,739	29,235	30,567	30,270	29,599	30,017	29,413
11,432	11,211	11,389	11,410	11,245	11,395	11,227
23,246	23,564	23,332	23,257	22,701	23,069	22,792
9,059	9,152	9,112	9,288	9,121	9,116	8,982
16,449	16,595	16,471	16,488	16,151	16,106	16,013
113	118	101	129	109	100	105
48	47	48	63	53	55	49
47	42	35	45	36	28	42
8	15	9	13	10	10	3
10	14	9	8	10	7	11
119,356	116,272	119,240	118,913	116,676	117,516	116,033
24,887	22,974	24,619	24,537	24,242	24,140	23,991
3,479	3,470	3,697	3,597	3,561	3,628	3,559
30,786	29,277	30,602	30,315	29,635	30,045	29,455
11,432	11,211	11,389	11,410	11,245	11,395	11,227
23,254	23,579	23,341	23,270	22,711	23,079	22,795
9,059	9,152	9,112	9,288	9,121	9,116	8,982
16,459	16,609	16,480	16,496	16,161	16,113	16,024

17-Aug-12	24-Aug-12	31-Aug-12	7-Sep-12	14-Sep-12	21-Sep-12	28-Sep-12
118,476	117,202	119,054	113,825	119,368	118,261	119,766
24,305	24,548	24,950	23,222	24,886	24,754	25,350
3,736	3,484	3,695	3,489	3,852	3,740	3,984
30,096	29,863	30,281	28,823	30,288	30,197	30,675
11,692	11,402	11,620	11,057	11,678	11,500	11,732
23,006	22,555	23,184	22,363	23,113	22,709	23,197
9,268	9,253	9,188	8,884	9,268	9,297	9,042
16,373	16,097	16,136	15,987	16,283	16,064	15,786
94	94	70	85	66	38	59
41	50	29	45	34	22	29
34	22	20	28	18	10	19
10	11	8	5	6	1	5
9	11	13	7	8	5	6
118,570	117,296	119,124	113,910	119,434	118,299	119,825
24,346	24,598	24,979	23,267	24,920	24,776	25,379
3,736	3,484	3,695	3,489	3,852	3,740	3,984
30,130	29,885	30,301	28,851	30,306	30,207	30,694
11,692	11,402	11,620	11,057	11,678	11,500	11,732
23,016	22,566	23,192	22,368	23,119	22,710	23,202
9,268	9,253	9,188	8,884	9,268	9,297	9,042
16,382	16,108	16,149	15,994	16,291	16,069	15,792

5-Oct-12	12-Oct-12	19-Oct-12	26-Oct-12	2-Nov-12	9-Nov-12	16-Nov-12	23-Nov-12
121,919	117,232	118,675	118,211	116,115	121,778	120,116	108,593
25,838	24,616	25,288	25,395	24,696	26,154	26,215	23,221
3,855	3,786	3,765	3,828	3,765	3,932	3,921	3,491
30,727	29,825	30,326	30,000	29,535	30,912	30,176	27,610
11,835	11,606	11,565	11,566	11,440	11,920	11,644	10,833
23,543	22,555	22,590	22,546	22,344	23,004	22,628	20,580
9,437	9,086	9,190	9,068	8,909	9,562	9,410	8,376
16,684	15,758	15,951	15,808	15,426	16,294	16,122	14,482
59	43	29	43	32	21	30	19
32	21	14	27	18	13	17	9
18	6	12	12	11	5	12	7
4	10	1		3	3		2
5	6	2	4			1	1
121,978	117,275	118,704	118,254	116,147	121,799	120,146	108,612
25,870	24,637	25,302	25,422	24,714	26,167	26,232	23,230
3,855	3,786	3,765	3,828	3,765	3,932	3,921	3,491
30,745	29,831	30,338	30,012	29,546	30,917	30,188	27,617
11,835	11,606	11,565	11,566	11,440	11,920	11,644	10,833
23,547	22,565	22,591	22,546	22,347	23,007	22,628	20,582
9,437	9,086	9,190	9,068	8,909	9,562	9,410	8,376
16,689	15,764	15,953	15,812	15,426	16,294	16,123	14,483

30-Nov-12	7-Dec-12	14-Dec-12	21-Dec-12	28-Dec-12	4-Jan-13	11-Jan-13
123,659	125,259	120,714	125,619	101,167	112,524	120,276
26,489	26,517	26,051	27,077	21,021	23,087	25,231
4,109	4,032	4,026	4,170	3,207	3,595	4,111
31,374	31,846	30,640	31,888	25,515	28,300	30,360
12,244	12,447	12,006	12,563	10,004	11,327	11,931
23,701	23,716	22,772	23,677	19,428	21,885	23,056
9,642	9,734	9,380	9,610	8,046	8,923	9,488
16,100	16,967	15,839	16,634	13,946	15,407	16,099
19	16	15	19	17	11	18
11	8	8	6	6	3	10
4	6	6	8	7	2	3
2			4	4	3	1
2	2	1	1		3	4
123,678	125,275	120,729	125,638	101,184	112,535	120,294
26,500	26,525	26,059	27,083	21,027	23,090	25,241
4,109	4,032	4,026	4,170	3,207	3,595	4,111
31,378	31,852	30,646	31,896	25,522	28,302	30,363
12,244	12,447	12,006	12,563	10,004	11,327	11,931
23,703	23,716	22,772	23,681	19,432	21,888	23,057
9,642	9,734	9,380	9,610	8,046	8,923	9,488
16,102	16,969	15,840	16,635	13,946	15,410	16,103

18-Jan-13	25-Jan-13	1-Feb-13	8-Feb-13	15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13
118,988	108,221	115,072	121,640	117,664	109,872	120,657	123,202
25,634	23,858	24,986	26,132	25,813	24,646	25,914	26,268
3,971	3,681	3,765	4,144	3,910	3,804	4,030	4,198
29,828	27,539	28,981	30,406	29,720	27,875	30,374	31,167
12,055	10,790	11,542	12,411	11,513	11,117	12,375	12,450
22,211	20,069	21,557	22,693	22,037	20,090	22,469	23,244
9,336	8,328	9,012	9,660	9,086	8,397	9,655	9,514
15,953	13,956	15,229	16,194	15,585	13,943	15,840	16,361
25	8	18	11	14	20	17	13
17	5	9	7	13	14	6	5
8		3	2		1	5	3
		3	1		1	4	
	3	3	1	1	4	2	5
119,013	108,229	115,090	121,651	117,678	109,892	120,674	123,215
25,651	23,863	24,995	26,139	25,826	24,660	25,920	26,273
3,971	3,681	3,765	4,144	3,910	3,804	4,030	4,198
29,836	27,539	28,984	30,408	29,720	27,876	30,379	31,170
12,055	10,790	11,542	12,411	11,513	11,117	12,375	12,450
22,211	20,069	21,560	22,694	22,037	20,091	22,473	23,244
9,336	8,328	9,012	9,660	9,086	8,397	9,655	9,514
15,953	13,959	15,232	16,195	15,586	13,947	15,842	16,366

15-Mar-13	22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13	19-Apr-13	26-Apr-13	3-May-13
116,106	111,519	110,562	116,985	113,283	109,820	111,523	119,075
25,511	24,829	24,147	24,786	24,574	24,247	24,428	25,505
3,983	3,849	3,806	4,016	4,071	3,886	3,884	4,204
29,367	28,215	27,841	29,443	28,561	27,759	28,034	29,677
11,612	11,419	11,413	11,917	11,576	11,535	11,556	12,166
21,400	20,358	20,331	22,027	20,935	20,003	20,692	22,404
9,026	8,713	8,840	9,295	8,954	8,650	8,791	9,372
15,207	14,136	14,184	15,501	14,612	13,740	14,138	15,747
15	15	8	14	17	13	12	9
12	9	7	11	10	6	11	5
3	6		2	2	5		2
		1	1	5	2	1	
							2
116,121	111,534	110,570	116,999	113,300	109,833	111,535	119,084
25,523	24,838	24,154	24,797	24,584	24,253	24,439	25,510
3,983	3,849	3,806	4,016	4,071	3,886	3,884	4,204
29,370	28,221	27,841	29,445	28,563	27,764	28,034	29,679
11,612	11,419	11,413	11,917	11,576	11,535	11,556	12,166
21,400	20,358	20,332	22,028	20,940	20,005	20,693	22,404
9,026	8,713	8,840	9,295	8,954	8,650	8,791	9,372
15,207	14,136	14,184	15,501	14,612	13,740	14,138	15,749

10-May-13	17-May-13	24-May-13	31-May-13	7-Jun-13	14-Jun-13	21-Jun-13	28-Jun-13
114,849	110,628	115,142	105,510	119,269	111,927	112,247	112,343
24,914	24,582	25,086	22,589	25,704	25,022	24,707	24,539
4,142	4,010	4,155	3,865	4,318	4,120	4,050	4,059
29,288	28,309	29,165	26,604	30,155	28,142	28,339	28,142
11,779	11,585	11,976	10,936	12,213	11,836	11,765	11,769
20,933	19,867	21,012	19,640	22,124	19,962	20,610	20,531
9,166	8,664	9,204	8,305	9,380	8,759	8,918	8,949
14,627	13,611	14,544	13,571	15,375	14,086	13,858	14,354
1	13	10	6	21	8	8	9
	5	4		10	4	5	7
	7	3	4	9	3	3	2
1		1	2	2			
	1	2			1		
114,850	110,641	115,152	105,516	119,290	111,935	112,255	112,352
24,914	24,587	25,090	22,589	25,714	25,026	24,712	24,546
4,142	4,010	4,155	3,865	4,318	4,120	4,050	4,059
29,288	28,316	29,168	26,608	30,164	28,145	28,342	28,144
11,779	11,585	11,976	10,936	12,213	11,836	11,765	11,769
20,934	19,867	21,013	19,642	22,126	19,962	20,610	20,531
9,166	8,664	9,204	8,305	9,380	8,759	8,918	8,949
14,627	13,612	14,546	13,571	15,375	14,087	13,858	14,354

5-Jul-13	12-Jul-13	19-Jul-13	26-Jul-13	2-Aug-13	9-Aug-13	16-Aug-13	1/1 Week Growth
111,143	114,323	113,158	111,365	112,367	111,677		-0.6%
23,583	25,049	24,866	23,971	24,485	24,322		-0.7%
4,071	4,348	4,135	4,200	4,116	4,358		5.9%
27,513	28,910	28,341	27,891	28,208	28,178		-0.1%
11,735	12,090	12,190	11,902	11,903	11,888		-0.1%
21,001	20,647	20,674	20,436	20,704	20,082		-3.0%
8,907	8,897	9,083	8,953	8,842	8,909		0.8%
14,333	14,382	13,869	14,012	14,109	13,940		-1.2%
13	11	14	8	8	8		0.0%
6	5	9	5	2	5		150.0%
5	3	2	1	6	2		-66.7%
2		1					#DIV/0!
	3	2	2		1		#DIV/0!
111,156	114,334	113,172	111,373	112,375	111,685		-0.6%
23,589	25,054	24,875	23,976	24,487	24,327		-0.7%
4,071	4,348	4,135	4,200	4,116	4,358		5.9%
27,518	28,913	28,343	27,892	28,214	28,180		-0.1%
11,735	12,090	12,190	11,902	11,903	11,888		-0.1%
21,003	20,647	20,675	20,436	20,704	20,082		-3.0%
8,907	8,897	9,083	8,953	8,842	8,909		0.8%
14,333	14,385	13,871	14,014	14,109	13,941		-1.2%

3/3 Week Growth	6/6 Week Growth
-0.9%	-0.4%
-1.0%	-0.9%
1.0%	2.7%
-0.6%	-0.9%
-0.9%	1.7%
-1.8%	-0.3%
-0.7%	0.1%
-1.2%	-1.3%
-36.8%	0.0%
-40.0%	6.7%
-10.0%	-20.8%
-100.0%	-40.0%
-40.0%	166.7%
-1.0%	-0.4%
-1.0%	-0.9%
1.0%	2.7%
-0.6%	-0.9%
-0.9%	1.7%
-1.8%	-0.3%
-0.7%	0.1%
-1.2%	-1.3%

Total Branded OxyContin

"= needs to be

Gross Up	0.55%	1.0055

notes: in Feb 2013, we changed to reporting from retail pharmacy only
the weekly budget is based on the agreed upon full year total, tl

	4-Jan-13	11-Jan-13	18-Jan-13	25-Jan-13
Actual Weekly TRx	112,524	120,276	118,988	108,221
Grossed Up Weekly TRx	113,143	120,938	119,642	108,816
YTD Grossed Up Weekly TRx	113,143	234,080	353,723	462,539
Budget TRx	115,687	121,404	117,758	112,236
YTD Budget Total	115,687	237,091	354,849	467,085
Weekly Difference	(2,544)	(467)	1,885	(3,420)
YTD Total Difference	(2,544)	(3,011)	(1,126)	(4,546)
Weekly % Difference	-2.2%	-0.4%	1.6%	-3.0%

New Numbers	
2013 TRx Goal	6,037,235
YTD Rolling Grossed Up Weekly TRx	3,673,028
Difference	2,364,207
Remaining Weeks	20
Revised 2012 Weekly TRx Goal	118,210

Goal to date	3,747,426
Actual to date (grossed up)	3,673,028
YTD Difference	-2.0%

: updated

to reporting retail pharmacies, mail order and LTC. The gross up simply reflects the recent difference
hen phased

1-Feb-13	8-Feb-13	15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13	15-Mar-13
115,072	121,640	117,664	109,872	120,657	123,202	116,106
115,705	122,309	118,311	110,476	121,321	123,880	116,745
578,244	700,553	818,864	929,340	1,050,661	1,174,541	1,291,285
115,207	114,753	112,314	108,273	123,591	119,804	114,547
582,292	697,045	809,359	917,632	1,041,223	1,161,027	1,275,574
498	7,556	5,997	2,203	(2,270)	4,076	2,197
(4,048)	3,508	9,505	11,708	9,438	13,514	15,711
0.4%	6.6%	5.3%	2.0%	-1.8%	3.4%	1.9%

between weekly and monthly Rx's over a 12 month period

22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13	19-Apr-13	26-Apr-13	3-May-13
111,519	110,562	116,985	113,283	109,820	111,523	119,075
112,132	111,170	117,628	113,906	110,424	112,136	119,730
1,403,418	1,514,588	1,632,216	1,746,122	1,856,546	1,968,683	2,088,412
111,238	113,687	125,840	119,544	119,811	121,039	125,092
1,386,812	1,500,499	1,626,339	1,745,883	1,865,694	1,986,733	2,111,825
895	(2,517)	(8,212)	(5,638)	(9,387)	(8,903)	(5,362)
16,606	14,089	5,877	240	(9,148)	(18,050)	(23,412)
0.8%	-2.2%	-6.5%	-4.7%	-7.8%	-7.4%	-4.3%

10-May-13	17-May-13	24-May-13	31-May-13	7-Jun-13	14-Jun-13	21-Jun-13
114,849	110,628	115,142	105,510	119,269	111,927	112,247
115,481	111,236	115,775	106,090	119,925	112,543	112,864
2,203,893	2,315,130	2,430,905	2,536,995	2,656,920	2,769,463	2,882,327
116,368	116,112	120,508	108,465	117,624	113,262	114,207
2,228,192	2,344,304	2,464,812	2,573,277	2,690,901	2,804,163	2,918,370
(887)	(4,876)	(4,733)	(2,375)	2,301	(719)	(1,343)
(24,299)	(29,175)	(33,907)	(36,282)	(33,981)	(34,701)	(36,043)
-0.8%	-4.2%	-3.9%	-2.2%	2.0%	-0.6%	-1.2%

28-Jun-13	5-Jul-13	12-Jul-13	19-Jul-13	26-Jul-13	2-Aug-13	9-Aug-13
112,343	111,143	114,323	113,158	111,365	112,367	111,677
112,961	111,754	114,952	113,780	111,978	112,985	112,291
2,995,288	3,107,042	3,221,994	3,335,774	3,447,752	3,560,737	3,673,028
115,360	117,630	120,357	119,919	117,559	119,679	118,551
3,033,730	3,151,360	3,271,718	3,391,637	3,509,196	3,628,875	3,747,426
(2,399)	(5,876)	(5,406)	(6,139)	(5,581)	(6,694)	(6,260)
(38,442)	(44,318)	(49,724)	(55,862)	(61,444)	(68,138)	(74,397)
-2.1%	-5.0%	-4.5%	-5.1%	-4.7%	-5.6%	-5.3%

16-Aug-13	23-Aug-13	30-Aug-13	6-Sep-13	13-Sep-13	20-Sep-13	27-Sep-13
120,708	119,089	115,023	110,440	115,685	114,074	115,729

4-Oct-13	11-Oct-13	18-Oct-13	25-Oct-13	1-Nov-13	8-Nov-13	15-Nov-13
118,520	117,059	117,551	117,540	113,593	116,583	114,587

22-Nov-13	29-Nov-13	6-Dec-13	13-Dec-13	20-Dec-13	27-Dec-13
103,144	115,825	117,538	112,710	117,934	96,477

OxyContin Weekly Tablets Dispensed Per Rx

IMS Health NPA

	8-Apr-11	15-Apr-11	22-Apr-11	29-Apr-11	6-May-11	13-May-11	20-May-11
10MG	54.93	53.90	54.07	53.95	55.14	54.06	53.89
15MG	59.58	59.05	58.56	58.97	58.71	60.03	59.35
20MG	66.14	66.06	66.05	65.95	66.80	66.25	65.99
30MG	65.43	65.33	65.18	66.63	65.70	64.93	65.84
40MG	76.54	75.93	75.30	76.39	76.43	76.46	75.51
60MG	72.89	73.23	72.29	72.85	72.39	73.40	73.46
80MG	93.04	93.22	93.53	92.68	92.57	93.66	92.35
Total	70.35	69.77	69.64	70.01	70.51	70.08	69.61

27-May-11	3-Jun-11	10-Jun-11	17-Jun-11	24-Jun-11	1-Jul-11	8-Jul-11	15-Jul-11	22-Jul-11	29-Jul-11
54.19	54.26	54.89	53.98	54.04	55.08	54.90	54.46	54.51	54.48
60.17	58.44	58.94	58.25	60.37	59.94	58.39	59.44	59.22	59.81
65.68	66.14	66.35	65.71	66.27	66.82	66.26	65.82	66.01	66.58
66.27	65.34	65.75	65.77	66.07	66.00	65.65	65.39	66.61	65.53
77.13	75.61	76.38	76.03	77.24	76.61	75.69	76.25	77.10	76.92
72.79	72.91	73.12	73.09	73.18	72.58	72.96	73.35	74.46	73.68
93.07	91.62	92.84	93.20	93.62	94.11	92.98	92.99	93.17	93.42
70.14	69.85	70.16	69.69	70.39	70.71	70.11	69.88	70.42	70.42

5-Aug-11	12-Aug-11	19-Aug-11	26-Aug-11	2-Sep-11	9-Sep-11	16-Sep-11	23-Sep-11	30-Sep-11
54.21	54.62	53.98	54.34	55.19	54.20	53.98	54.56	53.78
59.38	60.21	58.67	59.29	59.74	59.96	59.66	59.90	59.94
65.88	65.81	66.03	66.10	66.14	66.42	66.46	66.77	66.29
65.51	65.24	65.36	66.18	66.09	66.08	65.06	65.81	65.99
76.87	76.12	77.20	76.35	76.59	76.51	77.48	76.77	76.35
72.79	72.78	73.43	72.99	72.84	72.86	73.55	73.40	73.07
93.13	92.64	93.08	93.16	92.85	92.35	93.13	93.44	93.22
70.02	69.85	70.10	70.11	70.26	70.18	70.27	70.41	69.94

7-Oct-11	14-Oct-11	21-Oct-11	28-Oct-11	4-Nov-11	11-Nov-11	18-Nov-11	25-Nov-11	2-Dec-11
54.37	53.69	54.42	53.63	53.97	53.41	53.69	53.75	54.34
58.96	58.95	59.69	59.12	58.28	58.94	58.37	58.94	59.49
65.80	65.87	65.59	65.39	65.82	65.61	65.68	65.10	66.35
66.40	65.15	66.20	65.91	66.05	65.98	66.40	65.67	66.88
76.22	76.86	76.40	76.73	76.03	77.07	76.72	75.68	76.29
73.13	73.44	74.40	73.61	73.53	73.01	74.12	73.41	73.86
92.71	92.99	92.57	92.35	92.32	92.96	92.26	92.34	92.50
69.91	69.86	69.91	69.52	69.59	69.73	69.67	69.32	70.16

9-Dec-11	16-Dec-11	23-Dec-11	30-Dec-11	6-Jan-12	13-Jan-12	20-Jan-12	27-Jan-12	3-Feb-12
53.43	53.85	54.23	54.18	54.76	53.72	54.06	53.11	53.61
60.25	58.53	59.63	58.60	60.51	59.69	59.00	59.46	60.42
65.31	65.94	65.85	66.29	65.65	65.65	66.00	65.68	65.33
66.78	66.22	66.50	66.45	66.23	66.28	65.79	67.02	67.22
76.97	76.60	76.42	75.84	75.76	76.46	75.74	75.76	76.25
73.24	73.17	74.04	73.67	72.54	73.75	73.49	73.70	73.44
93.15	92.40	93.62	92.99	91.69	91.81	92.50	91.79	92.39
69.69	69.63	69.91	70.05	69.71	69.61	69.58	69.15	69.58

10-Feb-12	17-Feb-12	24-Feb-12	2-Mar-12	9-Mar-12	16-Mar-12	23-Mar-12	30-Mar-12	6-Apr-12
54.35	54.18	52.67	53.82	53.65	53.49	53.33	53.96	53.43
59.90	60.06	59.50	61.42	60.90	60.06	59.84	58.27	59.47
65.94	65.95	65.36	65.69	65.62	65.15	65.33	65.49	65.44
66.59	66.78	66.56	67.45	67.12	66.63	66.37	66.18	66.57
76.29	76.62	75.93	76.36	75.90	75.63	75.19	76.23	75.34
73.40	74.04	74.02	73.74	73.81	73.34	73.50	73.57	74.12
91.97	92.35	92.18	91.61	92.12	92.18	92.19	91.35	91.65
69.76	69.93	69.15	69.81	69.66	69.21	69.04	69.33	69.31

13-Apr-12	20-Apr-12	27-Apr-12	4-May-12	11-May-12	18-May-12	25-May-12	1-Jun-12	8-Jun-12
53.80	53.34	53.85	53.91	53.51	53.64	53.84	53.65	53.94
59.51	59.96	59.49	59.21	59.85	59.91	60.71	59.36	59.07
65.62	65.20	65.16	65.57	65.07	64.85	64.72	65.55	65.49
66.08	66.43	66.09	66.35	65.86	66.34	66.14	65.78	66.04
75.54	75.36	76.24	75.54	75.83	76.14	75.34	75.02	76.03
73.06	73.65	73.05	73.71	73.51	73.53	72.69	73.62	72.86
91.91	91.57	92.68	91.72	91.77	91.66	92.78	91.02	92.49
69.18	68.97	69.30	69.42	69.06	69.05	69.11	69.16	69.32

15-Jun-12	22-Jun-12	29-Jun-12	6-Jul-12	13-Jul-12	20-Jul-12	27-Jul-12	3-Aug-12	10-Aug-12	17-Aug-12
53.68	53.27	53.61	54.42	54.26	53.97	53.49	53.75	53.19	53.57
59.31	59.80	59.56	59.08	59.57	59.33	59.52	62.05	60.09	59.63
65.18	65.36	65.37	65.60	65.21	65.45	65.26	65.25	64.98	65.20
65.55	65.80	66.02	66.04	65.53	66.08	66.31	66.05	65.42	65.82
75.37	76.16	75.80	75.32	74.74	75.35	75.36	74.83	75.64	74.94
73.47	73.23	73.96	73.08	74.06	73.26	74.27	73.98	73.24	72.09
92.23	92.32	91.86	91.04	90.90	92.05	91.53	91.78	91.16	91.64
68.91	69.19	69.15	69.44	68.90	69.20	69.06	69.07	68.79	68.79

24-Aug-12	31-Aug-12	7-Sep-12	14-Sep-12	21-Sep-12	28-Sep-12	5-Oct-12	12-Oct-12	19-Oct-12
53.42	53.54	53.61	53.27	53.54	53.02	53.19	52.94	52.94
60.09	60.42	59.63	58.56	60.20	59.48	58.83	58.35	60.20
65.22	65.30	65.04	64.97	64.94	65.13	65.02	64.50	64.69
66.59	65.53	64.76	65.71	65.72	65.90	65.53	65.55	65.73
75.45	75.24	74.68	75.23	75.21	75.24	74.95	74.59	74.65
73.53	73.39	72.87	73.62	73.21	74.11	73.00	73.38	73.93
91.34	91.77	91.60	91.19	92.18	91.62	91.92	91.44	92.26
68.94	68.86	68.75	68.63	68.80	68.58	68.58	68.23	68.46

26-Oct-12	2-Nov-12	9-Nov-12	16-Nov-12	23-Nov-12	30-Nov-12	7-Dec-12	14-Dec-12	21-Dec-12
52.45	52.53	52.76	52.13	52.45	53.61	52.87	52.06	52.61
58.83	59.04	60.59	59.46	59.84	58.50	59.69	60.45	59.51
64.52	64.48	64.99	64.21	64.63	64.77	65.10	64.59	64.92
65.53	65.58	66.20	66.12	65.26	65.78	66.06	65.97	65.68
74.73	74.29	75.02	74.99	74.91	74.27	75.49	74.69	74.94
72.95	72.45	74.17	72.85	72.39	73.09	73.95	73.81	73.77
91.91	91.11	91.35	91.79	91.56	92.13	91.44	92.84	92.59
68.10	67.90	68.48	68.01	68.07	68.30	68.66	68.21	68.39

28-Dec-12	4-Jan-13	11-Jan-13	18-Jan-13	25-Jan-13	1-Feb-13	8-Feb-13	15-Feb-13	22-Feb-13
52.75	53.21	52.29	51.79	50.48	50.04	50.67	50.80	50.09
60.20	58.62	58.52	57.98	59.48	58.25	57.57	57.82	57.04
64.40	64.45	64.11	64.37	62.75	63.71	63.25	63.16	62.58
65.05	65.64	65.06	64.67	64.02	64.28	65.01	65.05	65.05
74.46	73.06	74.28	74.19	73.71	73.87	74.27	74.45	73.64
73.85	73.67	72.93	73.56	73.27	73.11	73.11	72.09	72.55
90.80	89.97	90.46	91.52	90.90	90.25	91.29	91.10	89.33
68.23	67.98	67.71	67.67	66.53	66.77	67.10	66.96	66.02

1-Mar-13	8-Mar-13	15-Mar-13	22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13	19-Apr-13	26-Apr-13
50.67	50.82	50.15	50.64	50.15	51.26	51.10	50.31	50.38
59.83	57.78	57.27	59.11	56.75	57.22	57.19	57.09	57.09
63.81	63.50	63.00	63.16	63.37	63.13	63.37	63.09	62.75
64.73	64.43	64.19	64.37	64.35	64.98	64.17	63.86	64.29
74.01	74.37	73.30	73.73	73.66	73.53	73.05	72.85	73.18
72.63	73.03	72.46	71.34	72.05	72.71	71.53	71.93	72.12
90.85	91.41	91.16	90.14	89.72	90.48	90.01	90.20	90.22
67.10	67.19	66.42	66.35	66.32	66.94	66.44	66.02	66.17

3-May-13	10-May-13	17-May-13	24-May-13	31-May-13	7-Jun-13	14-Jun-13	21-Jun-13	28-Jun-13
50.85	50.00	50.34	50.41	50.28	50.82	50.49	50.30	50.43
57.85	57.15	56.90	55.93	57.01	55.77	56.77	56.90	57.49
63.28	62.77	63.00	62.44	62.56	63.03	62.81	63.14	62.51
65.00	64.58	64.34	64.85	63.65	63.96	63.57	64.32	63.89
73.44	73.93	73.19	72.67	72.84	73.30	73.15	72.62	73.18
72.70	72.12	71.69	71.72	71.06	72.35	71.42	71.28	72.28
90.43	88.95	89.16	89.38	89.78	88.79	88.90	90.04	90.07
66.85	66.10	65.84	65.85	65.93	66.20	65.72	65.92	66.09

5-Jul-13	12-Jul-13	19-Jul-13	26-Jul-13	2-Aug-13	9-Aug-13	16-Aug-13	23-Aug-13	30-Aug-13	6-Sep-13
51.20	51.02	49.98	50.57	50.40	50.38				
57.28	56.93	57.45	56.73	56.15	56.68				
63.14	62.02	63.02	62.79	62.29	62.50				
64.00	64.09	63.95	64.41	64.09	63.76				
73.08	72.17	72.97	72.73	72.66	72.49				
71.75	71.84	71.67	71.53	70.91	71.29				
89.05	88.77	89.54	89.84	88.83	88.86				
66.41	65.60	65.82	66.04	65.60	65.56				

13-Sep-13	20-Sep-13	27-Sep-13	4-Oct-13	11-Oct-13	18-Oct-13	25-Oct-13	1-Nov-13	8-Nov-13


OxyContin Weekly Tabs Per Rx
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
-
8-Apr-11
8-May-11
8-Jun-11
8-Jul-11
8-Aug-11
8-Sep-11
8-Oct-11
8-Nov-11
8-Dec-11
8-Jan-12
8-Feb-12
8-Mar-12
8-Apr-12
8-May-12
8-Jun-12
8-Jul-12
8-Aug-12
8-Sep-12
8-Oct-12
8-Nov-12
8-Dec-12
8-Jan-13
8-Feb-13
8-Mar-13
8-Apr-13
8-May-13
8-Jun-13
8-Jul-13
8-Aug-13
OxyContin Tabs Per Rx


Weekly OxyContin Total Prescriptions
Retail Pharmacies, Mail order, and LTC
All Numbers are Absolute
160,000
140,000
120,000
100,000
80,000
60,000
40,000
20,000
-
3-Dec-10
31-Dec-10
28-Jan-11
25-Feb-11
25-Mar-11
22-Apr-11
20-May-11
17-Jun-11
15-Jul-11
12-Aug-11
9-Sep-11
7-Oct-11
4-Nov-11
2-Dec-11
30-Dec-11
27-Jan-12
24-Feb-12
23-Mar-12
20-Apr-12
18-May-12
15-Jun-12
13-Jul-12
10-Aug-12
7-Sep-12
5-Oct-12
2-Nov-12
30-Nov-12
28-Dec-12
25-Jan-13
22-Feb-13
22-Mar-13
19-Apr-13
17-May-13
14-Jun-13
12-Jul-13
9-Aug-13
OxyContin


OxyContin Total Prescriptions By Strength
Retail Pharmacies, Mail Order, and LTC
All Numbers Absolute
40,000
35,000
30,000
25,000
20,000
15,000
10,000
5,000
-
7-Jan-11
4-Feb-11
4-Mar-11
1-Apr-11
29-Apr-11
27-May-11
24-Jun-11
22-Jul-11
19-Aug-11
16-Sep-11
14-Oct-11
11-Nov-11
9-Dec-11
6-Jan-12
3-Feb-12
2-Mar-12
30-Mar-12
27-Apr-12
25-May-12
22-Jun-12
20-Jul-12
17-Aug-12
14-Sep-12
12-Oct-12
9-Nov-12
7-Dec-12
4-Jan-13
1-Feb-13
1-Mar-13
29-Mar-13
26-Apr-13
24-May-13
21-Jun-13
19-Jul-13
16-Aug-13
10MG
15MG
20MG
30MG
40MG
60MG
80MG


Comparison of Weekly OxyContin TRx's
2009-2013
Retail Pharmacies, Mail Order and LTC
160,000
140,000
120,000
100,000
80,000
60,000
40,000
20,000
-
Week 1
Week 3
Week 5
Week 7
Week 9
Week 11
Week 13
Week 15
Week 17
Week 19
Week 21
Week 23
Week 25
Week 27
Week 29
Week 31
Week 33
Week 35
Week 37
Week 39
Week 41
Week 43
Week 45
Week 47
Week 49
Week 51
2009
2010
2011
2012
2013

OxyContin Weekly TRx - Original Formulation and Reformulation							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 1	**Week 2**	**Week 3**	**Week 4**	**Week 5**	**Week 6**
Strength	**Week Ending**	**2-Jan-09**	**9-Jan-09**	**16-Jan-09**	**23-Jan-09**	**30-Jan-09**	**6-Feb-09**
10MG		14,904	18,498	18,242	16,859	16,605	18,379
15MG		1,087	1,490	1,336	1,171	1,128	1,300
20MG		28,407	34,398	32,742	27,630	25,232	28,854
30MG		4,284	5,468	5,380	4,921	4,603	5,327
40MG		25,393	30,567	30,047	27,015	24,862	28,662
60MG		4,336	5,273	5,095	4,783	4,541	5,349
80MG		21,508	26,618	25,483	21,655	20,320	24,194
Total	**2009**	99,919	122,312	118,325	104,034	97,291	112,065
		8-Jan-10	**15-Jan-10**	**22-Jan-10**	**29-Jan-10**	**5-Feb-10**	**12-Feb-10**
10MG		15,812	19,748	18,906	20,664	19,175	20,070
15MG		1,643	2,072	2,007	2,260	2,293	2,542
20MG		26,804	32,159	29,875	30,068	28,571	31,249
30MG		6,994	8,689	8,190	8,997	8,882	9,772
40MG		27,435	33,418	30,776	30,018	28,291	31,702
60MG		7,248	8,574	8,214	8,326	8,203	9,104
80MG		22,376	28,047	26,191	25,286	24,406	27,199
Total	**2010**	108,312	132,707	124,159	125,619	119,821	131,638
		7-Jan-11	**14-Jan-11**	**21-Jan-11**	**28-Jan-11**	**4-Feb-11**	**11-Feb-11**
10MG		27,567	27,181	27,431	26,218	27,359	28,076
15MG		3,125	2,986	2,963	2,913	3,054	3,117
20MG		35,502	34,019	33,496	32,085	33,707	34,570
30MG		11,149	10,736	10,255	9,720	10,743	10,563
40MG		27,583	25,880	24,853	23,601	26,130	26,037
60MG		9,745	9,326	8,988	8,333	9,199	9,239

OxyContin Weekly TRx - Original Formulation and Reformulation							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 1	**Week 2**	**Week 3**	**Week 4**	**Week 5**	**Week 6**
Strength	**Week Ending**	**2-Jan-09**	**9-Jan-09**	**16-Jan-09**	**23-Jan-09**	**30-Jan-09**	**6-Feb-09**
80MG		20,305	20,250	19,480	19,071	21,226	21,141
Total	**2011**	134,976	130,378	127,466	121,941	131,418	132,743
		6-Jan-12	**13-Jan-12**	**20-Jan-12**	**27-Jan-12**	**3-Feb-12**	**10-Feb-12**
10MG		23,413	25,422	24,657	24,317	25,318	25,339
15MG		3,181	3,323	3,275	3,165	3,227	3,349
20MG		30,028	31,200	30,546	29,447	31,100	30,832
30MG		10,274	10,686	10,528	10,002	10,602	10,646
40MG		23,382	24,667	23,720	22,374	24,012	24,017
60MG		8,527	8,821	8,660	8,192	8,907	8,745
80MG		16,876	17,560	16,865	15,856	17,372	17,425
Total	**2012**	115,681	121,679	118,251	113,353	120,538	120,353
		4-Jan-13	**11-Jan-13**	**18-Jan-13**	**25-Jan-13**	**1-Feb-13**	**8-Feb-13**
10MG		23,087	25,231	25,634	23,858	24,986	26,132
15MG		3,595	4,111	3,971	3,681	3,765	4,144
20MG		28,300	30,360	29,828	27,539	28,981	30,406
30MG		11,327	11,931	12,055	10,790	11,542	12,411
40MG		21,885	23,056	22,211	20,069	21,557	22,693
60MG		8,923	9,488	9,336	8,328	9,012	9,660
80MG		15,407	16,099	15,953	13,956	15,229	16,194
Total	**2013**	112,524	120,276	118,988	108,221	115,072	121,640
	1 week % Change						

OxyContin Weekly TRx - Original Formulation and Reformulation							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 1	**Week 2**	**Week 3**	**Week 4**	**Week 5**	**Week 6**
Strength	**Week Ending**	**2-Jan-09**	**9-Jan-09**	**16-Jan-09**	**23-Jan-09**	**30-Jan-09**	**6-Feb-09**
	2009		22.4%	-3.3%	-12.1%	-6.5%	15.2%
	2010		22.5%	-6.4%	1.2%	-4.6%	9.9%
	2011		-3.4%	-2.2%	-4.3%	7.8%	1.0%
	2012		5.2%	-2.8%	-4.1%	6.3%	-0.2%
	2013		6.9%	-1.1%	-9.0%	6.3%	5.7%

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 7	**Week 8**	**Week 9**	**Week 10**	**Week 11**	**Week 12**
Strength	**Week Ending**	**13-Feb-09**	**20-Feb-09**	**27-Feb-09**	**6-Mar-09**	**13-Mar-09**	**20-Mar-09**
10MG		17,330	16,337	16,651	18,382	17,352	16,603
15MG		1,363	1,309	1,274	1,510	1,458	1,345
20MG		28,074	25,718	25,443	29,400	26,232	24,425
30MG		5,470	5,143	5,251	6,063	5,884	5,381
40MG		27,221	24,850	25,527	30,276	27,307	24,659
60MG		5,271	4,996	5,200	6,169	5,591	5,413
80MG		23,351	20,896	21,620	25,823	22,901	20,977
Total	**2009**	108,080	99,249	100,966	117,623	106,725	98,803
		19-Feb-10	**26-Feb-10**	**5-Mar-10**	**12-Mar-10**	**19-Mar-10**	**26-Mar-10**
10MG		18,919	18,743	18,572	20,656	18,741	19,125
15MG		2,422	2,383	2,519	2,658	2,479	2,598
20MG		29,031	28,644	28,009	31,775	28,088	27,174
30MG		9,348	9,392	9,229	10,367	9,849	9,445
40MG		29,560	28,920	28,177	32,938	29,370	28,114
60MG		8,892	8,696	8,694	9,974	9,288	8,899
80MG		25,860	25,378	25,316	29,168	26,063	25,526
Total	**2010**	124,032	122,156	120,516	137,536	123,878	120,881
		18-Feb-11	**25-Feb-11**	**4-Mar-11**	**11-Mar-11**	**18-Mar-11**	**25-Mar-11**
10MG		27,450	25,995	28,804	27,569	26,286	26,368
15MG		3,108	3,010	3,314	3,116	2,844	2,889
20MG		33,726	32,427	37,890	34,704	33,241	32,998
30MG		10,562	9,898	11,629	10,588	10,115	9,991
40MG		25,722	25,009	30,008	26,733	26,005	25,511
60MG		9,083	8,484	10,061	9,130	8,755	8,496

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 7	**Week 8**	**Week 9**	**Week 10**	**Week 11**	**Week 12**
Strength	**Week Ending**	**13-Feb-09**	**20-Feb-09**	**27-Feb-09**	**6-Mar-09**	**13-Mar-09**	**20-Mar-09**
80MG		19,946	19,207	23,133	20,532	19,175	18,743
Total	**2011**	129,597	124,030	144,839	132,372	126,421	124,996
		17-Feb-12	**24-Feb-12**	**2-Mar-12**	**9-Mar-12**	**16-Mar-12**	**23-Mar-12**
10MG		24,539	24,320	26,245	25,819	25,038	24,587
15MG		3,308	3,182	3,453	3,404	3,416	3,222
20MG		30,339	29,474	32,682	31,516	30,350	29,821
30MG		10,254	10,272	11,277	10,982	10,724	10,438
40MG		23,621	22,660	25,519	24,714	23,867	22,869
60MG		8,771	8,308	9,681	9,222	8,802	8,554
80MG		16,881	16,304	18,557	18,062	16,832	16,203
Total	**2012**	117,713	114,520	127,414	123,719	119,029	115,694
		15-Feb-13	**22-Feb-13**	**1-Mar-13**	**8-Mar-13**	**15-Mar-13**	**22-Mar-13**
10MG		25,813	24,646	25,914	26,268	25,511	24,829
15MG		3,910	3,804	4,030	4,198	3,983	3,849
20MG		29,720	27,875	30,374	31,167	29,367	28,215
30MG		11,513	11,117	12,375	12,450	11,612	11,419
40MG		22,037	20,090	22,469	23,244	21,400	20,358
60MG		9,086	8,397	9,655	9,514	9,026	8,713
80MG		15,585	13,943	15,840	16,361	15,207	14,136
Total	**2013**	117,664	109,872	120,657	123,202	116,106	111,519
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 7	**Week 8**	**Week 9**	**Week 10**	**Week 11**	**Week 12**
Strength	**Week Ending**	**13-Feb-09**	**20-Feb-09**	**27-Feb-09**	**6-Mar-09**	**13-Mar-09**	**20-Mar-09**
	2009	-3.6%	-8.2%	1.7%	16.5%	-9.3%	-7.4%
	2010	-5.8%	-1.5%	-1.3%	14.1%	-9.9%	-2.4%
	2011	-2.4%	-4.3%	16.8%	-8.6%	-4.5%	-1.1%
	2012	-2.2%	-2.7%	11.3%	-2.9%	-3.8%	-2.8%
	2013	-3.3%	-6.6%	9.8%	2.1%	-5.8%	-4.0%

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 13	**Week 14**	**Week 15**	**Week 16**	**Week 17**	**Week 18**
Strength	**Week Ending**	**27-Mar-09**	**3-Apr-09**	**10-Apr-09**	**17-Apr-09**	**24-Apr-09**	**1-May-09**
10MG		16,754	17,752	17,975	17,966	18,416	19,519
15MG		1,322	1,411	1,521	1,366	1,358	1,552
20MG		23,351	25,206	24,024	23,246	22,976	24,072
30MG		5,358	5,860	5,860	5,530	5,771	6,125
40MG		24,560	26,463	25,609	24,575	24,212	25,574
60MG		5,401	5,987	5,839	5,641	5,963	6,128
80MG		21,019	22,986	22,665	21,276	21,245	22,540
Total	**2009**	97,765	105,665	103,493	99,600	99,941	105,510
		2-Apr-10	**9-Apr-10**	**16-Apr-10**	**23-Apr-10**	**30-Apr-10**	**7-May-10**
10MG		19,207	19,150	19,508	19,135	18,758	19,222
15MG		2,431	2,580	2,553	2,548	2,525	2,575
20MG		26,432	27,672	27,998	27,269	27,327	27,781
30MG		9,458	9,828	9,880	9,776	9,964	10,001
40MG		27,324	29,084	29,232	28,416	27,871	28,608
60MG		8,918	9,335	9,501	9,191	9,445	9,225
80MG		24,889	26,447	26,590	26,315	26,256	26,575
Total	**2010**	118,659	124,096	125,262	122,650	122,146	123,987
		1-Apr-11	**8-Apr-11**	**15-Apr-11**	**22-Apr-11**	**29-Apr-11**	**6-May-11**
10MG		25,999	26,920	26,486	25,724	26,052	26,976
15MG		2,975	3,076	3,052	2,964	3,042	3,154
20MG		33,707	34,637	33,185	32,785	33,260	35,802
30MG		10,220	10,590	10,316	9,934	10,006	10,915
40MG		26,360	26,853	25,596	25,226	25,665	27,613
60MG		8,772	9,215	8,999	8,445	8,758	9,670

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 13	**Week 14**	**Week 15**	**Week 16**	**Week 17**	**Week 18**
Strength	**Week Ending**	**27-Mar-09**	**3-Apr-09**	**10-Apr-09**	**17-Apr-09**	**24-Apr-09**	**1-May-09**
80MG		19,914	20,125	18,473	18,028	19,072	20,628
Total	**2011**	127,947	131,416	126,107	123,106	125,855	134,758
		30-Mar-12	**6-Apr-12**	**13-Apr-12**	**20-Apr-12**	**27-Apr-12**	**4-May-12**
10MG		24,510	25,298	24,741	24,631	25,096	25,823
15MG		3,293	3,456	3,396	3,479	3,337	3,655
20MG		30,389	31,676	30,161	30,298	30,562	32,072
30MG		10,692	11,134	10,693	10,968	11,218	11,808
40MG		23,292	24,654	23,285	23,106	23,307	25,335
60MG		8,955	9,248	8,737	8,813	9,005	9,673
80MG		16,562	17,712	16,370	16,368	16,598	17,978
Total	**2012**	117,693	123,178	117,383	117,663	119,123	126,344
		29-Mar-13	**5-Apr-13**	**12-Apr-13**	**19-Apr-13**	**26-Apr-13**	**3-May-13**
10MG		24,147	24,786	24,574	24,247	24,428	25,505
15MG		3,806	4,016	4,071	3,886	3,884	4,204
20MG		27,841	29,443	28,561	27,759	28,034	29,677
30MG		11,413	11,917	11,576	11,535	11,556	12,166
40MG		20,331	22,027	20,935	20,003	20,692	22,404
60MG		8,840	9,295	8,954	8,650	8,791	9,372
80MG		14,184	15,501	14,612	13,740	14,138	15,747
Total	**2013**	110,562	116,985	113,283	109,820	111,523	119,075
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 13	**Week 14**	**Week 15**	**Week 16**	**Week 17**	**Week 18**
Strength	**Week Ending**	**27-Mar-09**	**3-Apr-09**	**10-Apr-09**	**17-Apr-09**	**24-Apr-09**	**1-May-09**
	2009	-1.1%	8.1%	-2.1%	-3.8%	0.3%	5.6%
	2010	-1.8%	4.6%	0.9%	-2.1%	-0.4%	1.5%
	2011	2.4%	2.7%	-4.0%	-2.4%	2.2%	7.1%
	2012	1.7%	4.7%	-4.7%	0.2%	1.2%	6.1%
	2013	-0.9%	5.8%	-3.2%	-3.1%	1.6%	6.8%

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 19	**Week 20**	**Week 21**	**Week 22**	**Week 23**	**Week 24**
Strength	**Week Ending**	**8-May-09**	**15-May-09**	**22-May-09**	**29-May-09**	**5-Jun-09**	**12-Jun-09**
10MG		19,962	19,726	20,541	18,667	21,782	20,884
15MG		1,548	1,543	1,540	1,415	1,562	1,569
20MG		24,458	23,655	24,008	22,033	25,528	24,151
30MG		6,267	6,058	6,275	5,740	6,450	6,269
40MG		26,151	24,108	25,010	23,739	27,988	26,033
60MG		6,226	6,030	6,087	5,784	6,626	6,009
80MG		22,607	21,376	21,969	20,676	23,608	21,625
Total	**2009**	107,219	102,496	105,430	98,054	113,544	106,540
		14-May-10	**21-May-10**	**28-May-10**	**4-Jun-10**	**11-Jun-10**	**18-Jun-10**
10MG		20,056	19,914	20,002	20,648	19,283	20,900
15MG		2,607	2,562	2,601	2,775	2,535	2,689
20MG		29,096	27,159	27,586	28,796	27,208	28,398
30MG		10,490	9,983	10,218	10,817	9,730	10,274
40MG		32,256	28,866	28,629	30,133	29,493	29,131
60MG		10,159	9,802	9,480	9,785	9,453	9,650
80MG		29,082	26,528	26,718	27,826	26,558	27,488
Total	**2010**	133,746	124,814	125,234	130,780	124,260	128,530
		13-May-11	**20-May-11**	**27-May-11**	**3-Jun-11**	**10-Jun-11**	**17-Jun-11**
10MG		25,903	25,804	26,764	24,175	26,090	25,752
15MG		3,028	3,006	3,061	2,842	3,074	3,050
20MG		33,201	32,613	33,990	31,701	33,117	32,826
30MG		10,182	10,053	10,407	9,958	10,301	10,233
40MG		25,313	25,048	26,070	24,967	25,279	24,760
60MG		8,642	8,564	9,122	8,602	8,880	8,460

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 19	**Week 20**	**Week 21**	**Week 22**	**Week 23**	**Week 24**
Strength	**Week Ending**	**8-May-09**	**15-May-09**	**22-May-09**	**29-May-09**	**5-Jun-09**	**12-Jun-09**
80MG		18,461	18,078	19,286	18,450	18,580	18,059
Total	**2011**	124,730	123,166	128,700	120,695	125,321	123,140
		11-May-12	**18-May-12**	**25-May-12**	**1-Jun-12**	**8-Jun-12**	**15-Jun-12**
10MG		24,694	24,597	25,260	22,598	25,358	24,612
15MG		3,424	3,510	3,553	3,295	3,662	3,523
20MG		30,482	30,679	31,327	28,725	31,199	30,356
30MG		10,904	11,136	11,668	10,623	11,382	11,231
40MG		23,186	23,106	23,735	22,444	24,047	22,908
60MG		8,827	8,939	9,356	8,707	9,117	8,888
80MG		16,539	16,215	17,171	16,092	16,839	15,903
Total	**2012**	118,056	118,182	122,070	112,484	121,604	117,421
		10-May-13	**17-May-13**	**24-May-13**	**31-May-13**	**7-Jun-13**	**14-Jun-13**
10MG		24,914	24,582	25,086	22,589	25,704	25,022
15MG		4,142	4,010	4,155	3,865	4,318	4,120
20MG		29,288	28,309	29,165	26,604	30,155	28,142
30MG		11,779	11,585	11,976	10,936	12,213	11,836
40MG		20,933	19,867	21,012	19,640	22,124	19,962
60MG		9,166	8,664	9,204	8,305	9,380	8,759
80MG		14,627	13,611	14,544	13,571	15,375	14,086
Total	**2013**	114,849	110,628	115,142	105,510	119,269	111,927
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 19	**Week 20**	**Week 21**	**Week 22**	**Week 23**	**Week 24**
Strength	**Week Ending**	**8-May-09**	**15-May-09**	**22-May-09**	**29-May-09**	**5-Jun-09**	**12-Jun-09**
	2009	1.6%	-4.4%	2.9%	-7.0%	15.8%	-6.2%
	2010	7.9%	-6.7%	0.3%	4.4%	-5.0%	3.4%
	2011	-7.4%	-1.3%	4.5%	-6.2%	3.8%	-1.7%
	2012	-6.6%	0.1%	3.3%	-7.9%	8.1%	-3.4%
	2013	-3.5%	-3.7%	4.1%	-8.4%	13.0%	-6.2%

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 25	**Week 26**	**Week 27**	**Week 28**	**Week 29**	**Week 30**
Strength	**Week Ending**	**19-Jun-09**	**26-Jun-09**	**3-Jul-09**	**10-Jul-09**	**17-Jul-09**	**24-Jul-09**
10MG		20,963	20,962	22,353	20,917	21,614	21,439
15MG		1,602	1,514	1,666	1,505	1,590	1,597
20MG		24,357	24,272	26,827	24,524	25,695	25,836
30MG		6,268	6,105	6,919	6,351	6,578	6,392
40MG		27,124	27,548	31,107	27,653	29,049	28,512
60MG		6,364	6,336	6,743	6,290	6,494	6,416
80MG		21,837	21,973	24,120	21,551	22,428	21,947
Total	**2009**	108,515	108,710	119,735	108,791	113,448	112,139
		25-Jun-10	**2-Jul-10**	**9-Jul-10**	**16-Jul-10**	**23-Jul-10**	**30-Jul-10**
10MG		21,669	22,239	23,049	21,109	22,981	22,783
15MG		2,602	2,715	2,874	2,702	2,790	2,724
20MG		28,011	28,836	31,277	27,786	29,917	29,733
30MG		10,551	10,354	11,062	10,063	10,725	10,540
40MG		29,274	30,068	32,789	28,057	29,519	29,807
60MG		9,844	9,622	10,348	9,601	10,050	9,942
80MG		27,328	27,793	29,250	26,144	27,840	28,098
Total	**2010**	129,279	131,627	140,649	125,462	133,822	133,627
		24-Jun-11	**1-Jul-11**	**8-Jul-11**	**15-Jul-11**	**22-Jul-11**	**29-Jul-11**
10MG		25,756	26,776	23,375	25,477	25,092	25,513
15MG		2,991	3,160	2,924	3,089	3,088	2,944
20MG		32,617	35,184	30,589	32,817	32,473	31,894
30MG		10,293	11,014	9,766	10,441	10,091	10,189
40MG		25,288	26,387	23,718	24,752	24,919	25,179
60MG		8,896	9,423	8,281	8,798	8,525	8,755

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 25	**Week 26**	**Week 27**	**Week 28**	**Week 29**	**Week 30**
Strength	**Week Ending**	**19-Jun-09**	**26-Jun-09**	**3-Jul-09**	**10-Jul-09**	**17-Jul-09**	**24-Jul-09**
80MG		18,589	20,021	17,265	18,059	18,218	18,199
Total	**2011**	124,430	131,965	115,918	123,433	122,406	122,673
		22-Jun-12	**29-Jun-12**	**6-Jul-12**	**13-Jul-12**	**20-Jul-12**	**27-Jul-12**
10MG		24,878	24,839	22,927	24,571	24,474	24,189
15MG		3,529	3,479	3,470	3,697	3,597	3,561
20MG		30,061	30,739	29,235	30,567	30,270	29,599
30MG		11,293	11,432	11,211	11,389	11,410	11,245
40MG		23,175	23,246	23,564	23,332	23,257	22,701
60MG		9,219	9,059	9,152	9,112	9,288	9,121
80MG		16,571	16,449	16,595	16,471	16,488	16,151
Total	**2012**	118,726	119,243	116,154	119,139	118,784	116,567
		21-Jun-13	**28-Jun-13**	**5-Jul-13**	**12-Jul-13**	**19-Jul-13**	**26-Jul-13**
10MG		24,707	24,539	23,583	25,049	24,866	23,971
15MG		4,050	4,059	4,071	4,348	4,135	4,200
20MG		28,339	28,142	27,513	28,910	28,341	27,891
30MG		11,765	11,769	11,735	12,090	12,190	11,902
40MG		20,610	20,531	21,001	20,647	20,674	20,436
60MG		8,918	8,949	8,907	8,897	9,083	8,953
80MG		13,858	14,354	14,333	14,382	13,869	14,012
Total	**2013**	112,247	112,343	111,143	114,323	113,158	111,365
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 25	**Week 26**	**Week 27**	**Week 28**	**Week 29**	**Week 30**
Strength	**Week Ending**	**19-Jun-09**	**26-Jun-09**	**3-Jul-09**	**10-Jul-09**	**17-Jul-09**	**24-Jul-09**
	2009	1.9%	0.2%	10.1%	-9.1%	4.3%	-1.2%
	2010	0.6%	1.8%	6.9%	-10.8%	6.7%	-0.1%
	2011	1.0%	6.1%	-12.2%	6.5%	-0.8%	0.2%
	2012	1.1%	0.4%	-2.6%	2.6%	-0.3%	-1.9%
	2013	0.3%	0.1%	-1.1%	2.9%	-1.0%	-1.6%

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 31	**Week 32**	**Week 33**	**Week 34**	**Week 35**	**Week 36**
Strength	**Week Ending**	**31-Jul-09**	**7-Aug-09**	**14-Aug-09**	**21-Aug-09**	**28-Aug-09**	**4-Sep-09**
10MG		21,576	21,992	21,636	21,817	22,134	22,820
15MG		1,621	1,700	1,642	1,634	1,650	1,701
20MG		27,017	28,660	28,805	29,855	30,664	33,993
30MG		6,666	6,596	6,828	6,774	6,780	7,302
40MG		29,259	30,165	29,716	29,905	30,487	32,789
60MG		6,558	6,835	6,612	6,708	6,846	7,288
80MG		22,027	22,819	22,374	22,692	22,715	24,140
Total	**2009**	114,724	118,767	117,613	119,385	121,276	130,033
		6-Aug-10	**13-Aug-10**	**20-Aug-10**	**27-Aug-10**	**3-Sep-10**	**10-Sep-10**
10MG		22,890	22,558	22,560	22,605	22,678	23,977
15MG		2,808	2,780	2,753	2,695	2,902	3,121
20MG		29,518	29,945	29,409	30,746	30,977	33,480
30MG		10,523	10,722	10,810	10,896	10,466	11,424
40MG		29,486	29,810	28,567	29,602	29,254	31,078
60MG		9,671	10,114	10,138	10,139	10,045	10,814
80MG		26,984	28,428	28,029	28,195	26,769	27,275
Total	**2010**	131,880	134,357	132,266	134,878	133,091	141,169
		5-Aug-11	**12-Aug-11**	**19-Aug-11**	**26-Aug-11**	**2-Sep-11**	**9-Sep-11**
10MG		24,932	24,760	24,963	25,056	25,649	22,679
15MG		3,073	3,010	3,174	3,144	2,989	2,919
20MG		32,066	31,819	31,968	31,881	32,467	29,616
30MG		10,295	10,140	10,385	10,331	10,239	9,634
40MG		25,196	24,802	25,097	25,350	25,499	23,338
60MG		8,719	8,623	8,641	8,772	8,875	8,099

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 31	**Week 32**	**Week 33**	**Week 34**	**Week 35**	**Week 36**
Strength	**Week Ending**	**31-Jul-09**	**7-Aug-09**	**14-Aug-09**	**21-Aug-09**	**28-Aug-09**	**4-Sep-09**
80MG		17,684	17,567	17,906	17,951	18,126	16,843
Total	**2011**	121,965	120,721	122,134	122,485	123,844	113,128
		3-Aug-12	**10-Aug-12**	**17-Aug-12**	**24-Aug-12**	**31-Aug-12**	**7-Sep-12**
10MG		24,085	23,942	24,305	24,548	24,950	23,222
15MG		3,628	3,559	3,736	3,484	3,695	3,489
20MG		30,017	29,413	30,096	29,863	30,281	28,823
30MG		11,395	11,227	11,692	11,402	11,620	11,057
40MG		23,069	22,792	23,006	22,555	23,184	22,363
60MG		9,116	8,982	9,268	9,253	9,188	8,884
80MG		16,106	16,013	16,373	16,097	16,136	15,987
Total	**2012**	117,416	115,928	118,476	117,202	119,054	113,825
		2-Aug-13	**9-Aug-13**	**16-Aug-13**	**23-Aug-13**	**30-Aug-13**	**6-Sep-13**
10MG		24,485	24,322				
15MG		4,116	4,358				
20MG		28,208	28,178				
30MG		11,903	11,888				
40MG		20,704	20,082				
60MG		8,842	8,909				
80MG		14,109	13,940				
Total	**2013**	112,367	111,677				
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 31	**Week 32**	**Week 33**	**Week 34**	**Week 35**	**Week 36**
Strength	**Week Ending**	**31-Jul-09**	**7-Aug-09**	**14-Aug-09**	**21-Aug-09**	**28-Aug-09**	**4-Sep-09**
	2009	2.3%	3.5%	-1.0%	1.5%	1.6%	7.2%
	2010	-1.3%	1.9%	-1.6%	2.0%	-1.3%	6.1%
	2011	-0.6%	-1.0%	1.2%	0.3%	1.1%	-8.7%
	2012	0.7%	-1.3%	2.2%	-1.1%	1.6%	-4.4%
	2013	0.9%	-0.6%				

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 37	**Week 38**	**Week 39**	**Week 40**	**Week 41**	**Week 42**
Strength	**Week Ending**	**11-Sep-09**	**18-Sep-09**	**25-Sep-09**	**2-Oct-09**	**9-Oct-09**	**16-Oct-09**
10MG		20,094	22,738	22,421	22,854	21,841	22,171
15MG		1,587	1,819	1,676	1,809	1,723	1,739
20MG		29,938	33,349	33,400	36,149	33,743	34,078
30MG		6,443	7,158	6,765	7,433	6,870	7,202
40MG		29,230	32,284	32,096	34,177	32,136	32,649
60MG		6,298	7,111	6,808	7,496	6,809	7,144
80MG		21,491	23,682	23,946	25,310	24,334	24,945
Total	**2009**	115,081	128,141	127,112	135,228	127,456	129,928
		17-Sep-10	**24-Sep-10**	**1-Oct-10**	**8-Oct-10**	**15-Oct-10**	**22-Oct-10**
10MG		21,794	23,930	23,708	24,274	23,939	24,310
15MG		2,769	3,020	2,800	3,134	2,988	2,893
20MG		30,411	33,476	32,159	33,860	33,054	33,810
30MG		10,179	11,308	10,774	11,064	10,879	10,990
40MG		26,620	29,020	27,518	28,143	26,424	26,143
60MG		9,828	10,396	9,954	10,447	10,024	9,918
80MG		23,153	24,743	22,512	22,375	20,904	20,552
Total	**2010**	124,754	135,893	129,425	133,297	128,212	128,616
		16-Sep-11	**23-Sep-11**	**30-Sep-11**	**7-Oct-11**	**14-Oct-11**	**21-Oct-11**
10MG		25,600	25,315	25,531	25,173	25,182	25,253
15MG		3,178	3,121	3,173	3,230	3,150	3,163
20MG		32,268	31,633	32,218	32,005	31,677	31,346
30MG		10,415	10,237	10,480	10,386	10,382	10,222
40MG		25,367	24,928	25,082	25,214	24,779	24,444
60MG		8,733	8,654	8,822	8,825	8,634	8,580

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 37	**Week 38**	**Week 39**	**Week 40**	**Week 41**	**Week 42**
Strength	**Week Ending**	**11-Sep-09**	**18-Sep-09**	**25-Sep-09**	**2-Oct-09**	**9-Oct-09**	**16-Oct-09**
80MG		18,183	17,880	17,806	17,842	17,870	17,628
Total	**2011**	123,744	121,768	123,112	122,675	121,674	120,636
		14-Sep-12	**21-Sep-12**	**28-Sep-12**	**5-Oct-12**	**12-Oct-12**	**19-Oct-12**
10MG		24,886	24,754	25,350	25,838	24,616	25,288
15MG		3,852	3,740	3,984	3,855	3,786	3,765
20MG		30,288	30,197	30,675	30,727	29,825	30,326
30MG		11,678	11,500	11,732	11,835	11,606	11,565
40MG		23,113	22,709	23,197	23,543	22,555	22,590
60MG		9,268	9,297	9,042	9,437	9,086	9,190
80MG		16,283	16,064	15,786	16,684	15,758	15,951
Total	**2012**	119,368	118,261	119,766	121,919	117,232	118,675
		13-Sep-13	**20-Sep-13**	**27-Sep-13**	**4-Oct-13**	**11-Oct-13**	**18-Oct-13**
10MG							
15MG							
20MG							
30MG							
40MG							
60MG							
80MG							
Total	**2013**						
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							
		Week 37	**Week 38**	**Week 39**	**Week 40**	**Week 41**	**Week 42**
Strength	**Week Ending**	**11-Sep-09**	**18-Sep-09**	**25-Sep-09**	**2-Oct-09**	**9-Oct-09**	**16-Oct-09**
	2009	-11.5%	11.3%	-0.8%	6.4%	-5.7%	1.9%
	2010	-11.6%	8.9%	-4.8%	3.0%	-3.8%	0.3%
	2011	9.4%	-1.6%	1.1%	-0.4%	-0.8%	-0.9%
	2012	4.9%	-0.9%	1.3%	1.8%	-3.8%	1.2%
	2013						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							**Weekly Total Presc**
		Week 43	**Week 44**	**Week 45**	**Week 46**	**Week 47**	**Week 48**
Strength	**Week Ending**	**23-Oct-09**	**30-Oct-09**	**6-Nov-09**	**13-Nov-09**	**20-Nov-09**	**27-Nov-09**
10MG		22,567	22,054	21,863	21,463	21,895	18,595
15MG		1,742	1,727	1,885	1,793	1,833	1,706
20MG		34,754	34,649	34,277	32,522	33,862	29,406
30MG		7,103	7,259	7,275	7,391	7,709	6,789
40MG		32,809	32,823	33,577	31,791	32,627	29,053
60MG		6,992	7,228	7,340	7,288	7,468	6,678
80MG		25,436	24,782	25,802	25,325	26,045	23,031
Total	**2009**	131,403	130,522	132,019	127,573	131,439	115,258
		29-Oct-10	**5-Nov-10**	**12-Nov-10**	**19-Nov-10**	**26-Nov-10**	**3-Dec-10**
10MG		24,950	25,222	26,143	26,513	27,687	23,447
15MG		3,042	2,892	3,042	2,983	3,012	2,726
20MG		33,695	34,448	35,145	34,663	35,581	31,196
30MG		10,847	10,495	10,676	10,673	10,876	9,391
40MG		26,126	26,040	27,173	27,400	28,942	25,635
60MG		9,757	9,525	9,716	9,533	9,874	8,537
80MG		19,642	19,000	18,724	18,367	18,836	15,958
Total	**2010**	128,059	127,622	130,619	130,132	134,808	116,890
		28-Oct-11	**4-Nov-11**	**11-Nov-11**	**18-Nov-11**	**25-Nov-11**	**2-Dec-11**
10MG		25,300	25,314	25,302	25,776	22,486	26,481
15MG		3,143	3,109	3,177	3,278	2,899	3,251
20MG		31,483	31,178	31,529	31,779	28,017	33,356
30MG		10,340	10,417	10,255	10,541	9,246	11,315
40MG		24,446	24,252	24,246	24,618	21,864	26,379
60MG		8,761	8,568	8,639	8,952	7,876	9,465

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							**Weekly Total Presc**
		Week 43	**Week 44**	**Week 45**	**Week 46**	**Week 47**	**Week 48**
Strength	**Week Ending**	**23-Oct-09**	**30-Oct-09**	**6-Nov-09**	**13-Nov-09**	**20-Nov-09**	**27-Nov-09**
80MG		17,058	17,364	17,604	17,557	15,654	18,839
Total	**2011**	120,531	120,202	120,752	122,501	108,042	129,086
		26-Oct-12	**2-Nov-12**	**9-Nov-12**	**16-Nov-12**	**23-Nov-12**	**30-Nov-12**
10MG		25,395	24,696	26,154	26,215	23,221	26,489
15MG		3,828	3,765	3,932	3,921	3,491	4,109
20MG		30,000	29,535	30,912	30,176	27,610	31,374
30MG		11,566	11,440	11,920	11,644	10,833	12,244
40MG		22,546	22,344	23,004	22,628	20,580	23,701
60MG		9,068	8,909	9,562	9,410	8,376	9,642
80MG		15,808	15,426	16,294	16,122	14,482	16,100
Total	**2012**	118,211	116,115	121,778	120,116	108,593	123,659
		25-Oct-13	**1-Nov-13**	**8-Nov-13**	**15-Nov-13**	**22-Nov-13**	**29-Nov-13**
10MG							
15MG							
20MG							
30MG							
40MG							
60MG							
80MG							
Total	**2013**						
	1 week % Change						

OxyContin Weekly TRx - Original Formul							
Source: IMS Health NPA							
Retail, LTC, and Mail Order							
Numbers Are Absolute							**Weekly Total Presc**
		Week 43	**Week 44**	**Week 45**	**Week 46**	**Week 47**	**Week 48**
Strength	**Week Ending**	**23-Oct-09**	**30-Oct-09**	**6-Nov-09**	**13-Nov-09**	**20-Nov-09**	**27-Nov-09**
	2009	1.1%	-0.7%	1.1%	-3.4%	3.0%	-12.3%
	2010	-0.4%	-0.3%	2.3%	-0.4%	3.6%	-13.3%
	2011	-0.1%	-0.3%	0.5%	1.4%	-11.8%	19.5%
	2012	-0.4%	-1.8%	4.9%	-1.4%	-9.6%	13.9%
	2013						

OxyContin Weekly TRx - Original Formul					
Source: IMS Health NPA					
Retail, LTC, and Mail Order					
Numbers Are Absolute		**riptions**			
		Week 49	**Week 50**	**Week 51**	**Week 52**
Strength	**Week Ending**	**4-Dec-09**	**11-Dec-09**	**18-Dec-09**	**25-Dec-09**
10MG		22,639	20,166	20,630	16,597
15MG		2,035	1,951	2,018	1,640
20MG		36,781	31,249	32,379	26,619
30MG		8,421	7,564	8,002	6,672
40MG		36,299	31,623	32,218	26,653
60MG		8,677	7,583	8,094	6,744
80MG		29,078	25,527	26,567	21,644
Total	**2009**	143,930	125,663	129,908	106,569
		10-Dec-10	**17-Dec-10**	**24-Dec-10**	**31-Dec-10**
10MG		27,965	27,477	28,407	27,439
15MG		3,278	3,051	3,044	2,892
20MG		37,879	35,095	35,533	34,714
30MG		11,649	10,767	10,799	10,408
40MG		31,691	28,560	29,516	27,042
60MG		10,399	9,510	9,414	9,262
80MG		19,510	18,227	19,040	18,086
Total	**2010**	142,371	132,687	135,753	129,843
		9-Dec-11	**16-Dec-11**	**23-Dec-11**	**30-Dec-11**
10MG		25,722	26,431	26,774	21,386
15MG		3,338	3,378	3,332	2,757
20MG		31,760	31,757	32,674	27,251
30MG		10,557	10,790	10,741	9,248
40MG		24,313	24,853	25,292	21,455
60MG		8,662	9,102	9,080	7,741

OxyContin Weekly TRx - Original Formul					
Source: IMS Health NPA					
Retail, LTC, and Mail Order					
Numbers Are Absolute		**riptions**			
		Week 49	**Week 50**	**Week 51**	**Week 52**
Strength	**Week Ending**	**4-Dec-09**	**11-Dec-09**	**18-Dec-09**	**25-Dec-09**
80MG		17,560	17,690	17,758	15,431
Total	**2011**	121,912	124,001	125,651	105,269
		7-Dec-12	**14-Dec-12**	**21-Dec-12**	**28-Dec-12**
10MG		26,517	26,051	27,077	21,021
15MG		4,032	4,026	4,170	3,207
20MG		31,846	30,640	31,888	25,515
30MG		12,447	12,006	12,563	10,004
40MG		23,716	22,772	23,677	19,428
60MG		9,734	9,380	9,610	8,046
80MG		16,967	15,839	16,634	13,946
Total	**2012**	125,259	120,714	125,619	101,167
		6-Dec-13	**13-Dec-13**	**20-Dec-13**	**27-Dec-13**
10MG					
15MG					
20MG					
30MG					
40MG					
60MG					
80MG					
Total	**2013**				
	1 week % Change				

	OxyContin Weekly TRx - Original Formul						
	Source: IMS Health NPA						
	Retail, LTC, and Mail Order						
	Numbers Are Absolute		**riptions**				
			Week 49	**Week 50**	**Week 51**	**Week 52**	
	Strength	**Week Ending**	**4-Dec-09**	**11-Dec-09**	**18-Dec-09**	**25-Dec-09**	
		2009	24.9%	-12.7%	3.4%	-18.0%	
		2010	21.8%	-6.8%	2.3%	-4.4%	
		2011	-5.6%	1.7%	1.3%	-16.2%	
		2012	1.3%	-3.6%	4.1%	-19.5%	
		2013					

Product	2011/04/08 EUTRx	2011/04/15 EUTRx	2011/04/22 EUTRx	2011/04/29 EUTRx
OXYCONTIN 01/1996 PUF	9,245,201	8,798,770	8,573,636	8,811,087
10MG	1,478,660	1,427,631	1,390,912	1,405,432
15MG	183,269	180,224	173,573	179,380
20MG	2,290,945	2,192,332	2,165,596	2,193,475
30MG	692,907	673,958	647,518	666,744
40MG	2,055,364	1,943,620	1,899,504	1,960,507
60MG	671,650	658,988	610,461	638,010
80MG	1,872,406	1,722,017	1,686,072	1,767,539
Grand Total	**9,245,201**	**8,798,770**	**8,573,636**	**8,811,087**

MG Totals

OXYCONTIN 01/1996 PUF				
10MG	14,786,600	14,276,310	13,909,120	14,054,320
15MG	2,749,035	2,703,360	2,603,595	2,690,700
20MG	45,818,900	43,846,640	43,311,920	43,869,500
30MG	20,787,210	20,218,740	19,425,540	20,002,320
40MG	82,214,560	77,744,800	75,980,160	78,420,280
60MG	40,299,000	39,539,280	36,627,660	38,280,600
80MG	149,792,480	137,761,360	134,885,760	141,403,120
Grand Total	**356,447,785**	**336,090,490**	**326,743,755**	**338,720,840**

Millions of MG	4/8/2011	4/15/2011	4/22/2011	4/29/2011
OXYCONTIN 01/1996 PUF				
10MG	15	14	14	14
15MG	3	3	3	3
20MG	46	44	43	44
30MG	21	20	19	20
40MG	82	78	76	78
60MG	40	40	37	38
80MG	150	138	135	141
Grand Total	**356**	**336**	**327**	**339**

2011/05/06 EUTRx	2011/05/13 EUTRx	2011/05/20 EUTRx	2011/05/27 EUTRx	2011/06/03 EUTRx	2011/06/10 EUTRx
9,501,374	8,741,359	8,573,294	9,026,667	8,430,496	8,792,965
1,487,471	1,400,215	1,390,618	1,450,473	1,311,696	1,431,988
185,164	181,782	178,413	184,192	166,081	181,190
2,391,478	2,199,539	2,152,247	2,232,569	2,096,801	2,197,315
717,131	661,119	661,896	689,695	650,666	677,241
2,110,498	1,935,334	1,891,439	2,010,862	1,887,654	1,930,916
700,016	634,357	629,136	664,006	627,137	649,340
1,909,616	1,729,013	1,669,545	1,794,870	1,690,461	1,724,975
9,501,374	**8,741,359**	**8,573,294**	**9,026,667**	**8,430,496**	**8,792,965**

14,874,710	14,002,150	13,906,180	14,504,730	13,116,960	14,319,880
2,777,460	2,726,730	2,676,195	2,762,880	2,491,215	2,717,850
47,829,560	43,990,780	43,044,940	44,651,380	41,936,020	43,946,300
21,513,930	19,833,570	19,856,880	20,690,850	19,519,980	20,317,230
84,419,920	77,413,360	75,657,560	80,434,480	75,506,160	77,236,640
42,000,960	38,061,420	37,748,160	39,840,360	37,628,220	38,960,400
152,769,280	138,321,040	133,563,600	143,589,600	135,236,880	137,998,000
366,185,820	**334,349,050**	**326,453,515**	**346,474,280**	**325,435,435**	**335,496,300**

5/6/2011	5/13/2011	5/20/2011	5/27/2011	6/3/2011	6/10/2011
15	14	14	15	13	14
3	3	3	3	2	3
48	44	43	45	42	44
22	20	20	21	20	20
84	77	76	80	76	77
42	38	38	40	38	39
153	138	134	144	135	138
366	**334**	**326**	**346**	**325**	**335**

2011/06/17 EUTRx	2011/06/24 EUTRx	2011/07/01 EUTRx	2011/07/08 EUTRx	2011/07/15 EUTRx	2011/07/22 EUTRx
8,581,589	8,758,691	9,331,763	8,126,682	8,625,729	8,619,338
1,389,967	1,391,937	1,474,790	1,283,213	1,387,431	1,367,678
177,671	180,557	189,408	170,738	183,608	182,874
2,157,000	2,161,652	2,351,092	2,026,960	2,159,950	2,143,410
673,071	680,089	726,907	641,157	682,731	672,123
1,882,461	1,953,240	2,021,413	1,795,202	1,887,344	1,921,136
618,362	650,976	683,878	604,158	645,302	634,734
1,683,057	1,740,240	1,884,275	1,605,254	1,679,363	1,697,383
8,581,589	**8,758,691**	**9,331,763**	**8,126,682**	**8,625,729**	**8,619,338**

13,899,670	13,919,370	14,747,900	12,832,130	13,874,310	13,676,780
2,665,065	2,708,355	2,841,120	2,561,070	2,754,120	2,743,110
43,140,000	43,233,040	47,021,840	40,539,200	43,199,000	42,868,200
20,192,130	20,402,670	21,807,210	19,234,710	20,481,930	20,163,690
75,298,440	78,129,600	80,856,520	71,808,080	75,493,760	76,845,440
37,101,720	39,058,560	41,032,680	36,249,480	38,718,120	38,084,040
134,644,560	139,219,200	150,742,000	128,420,320	134,349,040	135,790,640
326,941,585	**336,670,795**	**359,049,270**	**311,644,990**	**328,870,280**	**330,171,900**

6/17/2011	6/24/2011	7/1/2011	7/8/2011	7/15/2011	7/22/2011
14	14	15	13	14	14
3	3	3	3	3	3
43	43	47	41	43	43
20	20	22	19	20	20
75	78	81	72	75	77
37	39	41	36	39	38
135	139	151	128	134	136
327	**337**	**359**	**312**	**329**	**330**

2011/07/29 EUTRx	2011/08/05 EUTRx	2011/08/12 EUTRx	2011/08/19 EUTRx	2011/08/26 EUTRx	2011/09/02 EUTRx
8,639,239	8,539,432	8,432,171	8,561,895	8,586,953	8,700,800
1,389,900	1,351,652	1,352,449	1,347,382	1,361,439	1,415,584
176,085	182,481	181,231	186,212	186,411	178,550
2,123,617	2,112,497	2,094,035	2,110,746	2,107,274	2,147,515
667,672	674,468	661,561	678,745	683,683	676,670
1,936,667	1,936,788	1,887,976	1,937,511	1,935,523	1,953,056
645,107	634,667	627,548	634,527	640,278	646,482
1,700,191	1,646,879	1,627,371	1,666,772	1,672,345	1,682,943
8,639,239	**8,539,432**	**8,432,171**	**8,561,895**	**8,586,953**	**8,700,800**

13,899,000	13,516,520	13,524,490	13,473,820	13,614,390	14,155,840
2,641,275	2,737,215	2,718,465	2,793,180	2,796,165	2,678,250
42,472,340	42,249,940	41,880,700	42,214,920	42,145,480	42,950,300
20,030,160	20,234,040	19,846,830	20,362,350	20,510,490	20,300,100
77,466,680	77,471,520	75,519,040	77,500,440	77,420,920	78,122,240
38,706,420	38,080,020	37,652,880	38,071,620	38,416,680	38,788,920
136,015,280	131,750,320	130,189,680	133,341,760	133,787,600	134,635,440
331,231,155	**326,039,575**	**321,332,085**	**327,758,090**	**328,691,725**	**331,631,090**

7/29/2011	8/5/2011	8/12/2011	8/19/2011	8/26/2011	9/2/2011
14	14	14	13	14	14
3	3	3	3	3	3
42	42	42	42	42	43
20	20	20	20	21	20
77	77	76	78	77	78
39	38	38	38	38	39
136	132	130	133	134	135
331	**326**	**321**	**328**	**329**	**332**

2011/09/09 EUTRx	2011/09/16 EUTRx	2011/09/23 EUTRx	2011/09/30 EUTRx	2011/10/07 EUTRx	2011/10/14 EUTRx
7,939,083	8,695,016	8,573,455	8,609,904	8,575,899	8,500,737
1,229,109	1,381,856	1,381,121	1,373,109	1,368,633	1,352,102
175,024	189,614	186,948	190,182	190,450	185,702
1,967,166	2,144,689	2,112,236	2,135,620	2,105,859	2,086,422
636,604	677,628	673,665	691,553	689,623	676,394
1,785,643	1,965,443	1,913,663	1,915,038	1,921,786	1,904,402
590,123	642,338	635,168	644,614	645,360	634,044
1,555,414	1,693,448	1,670,654	1,659,788	1,654,188	1,661,671
7,939,083	**8,695,016**	**8,573,455**	**8,609,904**	**8,575,899**	**8,500,737**

12,291,090	13,818,560	13,811,210	13,731,090	13,686,330	13,521,020
2,625,360	2,844,210	2,804,220	2,852,730	2,856,750	2,785,530
39,343,320	42,893,780	42,244,720	42,712,400	42,117,180	41,728,440
19,098,120	20,328,840	20,209,950	20,746,590	20,688,690	20,291,820
71,425,720	78,617,720	76,546,520	76,601,520	76,871,440	76,176,080
35,407,380	38,540,280	38,110,080	38,676,840	38,721,600	38,042,640
124,433,120	135,475,840	133,652,320	132,783,040	132,335,040	132,933,680
304,624,110	**332,519,230**	**327,379,020**	**328,104,210**	**327,277,030**	**325,479,210**

9/9/2011	9/16/2011	9/23/2011	9/30/2011	10/7/2011	10/14/2011
12	14	14	14	14	14
3	3	3	3	3	3
39	43	42	43	42	42
19	20	20	21	21	20
71	79	77	77	77	76
35	39	38	39	39	38
124	135	134	133	132	133
305	**333**	**327**	**328**	**327**	**325**

2011/10/21 EUTRx	2011/10/28 EUTRx	2011/11/04 EUTRx	2011/11/11 EUTRx	2011/11/18 EUTRx	2011/11/25 EUTRx
8,433,590	8,378,797	8,364,566	8,419,830	8,534,146	7,488,971
1,374,237	1,356,864	1,366,208	1,351,490	1,383,921	1,208,518
188,811	185,808	181,204	187,251	191,323	170,857
2,056,120	2,058,621	2,052,221	2,068,524	2,087,144	1,824,031
676,712	681,559	688,050	676,655	699,901	607,197
1,867,511	1,875,802	1,843,814	1,868,754	1,888,589	1,654,741
638,311	644,857	630,014	630,742	663,539	578,161
1,631,888	1,575,286	1,603,055	1,636,414	1,619,729	1,445,466
8,433,590	**8,378,797**	**8,364,566**	**8,419,830**	**8,534,146**	**7,488,971**

13,742,370	13,568,640	13,662,080	13,514,900	13,839,210	12,085,180
2,832,165	2,787,120	2,718,060	2,808,765	2,869,845	2,562,855
41,122,400	41,172,420	41,044,420	41,370,480	41,742,880	36,480,620
20,301,360	20,446,770	20,641,500	20,299,650	20,997,030	18,215,910
74,700,440	75,032,080	73,752,560	74,750,160	75,543,560	66,189,640
38,298,660	38,691,420	37,800,840	37,844,520	39,812,340	34,689,660
130,551,040	126,022,880	128,244,400	130,913,120	129,578,320	115,637,280
321,548,435	**317,721,330**	**317,863,860**	**321,501,595**	**324,383,185**	**285,861,145**

10/21/2011	10/28/2011	11/4/2011	11/11/2011	11/18/2011	11/25/2011
14	14	14	14	14	12
3	3	3	3	3	3
41	41	41	41	42	36
20	20	21	20	21	18
75	75	74	75	76	66
38	39	38	38	40	35
131	126	128	131	130	116
322	**318**	**318**	**322**	**324**	**286**

2011/12/02 EUTRx	2011/12/09 EUTRx	2011/12/16 EUTRx	2011/12/23 EUTRx	2011/12/30 EUTRx	2012/01/06 EUTRx
9,056,397	8,496,159	8,633,759	8,783,921	7,373,644	8,063,746
1,439,090	1,374,240	1,423,190	1,451,921	1,158,790	1,282,119
193,397	201,119	197,707	198,672	161,569	192,487
2,213,081	2,074,192	2,094,123	2,151,605	1,806,349	1,971,363
756,778	705,047	714,547	714,302	614,514	680,416
2,012,438	1,871,406	1,903,644	1,932,693	1,627,130	1,771,423
699,049	634,440	666,005	672,301	570,244	618,521
1,742,564	1,635,715	1,634,543	1,662,427	1,434,977	1,547,417
9,056,397	**8,496,159**	**8,633,759**	**8,783,921**	**7,373,644**	**8,063,746**

14,390,900	13,742,400	14,231,900	14,519,210	11,587,900	12,821,190
2,900,955	3,016,785	2,965,605	2,980,080	2,423,535	2,887,305
44,261,620	41,483,840	41,882,460	43,032,100	36,126,980	39,427,260
22,703,340	21,151,410	21,436,410	21,429,060	18,435,420	20,412,480
80,497,520	74,856,240	76,145,760	77,307,720	65,085,200	70,856,920
41,942,940	38,066,400	39,960,300	40,338,060	34,214,640	37,111,260
139,405,120	130,857,200	130,763,440	132,994,160	114,798,160	123,793,360
346,102,395	**323,174,275**	**327,385,875**	**332,600,390**	**282,671,835**	**307,309,775**

12/2/2011	12/9/2011	12/16/2011	12/23/2011	12/30/2011	1/6/2012
14	14	14	15	12	13
3	3	3	3	2	3
44	41	42	43	36	39
23	21	21	21	18	20
80	75	76	77	65	71
42	38	40	40	34	37
139	131	131	133	115	124
346	**323**	**327**	**333**	**283**	**307**

2012/01/13 EUTRx	2012/01/20 EUTRx	2012/01/27 EUTRx	2012/02/03 EUTRx	2012/02/10 EUTRx	2012/02/17 EUTRx
8,469,490	8,227,738	7,838,360	8,386,620	8,396,362	8,231,779
1,365,723	1,332,905	1,291,466	1,357,246	1,377,064	1,329,446
198,357	193,226	188,187	194,964	200,601	198,681
2,048,198	2,015,901	1,934,038	2,031,761	2,033,049	2,000,787
708,312	692,645	670,328	712,690	708,927	684,732
1,886,140	1,796,545	1,695,144	1,830,911	1,832,152	1,809,806
650,576	636,444	603,778	654,117	641,919	649,434
1,612,184	1,560,072	1,455,419	1,604,931	1,602,650	1,558,893
8,469,490	**8,227,738**	**7,838,360**	**8,386,620**	**8,396,362**	**8,231,779**

13,657,230	13,329,050	12,914,660	13,572,460	13,770,640	13,294,460
2,975,355	2,898,390	2,822,805	2,924,460	3,009,015	2,980,215
40,963,960	40,318,020	38,680,760	40,635,220	40,660,980	40,015,740
21,249,360	20,779,350	20,109,840	21,380,700	21,267,810	20,541,960
75,445,600	71,861,800	67,805,760	73,236,440	73,286,080	72,392,240
39,034,560	38,186,640	36,226,680	39,247,020	38,515,140	38,966,040
128,974,720	124,805,760	116,433,520	128,394,480	128,212,000	124,711,440
322,300,785	**312,179,010**	**294,994,025**	**319,390,780**	**318,721,665**	**312,902,095**

1/13/2012	1/20/2012	1/27/2012	2/3/2012	2/10/2012	2/17/2012
14	13	13	14	14	13
3	3	3	3	3	3
41	40	39	41	41	40
21	21	20	21	21	21
75	72	68	73	73	72
39	38	36	39	39	39
129	125	116	128	128	125
322	**312**	**295**	**319**	**319**	**313**

2012/02/24 EUTRx	2012/03/02 EUTRx	2012/03/09 EUTRx	2012/03/16 EUTRx	2012/03/23 EUTRx	2012/03/30 EUTRx
7,919,014	8,894,547	8,618,055	8,238,496	7,986,979	8,159,404
1,281,004	1,412,394	1,385,138	1,339,355	1,311,232	1,322,454
189,318	212,086	207,306	205,175	192,796	191,879
1,926,520	2,146,918	2,067,955	1,977,236	1,948,165	1,990,219
683,706	760,671	737,152	714,539	692,787	707,556
1,720,587	1,948,642	1,875,887	1,805,137	1,719,569	1,775,618
614,941	713,838	680,668	645,508	628,753	658,812
1,502,938	1,699,998	1,663,949	1,551,546	1,493,677	1,512,866
7,919,014	**8,894,547**	**8,618,055**	**8,238,496**	**7,986,979**	**8,159,404**

12,810,040	14,123,940	13,851,380	13,393,550	13,112,320	13,224,540
2,839,770	3,181,290	3,109,590	3,077,625	2,891,940	2,878,185
38,530,400	42,938,360	41,359,100	39,544,720	38,963,300	39,804,380
20,511,180	22,820,130	22,114,560	21,436,170	20,783,610	21,226,680
68,823,480	77,945,680	75,035,480	72,205,480	68,782,760	71,024,720
36,896,460	42,830,280	40,840,080	38,730,480	37,725,180	39,528,720
120,235,040	135,999,840	133,115,920	124,123,680	119,494,160	121,029,280
300,646,370	**339,839,520**	**329,426,110**	**312,511,705**	**301,753,270**	**308,716,505**

2/24/2012	3/2/2012	3/9/2012	3/16/2012	3/23/2012	3/30/2012
13	14	14	13	13	13
3	3	3	3	3	3
39	43	41	40	39	40
21	23	22	21	21	21
69	78	75	72	69	71
37	43	41	39	38	40
120	136	133	124	119	121
301	**340**	**329**	**313**	**302**	**309**

2012/04/06 EUTRx	2012/04/13 EUTRx	2012/04/20 EUTRx	2012/04/27 EUTRx	2012/05/04 EUTRx	2012/05/11 EUTRx
8,537,435	8,120,425	8,115,483	8,255,699	8,770,748	8,152,744
1,351,771	1,330,947	1,313,770	1,351,314	1,392,200	1,321,258
205,525	202,082	208,611	198,534	216,422	204,934
2,072,855	1,979,017	1,975,352	1,991,462	2,102,921	1,983,488
741,174	706,575	728,585	741,427	783,483	718,178
1,857,322	1,758,891	1,741,258	1,776,930	1,913,749	1,758,181
685,446	638,319	649,055	657,771	712,984	648,911
1,623,342	1,504,594	1,498,852	1,538,261	1,648,989	1,517,794
8,537,435	**8,120,425**	**8,115,483**	**8,255,699**	**8,770,748**	**8,152,744**

13,517,710	13,309,470	13,137,700	13,513,140	13,922,000	13,212,580
3,082,875	3,031,230	3,129,165	2,978,010	3,246,330	3,074,010
41,457,100	39,580,340	39,507,040	39,829,240	42,058,420	39,669,760
22,235,220	21,197,250	21,857,550	22,242,810	23,504,490	21,545,340
74,292,880	70,355,640	69,650,320	71,077,200	76,549,960	70,327,240
41,126,760	38,299,140	38,943,300	39,466,260	42,779,040	38,934,660
129,867,360	120,367,520	119,908,160	123,060,880	131,919,120	121,423,520
325,579,905	**306,140,590**	**306,133,235**	**312,167,540**	**333,979,360**	**308,187,110**

4/6/2012	4/13/2012	4/20/2012	4/27/2012	5/4/2012	5/11/2012
14	13	13	14	14	13
3	3	3	3	3	3
41	40	40	40	42	40
22	21	22	22	24	22
74	70	70	71	77	70
41	38	39	39	43	39
130	120	120	123	132	121
326	**306**	**306**	**312**	**334**	**308**

2012/05/18 EUTRx	2012/05/25 EUTRx	2012/06/01 EUTRx	2012/06/08 EUTRx	2012/06/15 EUTRx	2012/06/22 EUTRx
8,160,756	8,436,049	7,779,099	8,429,255	8,091,145	8,214,130
1,319,504	1,359,946	1,212,462	1,367,916	1,321,120	1,325,251
210,277	215,693	195,602	216,327	208,959	211,049
1,989,425	2,027,346	1,882,797	2,043,311	1,978,591	1,964,917
738,781	771,686	698,729	751,715	736,161	743,060
1,759,297	1,788,154	1,683,841	1,828,265	1,726,539	1,764,927
657,251	680,108	641,045	664,304	653,013	675,115
1,486,221	1,593,116	1,464,623	1,557,417	1,466,762	1,529,811
8,160,756	**8,436,049**	**7,779,099**	**8,429,255**	**8,091,145**	**8,214,130**

13,195,040	13,599,460	12,124,620	13,679,160	13,211,200	13,252,510
3,154,155	3,235,395	2,934,030	3,244,905	3,134,385	3,165,735
39,788,500	40,546,920	37,655,940	40,866,220	39,571,820	39,298,340
22,163,430	23,150,580	20,961,870	22,551,450	22,084,830	22,291,800
70,371,880	71,526,160	67,353,640	73,130,600	69,061,560	70,597,080
39,435,060	40,806,480	38,462,700	39,858,240	39,180,780	40,506,900
118,897,680	127,449,280	117,169,840	124,593,360	117,340,960	122,384,880
307,005,745	**320,314,275**	**296,662,640**	**317,923,935**	**303,585,535**	**311,497,245**

5/18/2012	5/25/2012	6/1/2012	6/8/2012	6/15/2012	6/22/2012
13	14	12	14	13	13
3	3	3	3	3	3
40	41	38	41	40	39
22	23	21	23	22	22
70	72	67	73	69	71
39	41	38	40	39	41
119	127	117	125	117	122
307	**320**	**297**	**318**	**304**	**311**

2012/06/29 EUTRx	2012/07/06 EUTRx	2012/07/13 EUTRx	2012/07/20 EUTRx	2012/07/27 EUTRx	2012/08/03 EUTRx
8,246,084	8,065,352	8,208,806	8,219,836	8,049,688	8,109,693
1,331,557	1,247,785	1,333,196	1,320,775	1,293,848	1,294,651
207,192	205,022	220,230	213,404	211,946	225,106
2,009,525	1,917,797	1,993,330	1,981,127	1,931,675	1,958,511
754,691	740,361	746,328	753,942	745,686	752,622
1,762,116	1,774,739	1,743,741	1,752,346	1,710,773	1,726,301
669,984	668,827	674,817	680,461	677,459	674,364
1,511,019	1,510,821	1,497,164	1,517,781	1,478,301	1,478,138
8,246,084	**8,065,352**	**8,208,806**	**8,219,836**	**8,049,688**	**8,109,693**

13,315,570	12,477,850	13,331,960	13,207,750	12,938,480	12,946,510
3,107,880	3,075,330	3,303,450	3,201,060	3,179,190	3,376,590
40,190,500	38,355,940	39,866,600	39,622,540	38,633,500	39,170,220
22,640,730	22,210,830	22,389,840	22,618,260	22,370,580	22,578,660
70,484,640	70,989,560	69,749,640	70,093,840	68,430,920	69,052,040
40,199,040	40,129,620	40,489,020	40,827,660	40,647,540	40,461,840
120,881,520	120,865,680	119,773,120	121,422,480	118,264,080	118,251,040
310,819,880	**308,104,810**	**308,903,630**	**310,993,590**	**304,464,290**	**305,836,900**

6/29/2012	7/6/2012	7/13/2012	7/20/2012	7/27/2012	8/3/2012
13	12	13	13	13	13
3	3	3	3	3	3
40	38	40	40	39	39
23	22	22	23	22	23
70	71	70	70	68	69
40	40	40	41	41	40
121	121	120	121	118	118
311	**308**	**309**	**311**	**304**	**306**

2012/08/10 EUTRx	2012/08/17 EUTRx	2012/08/24 EUTRx	2012/08/31 EUTRx	2012/09/07 EUTRx	2012/09/14 EUTRx
7,974,578	8,149,473	8,080,157	8,197,503	7,825,427	8,192,273
1,273,489	1,301,949	1,311,403	1,335,840	1,244,933	1,325,606
213,871	222,794	209,361	223,269	208,040	225,574
1,911,171	1,962,404	1,947,527	1,977,330	1,874,717	1,967,788
734,455	769,565	759,252	761,468	716,018	767,384
1,723,897	1,724,155	1,701,861	1,744,427	1,670,009	1,738,777
657,871	668,116	680,407	674,342	647,370	682,306
1,459,824	1,500,490	1,470,346	1,480,827	1,464,340	1,484,838
7,974,578	**8,149,473**	**8,080,157**	**8,197,503**	**7,825,427**	**8,192,273**

12,734,890	13,019,490	13,114,030	13,358,400	12,449,330	13,256,060
3,208,065	3,341,910	3,140,415	3,349,035	3,120,600	3,383,610
38,223,420	39,248,080	38,950,540	39,546,600	37,494,340	39,355,760
22,033,650	23,086,950	22,777,560	22,844,040	21,480,540	23,021,520
68,955,880	68,966,200	68,074,440	69,777,080	66,800,360	69,551,080
39,472,260	40,086,960	40,824,420	40,460,520	38,842,200	40,938,360
116,785,920	120,039,200	117,627,680	118,466,160	117,147,200	118,787,040
301,414,085	**307,788,790**	**304,509,085**	**307,801,835**	**297,334,570**	**308,293,430**

8/10/2012	8/17/2012	8/24/2012	8/31/2012	9/7/2012	9/14/2012
13	13	13	13	12	13
3	3	3	3	3	3
38	39	39	40	37	39
22	23	23	23	21	23
69	69	68	70	67	70
39	40	41	40	39	41
117	120	118	118	117	119
301	**308**	**305**	**308**	**297**	**308**

2012/09/21 EUTRx	2012/09/28 EUTRx	2012/10/05 EUTRx	2012/10/12 EUTRx	2012/10/19 EUTRx	2012/10/26 EUTRx
8,136,521	8,213,947	8,361,496	7,998,840	8,124,850	8,050,027
1,325,313	1,344,176	1,374,362	1,303,257	1,338,856	1,331,872
225,149	236,966	226,804	220,912	226,671	225,216
1,961,098	1,998,014	1,997,873	1,923,789	1,961,642	1,935,649
755,777	773,138	775,524	760,819	760,116	757,949
1,707,833	1,745,287	1,764,524	1,682,430	1,686,399	1,684,899
680,595	670,088	688,895	666,696	679,457	661,482
1,480,756	1,446,278	1,533,514	1,440,937	1,471,709	1,452,960
8,136,521	**8,213,947**	**8,361,496**	**7,998,840**	**8,124,850**	**8,050,027**

13,253,130	13,441,760	13,743,620	13,032,570	13,388,560	13,318,720
3,377,235	3,554,490	3,402,060	3,313,680	3,400,065	3,378,240
39,221,960	39,960,280	39,957,460	38,475,780	39,232,840	38,712,980
22,673,310	23,194,140	23,265,720	22,824,570	22,803,480	22,738,470
68,313,320	69,811,480	70,580,960	67,297,200	67,455,960	67,395,960
40,835,700	40,205,280	41,333,700	40,001,760	40,767,420	39,688,920
118,460,480	115,702,240	122,681,120	115,274,960	117,736,720	116,236,800
306,135,135	**305,869,670**	**314,964,640**	**300,220,520**	**304,785,045**	**301,470,090**

9/21/2012	9/28/2012	10/5/2012	10/12/2012	10/19/2012	10/26/2012
13	13	14	13	13	13
3	4	3	3	3	3
39	40	40	38	39	39
23	23	23	23	23	23
68	70	71	67	67	67
41	40	41	40	41	40
118	116	123	115	118	116
306	**306**	**315**	**300**	**305**	**301**

2012/11/02 EUTRx	2012/11/09 EUTRx	2012/11/16 EUTRx	2012/11/23 EUTRx	2012/11/30 EUTRx	2012/12/07 EUTRx
7,884,768	8,339,872	8,169,418	7,392,202	8,446,015	8,599,666
1,297,235	1,379,991	1,366,641	1,217,989	1,419,962	1,401,942
222,271	238,223	233,136	208,902	240,382	240,681
1,904,322	2,009,064	1,937,501	1,784,409	2,032,073	2,073,229
750,263	789,110	769,893	707,008	805,363	822,187
1,659,852	1,725,846	1,696,914	1,541,620	1,760,216	1,790,300
645,429	709,182	685,531	606,318	704,753	719,867
1,405,396	1,488,456	1,479,802	1,325,956	1,483,266	1,551,460
7,884,768	**8,339,872**	**8,169,418**	**7,392,202**	**8,446,015**	**8,599,666**

12,972,350	13,799,910	13,666,410	12,179,890	14,199,620	14,019,420
3,334,065	3,573,345	3,497,040	3,133,530	3,605,730	3,610,215
38,086,440	40,181,280	38,750,020	35,688,180	40,641,460	41,464,580
22,507,890	23,673,300	23,096,790	21,210,240	24,160,890	24,665,610
66,394,080	69,033,840	67,876,560	61,664,800	70,408,640	71,612,000
38,725,740	42,550,920	41,131,860	36,379,080	42,285,180	43,192,020
112,431,680	119,076,480	118,384,160	106,076,480	118,661,280	124,116,800
294,452,245	**311,889,075**	**306,402,840**	**276,332,200**	**313,962,800**	**322,680,645**

11/2/2012	11/9/2012	11/16/2012	11/23/2012	11/30/2012	12/7/2012
13	14	14	12	14	14
3	4	3	3	4	4
38	40	39	36	41	41
23	24	23	21	24	25
66	69	68	62	70	72
39	43	41	36	42	43
112	119	118	106	119	124
294	**312**	**306**	**276**	**314**	**323**

2012/12/14 EUTRx	2012/12/21 EUTRx	2012/12/28 EUTRx	2013/01/04 EUTRx	2013/01/11 EUTRx	2013/01/18 EUTRx
8,234,376	8,591,485	6,903,075	7,648,883	8,143,336	8,052,086
1,356,149	1,424,601	1,108,913	1,228,344	1,319,309	1,327,537
243,353	248,169	193,069	210,753	240,570	230,249
1,979,123	2,070,155	1,643,246	1,823,867	1,946,375	1,919,911
792,021	825,149	650,731	743,527	776,260	779,645
1,700,905	1,774,350	1,446,706	1,598,914	1,712,556	1,647,897
692,300	708,922	594,161	657,326	691,962	686,765
1,470,525	1,540,139	1,266,249	1,386,152	1,456,304	1,460,082
8,234,376	**8,591,485**	**6,903,075**	**7,648,883**	**8,143,336**	**8,052,086**

13,561,490	14,246,010	11,089,130	12,283,440	13,193,090	13,275,370
3,650,295	3,722,535	2,896,035	3,161,295	3,608,550	3,453,735
39,582,460	41,403,100	32,864,920	36,477,340	38,927,500	38,398,220
23,760,630	24,754,470	19,521,930	22,305,810	23,287,800	23,389,350
68,036,200	70,974,000	57,868,240	63,956,560	68,502,240	65,915,880
41,538,000	42,535,320	35,649,660	39,439,560	41,517,720	41,205,900
117,642,000	123,211,120	101,299,920	110,892,160	116,504,320	116,806,560
307,771,075	**320,846,555**	**261,189,835**	**288,516,165**	**305,541,220**	**302,445,015**

12/14/2012	12/21/2012	12/28/2012	1/4/2013	1/11/2013	1/18/2013
14	14	11	12	13	13
4	4	3	3	4	3
40	41	33	36	39	38
24	25	20	22	23	23
68	71	58	64	69	66
42	43	36	39	42	41
118	123	101	111	117	117
308	**321**	**261**	**289**	**306**	**302**

2013/01/25 EUTRx	2013/02/01 EUTRx	2013/02/08 EUTRx	2013/02/15 EUTRx	2013/02/22 EUTRx	2013/03/01 EUTRx
7,200,338	7,683,391	8,162,552	7,879,116	7,253,340	8,096,634
1,204,426	1,250,185	1,323,987	1,311,402	1,234,444	1,313,174
218,947	219,310	238,577	226,095	216,995	241,102
1,728,049	1,846,356	1,923,103	1,877,138	1,744,529	1,938,072
690,742	741,895	806,799	748,911	723,181	801,071
1,479,337	1,592,447	1,685,464	1,640,730	1,479,375	1,662,896
610,193	658,830	706,251	655,037	609,224	701,244
1,268,644	1,374,368	1,478,371	1,419,803	1,245,592	1,439,075
7,200,338	**7,683,391**	**8,162,552**	**7,879,116**	**7,253,340**	**8,096,634**

12,044,260	12,501,850	13,239,870	13,114,020	12,344,440	13,131,740
3,284,205	3,289,650	3,578,655	3,391,425	3,254,925	3,616,530
34,560,980	36,927,120	38,462,060	37,542,760	34,890,580	38,761,440
20,722,260	22,256,850	24,203,970	22,467,330	21,695,430	24,032,130
59,173,480	63,697,880	67,418,560	65,629,200	59,175,000	66,515,840
36,611,580	39,529,800	42,375,060	39,302,220	36,553,440	42,074,640
101,491,520	109,949,440	118,269,680	113,584,240	99,647,360	115,126,000
267,888,285	**288,152,590**	**307,547,855**	**295,031,195**	**267,561,175**	**303,258,320**

1/25/2013	2/1/2013	2/8/2013	2/15/2013	2/22/2013	3/1/2013
12	13	13	13	12	13
3	3	4	3	3	4
35	37	38	38	35	39
21	22	24	22	22	24
59	64	67	66	59	67
37	40	42	39	37	42
101	110	118	114	100	115
268	**288**	**308**	**295**	**268**	**303**

2013/03/08 EUTRx	2013/03/15 EUTRx	2013/03/22 EUTRx	2013/03/29 EUTRx	2013/04/05 EUTRx	2013/04/12 EUTRx
8,277,776	7,711,915	7,398,795	7,332,806	7,831,508	7,526,041
1,334,871	1,279,468	1,257,307	1,210,871	1,270,528	1,255,679
242,567	228,095	227,500	216,006	229,814	232,819
1,979,090	1,850,109	1,782,160	1,764,374	1,858,814	1,809,809
802,211	745,368	735,041	734,465	774,321	742,801
1,728,659	1,568,602	1,501,003	1,497,569	1,619,675	1,529,222
694,780	654,045	621,622	636,926	675,819	640,477
1,495,598	1,386,228	1,274,162	1,272,595	1,402,537	1,315,234
8,277,776	**7,711,915**	**7,398,795**	**7,332,806**	**7,831,508**	**7,526,041**

13,348,710	12,794,680	12,573,070	12,108,710	12,705,280	12,556,790
3,638,505	3,421,425	3,412,500	3,240,090	3,447,210	3,492,285
39,581,800	37,002,180	35,643,200	35,287,480	37,176,280	36,196,180
24,066,330	22,361,040	22,051,230	22,033,950	23,229,630	22,284,030
69,146,360	62,744,080	60,040,120	59,902,760	64,787,000	61,168,880
41,686,800	39,242,700	37,297,320	38,215,560	40,549,140	38,428,620
119,647,840	110,898,240	101,932,960	101,807,600	112,202,960	105,218,720
311,116,345	**288,464,345**	**272,950,400**	**272,596,150**	**294,097,500**	**279,345,505**

3/8/2013	3/15/2013	3/22/2013	3/29/2013	4/5/2013	4/12/2013
13	13	13	12	13	13
4	3	3	3	3	3
40	37	36	35	37	36
24	22	22	22	23	22
69	63	60	60	65	61
42	39	37	38	41	38
120	111	102	102	112	105
311	**288**	**273**	**273**	**294**	**279**

2013/04/19 EUTRx	2013/04/26 EUTRx	2013/05/03 EUTRx	2013/05/10 EUTRx	2013/05/17 EUTRx	2013/05/24 EUTRx
7,248,633	7,378,376	7,960,202	7,591,448	7,283,133	7,581,531
1,219,931	1,230,749	1,297,032	1,245,752	1,237,341	1,264,585
221,863	221,743	243,182	236,717	228,184	232,396
1,751,426	1,759,156	1,877,871	1,838,489	1,783,506	1,820,998
736,584	742,974	790,780	760,706	745,344	776,599
1,457,311	1,514,307	1,645,401	1,547,612	1,454,076	1,526,871
622,198	633,976	681,333	661,094	621,112	660,081
1,239,320	1,275,471	1,424,066	1,301,078	1,213,570	1,300,001
7,249,798	**7,379,028**	**7,960,361**	**7,591,535**	**7,283,970**	**7,581,999**

12,199,310	12,307,490	12,970,320	12,457,520	12,373,410	12,645,850
3,327,945	3,326,145	3,647,730	3,550,755	3,422,760	3,485,940
35,028,520	35,183,120	37,557,420	36,769,780	35,670,120	36,419,960
22,097,520	22,289,220	23,723,400	22,821,180	22,360,320	23,297,970
58,292,440	60,572,280	65,816,040	61,904,480	58,163,040	61,074,840
37,331,880	38,038,560	40,879,980	39,665,640	37,266,720	39,604,860
99,145,600	102,037,680	113,925,280	104,086,240	97,085,600	104,000,080
267,423,215	**273,754,495**	**298,520,170**	**281,255,595**	**266,341,970**	**280,529,500**

4/19/2013	4/26/2013	5/3/2013	5/10/2013	5/17/2013	5/24/2013
12	12	13	12	12	13
3	3	4	4	3	3
35	35	38	37	36	36
22	22	24	23	22	23
58	61	66	62	58	61
37	38	41	40	37	40
99	102	114	104	97	104
267	**274**	**299**	**281**	**266**	**281**

2013/05/31 EUTRx	2013/06/07 EUTRx	2013/06/14 EUTRx	2013/06/21 EUTRx	2013/06/28 EUTRx	2013/07/05 EUTRx
6,955,687	7,894,454	7,355,086	7,399,395	7,424,086	7,379,096
1,135,887	1,306,249	1,263,289	1,242,713	1,237,575	1,207,400
220,347	240,832	233,898	230,435	233,365	233,200
1,664,311	1,900,664	1,767,584	1,789,389	1,759,085	1,737,213
696,081	781,148	752,408	756,718	751,958	751,044
1,430,577	1,621,728	1,460,150	1,496,701	1,502,463	1,534,736
590,116	678,679	625,534	635,692	646,804	639,096
1,218,368	1,365,154	1,252,223	1,247,747	1,292,836	1,276,407
6,956,349	**7,895,170**	**7,355,525**	**7,399,769**	**7,424,477**	**7,380,613**

11,358,870	13,062,490	12,632,890	12,427,130	12,375,750	12,074,000
3,305,205	3,612,480	3,508,470	3,456,525	3,500,475	3,498,000
33,286,220	38,013,280	35,351,680	35,787,780	35,181,700	34,744,260
20,882,430	23,434,440	22,572,240	22,701,540	22,558,740	22,531,320
57,223,080	64,869,120	58,406,000	59,868,040	60,098,520	61,389,440
35,406,960	40,720,740	37,532,040	38,141,520	38,808,240	38,345,760
97,469,440	109,212,320	100,177,840	99,819,760	103,426,880	102,112,560
258,932,205	**292,924,870**	**270,181,160**	**272,202,295**	**275,950,305**	**274,695,340**

5/31/2013	6/7/2013	6/14/2013	6/21/2013	6/28/2013	7/5/2013
11	13	13	12	12	12
3	4	4	3	4	3
33	38	35	36	35	35
21	23	23	23	23	23
57	65	58	60	60	61
35	41	38	38	39	38
97	109	100	100	103	102
259	**293**	**270**	**272**	**276**	**275**

2013/07/12 EUTRx	2013/07/19 EUTRx	2013/07/26 EUTRx	2013/08/02 EUTRx	2013/08/09 EUTRx
7,499,488	7,447,428	7,353,787	7,369,790	7,321,211
1,278,032	1,242,710	1,212,132	1,234,035	1,225,447
247,538	237,555	238,275	231,112	247,005
1,793,058	1,786,137	1,751,271	1,757,105	1,761,112
774,868	779,594	766,613	762,892	758,036
1,490,155	1,508,581	1,486,343	1,504,386	1,455,839
639,162	650,968	640,377	626,991	635,082
1,276,675	1,241,883	1,258,776	1,253,269	1,238,690
7,500,116	**7,448,280**	**7,354,329**	**7,370,813**	**7,321,789**

12,780,320	12,427,100	12,121,320	12,340,350	12,254,470
3,713,070	3,563,325	3,574,125	3,466,680	3,705,075
35,861,160	35,722,740	35,025,420	35,142,100	35,222,240
23,246,040	23,387,820	22,998,390	22,886,760	22,741,080
59,606,200	60,343,240	59,453,720	60,175,440	58,233,560
38,349,720	39,058,080	38,422,620	37,619,460	38,104,920
102,134,000	99,350,640	100,702,080	100,261,520	99,095,200
275,690,510	**273,852,945**	**272,297,675**	**271,892,310**	**269,356,545**

7/12/2013	7/19/2013	7/26/2013	8/2/2013	8/2/2013

13	12	12	12	12
4	4	4	3	4
36	36	35	35	35
23	23	23	23	23
60	60	59	60	58
38	39	38	38	38
102	99	101	100	99
276	**274**	**272**	**272**	**269**

OxyContin Units and Kg Dispensed
IMS Health NPA
numbers are absolute. Retail pharmacies, mail order and LTC

Product	2011/04/08 EUTRx	2011/04/15 EUTRx	2011/04/22 EUTRx	2011/04/29 EUTRx
OXYCONTIN 01/1996 PUF	9,245,201	8,798,770	8,573,636	8,811,087
10MG	1,478,660	1,427,631	1,390,912	1,405,432
15MG	183,269	180,224	173,573	179,380
20MG	2,290,945	2,192,332	2,165,596	2,193,475
30MG	692,907	673,958	647,518	666,744
40MG	2,055,364	1,943,620	1,899,504	1,960,507
60MG	671,650	658,988	610,461	638,010
80MG	1,872,406	1,722,017	1,686,072	1,767,539
Grand Total	**9,245,201**	**8,798,770**	**8,573,636**	**8,811,087**

Kg Dispensed

OXYCONTIN 01/1996 PUF				
10MG	14.8	14.3	13.9	14.1
15MG	2.7	2.7	2.6	2.7
20MG	45.8	43.8	43.3	43.9
30MG	20.8	20.2	19.4	20.0
40MG	82.2	77.7	76.0	78.4
60MG	40.3	39.5	36.6	38.3
80MG	149.8	137.8	134.9	141.4
Grand Total	**356.4**	**336.1**	**326.7**	**338.7**

2011/05/06 EUTRx	2011/05/13 EUTRx	2011/05/20 EUTRx	2011/05/27 EUTRx	2011/06/03 EUTRx	2011/06/10 EUTRx
9,501,374	8,741,359	8,573,294	9,026,667	8,430,496	8,792,965
1,487,471	1,400,215	1,390,618	1,450,473	1,311,696	1,431,988
185,164	181,782	178,413	184,192	166,081	181,190
2,391,478	2,199,539	2,152,247	2,232,569	2,096,801	2,197,315
717,131	661,119	661,896	689,695	650,666	677,241
2,110,498	1,935,334	1,891,439	2,010,862	1,887,654	1,930,916
700,016	634,357	629,136	664,006	627,137	649,340
1,909,616	1,729,013	1,669,545	1,794,870	1,690,461	1,724,975
9,501,374	**8,741,359**	**8,573,294**	**9,026,667**	**8,430,496**	**8,792,965**

14.9	14.0	13.9	14.5	13.1	14.3
2.8	2.7	2.7	2.8	2.5	2.7
47.8	44.0	43.0	44.7	41.9	43.9
21.5	19.8	19.9	20.7	19.5	20.3
84.4	77.4	75.7	80.4	75.5	77.2
42.0	38.1	37.7	39.8	37.6	39.0
152.8	138.3	133.6	143.6	135.2	138.0
366.2	**334.3**	**326.5**	**346.5**	**325.4**	**335.5**

2011/06/17 EUTRx	2011/06/24 EUTRx	2011/07/01 EUTRx	2011/07/08 EUTRx	2011/07/15 EUTRx	2011/07/22 EUTRx
8,581,589	8,758,691	9,331,763	8,126,682	8,625,729	8,619,338
1,389,967	1,391,937	1,474,790	1,283,213	1,387,431	1,367,678
177,671	180,557	189,408	170,738	183,608	182,874
2,157,000	2,161,652	2,351,092	2,026,960	2,159,950	2,143,410
673,071	680,089	726,907	641,157	682,731	672,123
1,882,461	1,953,240	2,021,413	1,795,202	1,887,344	1,921,136
618,362	650,976	683,878	604,158	645,302	634,734
1,683,057	1,740,240	1,884,275	1,605,254	1,679,363	1,697,383
8,581,589	**8,758,691**	**9,331,763**	**8,126,682**	**8,625,729**	**8,619,338**

13.9	13.9	14.7	12.8	13.9	13.7
2.7	2.7	2.8	2.6	2.8	2.7
43.1	43.2	47.0	40.5	43.2	42.9
20.2	20.4	21.8	19.2	20.5	20.2
75.3	78.1	80.9	71.8	75.5	76.8
37.1	39.1	41.0	36.2	38.7	38.1
134.6	139.2	150.7	128.4	134.3	135.8
326.9	**336.7**	**359.0**	**311.6**	**328.9**	**330.2**

2011/07/29 EUTRx	2011/08/05 EUTRx	2011/08/12 EUTRx	2011/08/19 EUTRx	2011/08/26 EUTRx	2011/09/02 EUTRx
8,639,239	8,539,432	8,432,171	8,561,895	8,586,953	8,700,800
1,389,900	1,351,652	1,352,449	1,347,382	1,361,439	1,415,584
176,085	182,481	181,231	186,212	186,411	178,550
2,123,617	2,112,497	2,094,035	2,110,746	2,107,274	2,147,515
667,672	674,468	661,561	678,745	683,683	676,670
1,936,667	1,936,788	1,887,976	1,937,511	1,935,523	1,953,056
645,107	634,667	627,548	634,527	640,278	646,482
1,700,191	1,646,879	1,627,371	1,666,772	1,672,345	1,682,943
8,639,239	**8,539,432**	**8,432,171**	**8,561,895**	**8,586,953**	**8,700,800**

13.9	13.5	13.5	13.5	13.6	14.2
2.6	2.7	2.7	2.8	2.8	2.7
42.5	42.2	41.9	42.2	42.1	43.0
20.0	20.2	19.8	20.4	20.5	20.3
77.5	77.5	75.5	77.5	77.4	78.1
38.7	38.1	37.7	38.1	38.4	38.8
136.0	131.8	130.2	133.3	133.8	134.6
331.2	**326.0**	**321.3**	**327.8**	**328.7**	**331.6**

2011/09/09 EUTRx	2011/09/16 EUTRx	2011/09/23 EUTRx	2011/09/30 EUTRx	2011/10/07 EUTRx	2011/10/14 EUTRx
7,939,083	8,695,016	8,573,455	8,609,904	8,575,899	8,500,737
1,229,109	1,381,856	1,381,121	1,373,109	1,368,633	1,352,102
175,024	189,614	186,948	190,182	190,450	185,702
1,967,166	2,144,689	2,112,236	2,135,620	2,105,859	2,086,422
636,604	677,628	673,665	691,553	689,623	676,394
1,785,643	1,965,443	1,913,663	1,915,038	1,921,786	1,904,402
590,123	642,338	635,168	644,614	645,360	634,044
1,555,414	1,693,448	1,670,654	1,659,788	1,654,188	1,661,671
7,939,083	**8,695,016**	**8,573,455**	**8,609,904**	**8,575,899**	**8,500,737**

12.3	13.8	13.8	13.7	13.7	13.5
2.6	2.8	2.8	2.9	2.9	2.8
39.3	42.9	42.2	42.7	42.1	41.7
19.1	20.3	20.2	20.7	20.7	20.3
71.4	78.6	76.5	76.6	76.9	76.2
35.4	38.5	38.1	38.7	38.7	38.0
124.4	135.5	133.7	132.8	132.3	132.9
304.6	**332.5**	**327.4**	**328.1**	**327.3**	**325.5**

2011/10/21 EUTRx	2011/10/28 EUTRx	2011/11/04 EUTRx	2011/11/11 EUTRx	2011/11/18 EUTRx	2011/11/25 EUTRx
8,433,590	8,378,797	8,364,566	8,419,830	8,534,146	7,488,971
1,374,237	1,356,864	1,366,208	1,351,490	1,383,921	1,208,518
188,811	185,808	181,204	187,251	191,323	170,857
2,056,120	2,058,621	2,052,221	2,068,524	2,087,144	1,824,031
676,712	681,559	688,050	676,655	699,901	607,197
1,867,511	1,875,802	1,843,814	1,868,754	1,888,589	1,654,741
638,311	644,857	630,014	630,742	663,539	578,161
1,631,888	1,575,286	1,603,055	1,636,414	1,619,729	1,445,466
8,433,590	**8,378,797**	**8,364,566**	**8,419,830**	**8,534,146**	**7,488,971**

13.7	13.6	13.7	13.5	13.8	12.1
2.8	2.8	2.7	2.8	2.9	2.6
41.1	41.2	41.0	41.4	41.7	36.5
20.3	20.4	20.6	20.3	21.0	18.2
74.7	75.0	73.8	74.8	75.5	66.2
38.3	38.7	37.8	37.8	39.8	34.7
130.6	126.0	128.2	130.9	129.6	115.6
321.5	**317.7**	**317.9**	**321.5**	**324.4**	**285.9**

2011/12/02 EUTRx	2011/12/09 EUTRx	2011/12/16 EUTRx	2011/12/23 EUTRx	2011/12/30 EUTRx	2012/01/06 EUTRx
9,056,397	8,496,159	8,633,759	8,783,921	7,373,644	8,063,746
1,439,090	1,374,240	1,423,190	1,451,921	1,158,790	1,282,119
193,397	201,119	197,707	198,672	161,569	192,487
2,213,081	2,074,192	2,094,123	2,151,605	1,806,349	1,971,363
756,778	705,047	714,547	714,302	614,514	680,416
2,012,438	1,871,406	1,903,644	1,932,693	1,627,130	1,771,423
699,049	634,440	666,005	672,301	570,244	618,521
1,742,564	1,635,715	1,634,543	1,662,427	1,434,977	1,547,417
9,056,397	**8,496,159**	**8,633,759**	**8,783,921**	**7,373,644**	**8,063,746**

14.4	13.7	14.2	14.5	11.6	12.8
2.9	3.0	3.0	3.0	2.4	2.9
44.3	41.5	41.9	43.0	36.1	39.4
22.7	21.2	21.4	21.4	18.4	20.4
80.5	74.9	76.1	77.3	65.1	70.9
41.9	38.1	40.0	40.3	34.2	37.1
139.4	130.9	130.8	133.0	114.8	123.8
346.1	**323.2**	**327.4**	**332.6**	**282.7**	**307.3**

2012/01/13 EUTRx	2012/01/20 EUTRx	2012/01/27 EUTRx	2012/02/03 EUTRx	2012/02/10 EUTRx	2012/02/17 EUTRx
8,469,490	8,227,738	7,838,360	8,386,620	8,396,362	8,231,779
1,365,723	1,332,905	1,291,466	1,357,246	1,377,064	1,329,446
198,357	193,226	188,187	194,964	200,601	198,681
2,048,198	2,015,901	1,934,038	2,031,761	2,033,049	2,000,787
708,312	692,645	670,328	712,690	708,927	684,732
1,886,140	1,796,545	1,695,144	1,830,911	1,832,152	1,809,806
650,576	636,444	603,778	654,117	641,919	649,434
1,612,184	1,560,072	1,455,419	1,604,931	1,602,650	1,558,893
8,469,490	**8,227,738**	**7,838,360**	**8,386,620**	**8,396,362**	**8,231,779**

13.7	13.3	12.9	13.6	13.8	13.3
3.0	2.9	2.8	2.9	3.0	3.0
41.0	40.3	38.7	40.6	40.7	40.0
21.2	20.8	20.1	21.4	21.3	20.5
75.4	71.9	67.8	73.2	73.3	72.4
39.0	38.2	36.2	39.2	38.5	39.0
129.0	124.8	116.4	128.4	128.2	124.7
322.3	**312.2**	**295.0**	**319.4**	**318.7**	**312.9**

2012/02/24 EUTRx	2012/03/02 EUTRx	2012/03/09 EUTRx	2012/03/16 EUTRx	2012/03/23 EUTRx	2012/03/30 EUTRx
7,919,014	8,894,547	8,618,055	8,238,496	7,986,979	8,159,404
1,281,004	1,412,394	1,385,138	1,339,355	1,311,232	1,322,454
189,318	212,086	207,306	205,175	192,796	191,879
1,926,520	2,146,918	2,067,955	1,977,236	1,948,165	1,990,219
683,706	760,671	737,152	714,539	692,787	707,556
1,720,587	1,948,642	1,875,887	1,805,137	1,719,569	1,775,618
614,941	713,838	680,668	645,508	628,753	658,812
1,502,938	1,699,998	1,663,949	1,551,546	1,493,677	1,512,866
7,919,014	**8,894,547**	**8,618,055**	**8,238,496**	**7,986,979**	**8,159,404**

12.8	14.1	13.9	13.4	13.1	13.2
2.8	3.2	3.1	3.1	2.9	2.9
38.5	42.9	41.4	39.5	39.0	39.8
20.5	22.8	22.1	21.4	20.8	21.2
68.8	77.9	75.0	72.2	68.8	71.0
36.9	42.8	40.8	38.7	37.7	39.5
120.2	136.0	133.1	124.1	119.5	121.0
300.6	**339.8**	**329.4**	**312.5**	**301.8**	**308.7**

2012/04/06 EUTRx	2012/04/13 EUTRx	2012/04/20 EUTRx	2012/04/27 EUTRx	2012/05/04 EUTRx	2012/05/11 EUTRx
8,537,435	8,120,425	8,115,483	8,255,699	8,770,748	8,152,744
1,351,771	1,330,947	1,313,770	1,351,314	1,392,200	1,321,258
205,525	202,082	208,611	198,534	216,422	204,934
2,072,855	1,979,017	1,975,352	1,991,462	2,102,921	1,983,488
741,174	706,575	728,585	741,427	783,483	718,178
1,857,322	1,758,891	1,741,258	1,776,930	1,913,749	1,758,181
685,446	638,319	649,055	657,771	712,984	648,911
1,623,342	1,504,594	1,498,852	1,538,261	1,648,989	1,517,794
8,537,435	**8,120,425**	**8,115,483**	**8,255,699**	**8,770,748**	**8,152,744**

13.5	13.3	13.1	13.5	13.9	13.2
3.1	3.0	3.1	3.0	3.2	3.1
41.5	39.6	39.5	39.8	42.1	39.7
22.2	21.2	21.9	22.2	23.5	21.5
74.3	70.4	69.7	71.1	76.5	70.3
41.1	38.3	38.9	39.5	42.8	38.9
129.9	120.4	119.9	123.1	131.9	121.4
325.6	**306.1**	**306.1**	**312.2**	**334.0**	**308.2**

2012/05/18 EUTRx	2012/05/25 EUTRx	2012/06/01 EUTRx	2012/06/08 EUTRx	2012/06/15 EUTRx	2012/06/22 EUTRx
8,160,756	8,436,049	7,779,099	8,429,255	8,091,145	8,214,130
1,319,504	1,359,946	1,212,462	1,367,916	1,321,120	1,325,251
210,277	215,693	195,602	216,327	208,959	211,049
1,989,425	2,027,346	1,882,797	2,043,311	1,978,591	1,964,917
738,781	771,686	698,729	751,715	736,161	743,060
1,759,297	1,788,154	1,683,841	1,828,265	1,726,539	1,764,927
657,251	680,108	641,045	664,304	653,013	675,115
1,486,221	1,593,116	1,464,623	1,557,417	1,466,762	1,529,811
8,160,756	**8,436,049**	**7,779,099**	**8,429,255**	**8,091,145**	**8,214,130**

13.2	13.6	12.1	13.7	13.2	13.3
3.2	3.2	2.9	3.2	3.1	3.2
39.8	40.5	37.7	40.9	39.6	39.3
22.2	23.2	21.0	22.6	22.1	22.3
70.4	71.5	67.4	73.1	69.1	70.6
39.4	40.8	38.5	39.9	39.2	40.5
118.9	127.4	117.2	124.6	117.3	122.4
307.0	**320.3**	**296.7**	**317.9**	**303.6**	**311.5**

2012/06/29 EUTRx	2012/07/06 EUTRx	2012/07/13 EUTRx	2012/07/20 EUTRx	2012/07/27 EUTRx	2012/08/03 EUTRx
8,246,084	8,065,352	8,208,806	8,219,836	8,049,688	8,109,693
1,331,557	1,247,785	1,333,196	1,320,775	1,293,848	1,294,651
207,192	205,022	220,230	213,404	211,946	225,106
2,009,525	1,917,797	1,993,330	1,981,127	1,931,675	1,958,511
754,691	740,361	746,328	753,942	745,686	752,622
1,762,116	1,774,739	1,743,741	1,752,346	1,710,773	1,726,301
669,984	668,827	674,817	680,461	677,459	674,364
1,511,019	1,510,821	1,497,164	1,517,781	1,478,301	1,478,138
8,246,084	**8,065,352**	**8,208,806**	**8,219,836**	**8,049,688**	**8,109,693**

13.3	12.5	13.3	13.2	12.9	12.9
3.1	3.1	3.3	3.2	3.2	3.4
40.2	38.4	39.9	39.6	38.6	39.2
22.6	22.2	22.4	22.6	22.4	22.6
70.5	71.0	69.7	70.1	68.4	69.1
40.2	40.1	40.5	40.8	40.6	40.5
120.9	120.9	119.8	121.4	118.3	118.3
310.8	**308.1**	**308.9**	**311.0**	**304.5**	**305.8**

2012/08/10 EUTRx	2012/08/17 EUTRx	2012/08/24 EUTRx	2012/08/31 EUTRx	2012/09/07 EUTRx	2012/09/14 EUTRx
7,974,578	8,149,473	8,080,157	8,197,503	7,825,427	8,192,273
1,273,489	1,301,949	1,311,403	1,335,840	1,244,933	1,325,606
213,871	222,794	209,361	223,269	208,040	225,574
1,911,171	1,962,404	1,947,527	1,977,330	1,874,717	1,967,788
734,455	769,565	759,252	761,468	716,018	767,384
1,723,897	1,724,155	1,701,861	1,744,427	1,670,009	1,738,777
657,871	668,116	680,407	674,342	647,370	682,306
1,459,824	1,500,490	1,470,346	1,480,827	1,464,340	1,484,838
7,974,578	**8,149,473**	**8,080,157**	**8,197,503**	**7,825,427**	**8,192,273**

12.7	13.0	13.1	13.4	12.4	13.3
3.2	3.3	3.1	3.3	3.1	3.4
38.2	39.2	39.0	39.5	37.5	39.4
22.0	23.1	22.8	22.8	21.5	23.0
69.0	69.0	68.1	69.8	66.8	69.6
39.5	40.1	40.8	40.5	38.8	40.9
116.8	120.0	117.6	118.5	117.1	118.8
301.4	**307.8**	**304.5**	**307.8**	**297.3**	**308.3**

2012/09/21 EUTRx	2012/09/28 EUTRx	2012/10/05 EUTRx	2012/10/12 EUTRx	2012/10/19 EUTRx	2012/10/26 EUTRx
8,136,521	8,213,947	8,361,496	7,998,840	8,124,850	8,050,027
1,325,313	1,344,176	1,374,362	1,303,257	1,338,856	1,331,872
225,149	236,966	226,804	220,912	226,671	225,216
1,961,098	1,998,014	1,997,873	1,923,789	1,961,642	1,935,649
755,777	773,138	775,524	760,819	760,116	757,949
1,707,833	1,745,287	1,764,524	1,682,430	1,686,399	1,684,899
680,595	670,088	688,895	666,696	679,457	661,482
1,480,756	1,446,278	1,533,514	1,440,937	1,471,709	1,452,960
8,136,521	**8,213,947**	**8,361,496**	**7,998,840**	**8,124,850**	**8,050,027**

13.3	13.4	13.7	13.0	13.4	13.3
3.4	3.6	3.4	3.3	3.4	3.4
39.2	40.0	40.0	38.5	39.2	38.7
22.7	23.2	23.3	22.8	22.8	22.7
68.3	69.8	70.6	67.3	67.5	67.4
40.8	40.2	41.3	40.0	40.8	39.7
118.5	115.7	122.7	115.3	117.7	116.2
306.1	**305.9**	**315.0**	**300.2**	**304.8**	**301.5**

2012/11/02 EUTRx	2012/11/09 EUTRx	2012/11/16 EUTRx	2012/11/23 EUTRx	2012/11/30 EUTRx	2012/12/07 EUTRx
7,884,768	8,339,872	8,169,418	7,392,202	8,446,015	8,599,666
1,297,235	1,379,991	1,366,641	1,217,989	1,419,962	1,401,942
222,271	238,223	233,136	208,902	240,382	240,681
1,904,322	2,009,064	1,937,501	1,784,409	2,032,073	2,073,229
750,263	789,110	769,893	707,008	805,363	822,187
1,659,852	1,725,846	1,696,914	1,541,620	1,760,216	1,790,300
645,429	709,182	685,531	606,318	704,753	719,867
1,405,396	1,488,456	1,479,802	1,325,956	1,483,266	1,551,460
7,884,768	**8,339,872**	**8,169,418**	**7,392,202**	**8,446,015**	**8,599,666**

13.0	13.8	13.7	12.2	14.2	14.0
3.3	3.6	3.5	3.1	3.6	3.6
38.1	40.2	38.8	35.7	40.6	41.5
22.5	23.7	23.1	21.2	24.2	24.7
66.4	69.0	67.9	61.7	70.4	71.6
38.7	42.6	41.1	36.4	42.3	43.2
112.4	119.1	118.4	106.1	118.7	124.1
294.5	**311.9**	**306.4**	**276.3**	**314.0**	**322.7**

2012/12/14 EUTRx	2012/12/21 EUTRx	2012/12/28 EUTRx	2013/01/04 EUTRx	2013/01/11 EUTRx	2013/01/18 EUTRx
8,234,376	8,591,485	6,903,075	7,648,883	8,143,336	8,052,086
1,356,149	1,424,601	1,108,913	1,228,344	1,319,309	1,327,537
243,353	248,169	193,069	210,753	240,570	230,249
1,979,123	2,070,155	1,643,246	1,823,867	1,946,375	1,919,911
792,021	825,149	650,731	743,527	776,260	779,645
1,700,905	1,774,350	1,446,706	1,598,914	1,712,556	1,647,897
692,300	708,922	594,161	657,326	691,962	686,765
1,470,525	1,540,139	1,266,249	1,386,152	1,456,304	1,460,082
8,234,376	**8,591,485**	**6,903,075**	**7,648,883**	**8,143,336**	**8,052,086**

13.6	14.2	11.1	12.3	13.2	13.3
3.7	3.7	2.9	3.2	3.6	3.5
39.6	41.4	32.9	36.5	38.9	38.4
23.8	24.8	19.5	22.3	23.3	23.4
68.0	71.0	57.9	64.0	68.5	65.9
41.5	42.5	35.6	39.4	41.5	41.2
117.6	123.2	101.3	110.9	116.5	116.8
307.8	**320.8**	**261.2**	**288.5**	**305.5**	**302.4**

2013/01/25 EUTRx	2013/02/01 EUTRx	2013/02/08 EUTRx	2013/02/15 EUTRx	2013/02/22 EUTRx	2013/03/01 EUTRx
7,200,338	7,683,391	8,162,552	7,879,116	7,253,340	8,096,634
1,204,426	1,250,185	1,323,987	1,311,402	1,234,444	1,313,174
218,947	219,310	238,577	226,095	216,995	241,102
1,728,049	1,846,356	1,923,103	1,877,138	1,744,529	1,938,072
690,742	741,895	806,799	748,911	723,181	801,071
1,479,337	1,592,447	1,685,464	1,640,730	1,479,375	1,662,896
610,193	658,830	706,251	655,037	609,224	701,244
1,268,644	1,374,368	1,478,371	1,419,803	1,245,592	1,439,075
7,200,338	**7,683,391**	**8,162,552**	**7,879,116**	**7,253,340**	**8,096,634**

12.0	12.5	13.2	13.1	12.3	13.1
3.3	3.3	3.6	3.4	3.3	3.6
34.6	36.9	38.5	37.5	34.9	38.8
20.7	22.3	24.2	22.5	21.7	24.0
59.2	63.7	67.4	65.6	59.2	66.5
36.6	39.5	42.4	39.3	36.6	42.1
101.5	109.9	118.3	113.6	99.6	115.1
267.9	**288.2**	**307.5**	**295.0**	**267.6**	**303.3**

2013/03/08 EUTRx	2013/03/15 EUTRx	2013/03/22 EUTRx	2013/03/29 EUTRx	2013/04/05 EUTRx	2013/04/12 EUTRx
8,277,776	7,711,915	7,398,795	7,332,806	7,831,508	7,526,041
1,334,871	1,279,468	1,257,307	1,210,871	1,270,528	1,255,679
242,567	228,095	227,500	216,006	229,814	232,819
1,979,090	1,850,109	1,782,160	1,764,374	1,858,814	1,809,809
802,211	745,368	735,041	734,465	774,321	742,801
1,728,659	1,568,602	1,501,003	1,497,569	1,619,675	1,529,222
694,780	654,045	621,622	636,926	675,819	640,477
1,495,598	1,386,228	1,274,162	1,272,595	1,402,537	1,315,234
8,277,776	**7,711,915**	**7,398,795**	**7,332,806**	**7,831,508**	**7,526,041**

13.3	12.8	12.6	12.1	12.7	12.6
3.6	3.4	3.4	3.2	3.4	3.5
39.6	37.0	35.6	35.3	37.2	36.2
24.1	22.4	22.1	22.0	23.2	22.3
69.1	62.7	60.0	59.9	64.8	61.2
41.7	39.2	37.3	38.2	40.5	38.4
119.6	110.9	101.9	101.8	112.2	105.2
311.1	**288.5**	**273.0**	**272.6**	**294.1**	**279.3**

2013/04/19 EUTRx	2013/04/26 EUTRx	2013/05/03 EUTRx	2013/05/10 EUTRx	2013/05/17 EUTRx	2013/05/24 EUTRx
7,248,633	7,378,376	7,960,202	7,591,448	7,283,133	7,581,531
1,219,931	1,230,749	1,297,032	1,245,752	1,237,341	1,264,585
221,863	221,743	243,182	236,717	228,184	232,396
1,751,426	1,759,156	1,877,871	1,838,489	1,783,506	1,820,998
736,584	742,974	790,780	760,706	745,344	776,599
1,457,311	1,514,307	1,645,401	1,547,612	1,454,076	1,526,871
622,198	633,976	681,333	661,094	621,112	660,081
1,239,320	1,275,471	1,424,066	1,301,078	1,213,570	1,300,001
7,249,798	**7,379,028**	**7,960,361**	**7,591,535**	**7,283,970**	**7,581,999**

12.2	12.3	13.0	12.5	12.4	12.6
3.3	3.3	3.6	3.6	3.4	3.5
35.0	35.2	37.6	36.8	35.7	36.4
22.1	22.3	23.7	22.8	22.4	23.3
58.3	60.6	65.8	61.9	58.2	61.1
37.3	38.0	40.9	39.7	37.3	39.6
99.1	102.0	113.9	104.1	97.1	104.0
267.4	**273.8**	**298.5**	**281.3**	**266.3**	**280.5**

2013/05/31 EUTRx	2013/06/07 EUTRx	2013/06/14 EUTRx	2013/06/21 EUTRx	2013/06/28 EUTRx
6,955,687	7,894,454	7,355,086	7,399,395	7,424,086
1,135,887	1,306,249	1,263,289	1,242,713	1,237,575
220,347	240,832	233,898	230,435	233,365
1,664,311	1,900,664	1,767,584	1,789,389	1,759,085
696,081	781,148	752,408	756,718	751,958
1,430,577	1,621,728	1,460,150	1,496,701	1,502,463
590,116	678,679	625,534	635,692	646,804
1,218,368	1,365,154	1,252,223	1,247,747	1,292,836
6,956,349	**7,895,170**	**7,355,525**	**7,399,769**	**7,424,477**

11.4	13.1	12.6	12.4	12.4
3.3	3.6	3.5	3.5	3.5
33.3	38.0	35.4	35.8	35.2
20.9	23.4	22.6	22.7	22.6
57.2	64.9	58.4	59.9	60.1
35.4	40.7	37.5	38.1	38.8
97.5	109.2	100.2	99.8	103.4
258.9	**292.9**	**270.2**	**272.2**	**276.0**

2013/07/05 EUTRx	2013/07/12 EUTRx	2013/07/19 EUTRx	2013/07/26 EUTRx	2013/08/02 EUTRx	2013/08/09 EUTRx
7,379,096	7,499,488	7,447,428	7,353,787	7,369,790	7,321,211
1,207,400	1,278,032	1,242,710	1,212,132	1,234,035	1,225,447
233,200	247,538	237,555	238,275	231,112	247,005
1,737,213	1,793,058	1,786,137	1,751,271	1,757,105	1,761,112
751,044	774,868	779,594	766,613	762,892	758,036
1,534,736	1,490,155	1,508,581	1,486,343	1,504,386	1,455,839
639,096	639,162	650,968	640,377	626,991	635,082
1,276,407	1,276,675	1,241,883	1,258,776	1,253,269	1,238,690
7,380,613	**7,500,116**	**7,448,280**	**7,354,329**	**7,370,813**	**7,321,789**

12.1	12.8	12.4	12.1	12.3	12.3
3.5	3.7	3.6	3.6	3.5	3.7
34.7	35.9	35.7	35.0	35.1	35.2
22.5	23.2	23.4	23.0	22.9	22.7
61.4	59.6	60.3	59.5	60.2	58.2
38.3	38.3	39.1	38.4	37.6	38.1
102.1	102.1	99.4	100.7	100.3	99.1
274.7	**275.7**	**273.9**	**272.3**	**271.9**	**269.4**

Kg Dispensed Actual V Budget

	4-Jan-13	11-Jan-13	18-Jan-13	25-Jan-13	1-Feb-13	8-Feb-13
Actual Weekly Kg Dispensed	288.5	305.5	302.4	267.9	288.2	307.5
Budget Kg Dispened	305.5	318.2	307.3	290.5	300.9	300.1
Weekly Difference	(17.02)	(12.69)	(4.87)	(22.62)	(12.77)	7.46
Weekly % variance	-5.6%	-4.0%	-1.6%	-7.8%	-4.2%	2.5%
YTD Actual Total	288.5	594.06	896.50	1,164.39	1,452.54	1,760.09
YTD Budget Total	305.5	623.76	931.08	1,221.59	1,522.51	1,822.60
YTD Total Difference	(17.02)	(29.71)	(34.58)	(57.20)	(69.97)	(62.51)
YTD % Variance	-5.6%	-4.8%	-3.7%	-4.7%	-4.6%	-3.4%
2013 Kg Disp Goal	15,801.3					
YTD Actual	9,020.3	<- change each week				
YTD Budget	9,789.2	<- change each week				
Actual YTD % of 2013 Goal	57.1%					
Budget YTD % of 2013 Goal	62.0%					



15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13	15-Mar-13	22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13
295.0	267.6	303.3	311.1	288.5	273.0	272.6	294.1	279.3
293.3	281.8	326.8	315.6	299.0	289.0	297.0	332.5	310.8
1.72	(14.21)	(23.50)	(4.48)	(10.54)	(16.04)	(24.43)	(38.44)	(31.45)
0.6%	-5.0%	-7.2%	-1.4%	-3.5%	-5.6%	-8.2%	-11.6%	-10.1%
2,055.12	2,322.68	2,625.94	2,937.06	3,225.52	3,498.47	3,771.07	4,065.17	4,344.51
2,115.91	2,397.68	2,724.44	3,040.03	3,339.04	3,628.02	3,925.05	4,257.58	4,568.38
(60.78)	(75.00)	(98.50)	(102.97)	(113.51)	(129.55)	(153.98)	(192.42)	(223.87)
-2.9%	-3.1%	-3.6%	-3.4%	-3.4%	-3.6%	-3.9%	-4.5%	-4.9%



19-Apr-13	26-Apr-13	3-May-13	10-May-13	17-May-13	24-May-13	31-May-13	7-Jun-13	14-Jun-13
267.4	273.8	298.5	281.3	266.3	280.5	258.9	292.9	270.2
311.3	315.9	329.9	302.9	301.0	314.4	288.8	307.2	294.3
(43.90)	(42.17)	(31.37)	(21.65)	(34.64)	(33.89)	(29.91)	(14.28)	(24.09)
-14.1%	-13.3%	-9.5%	-7.1%	-11.5%	-10.8%	-10.4%	-4.6%	-8.2%
4,611.94	4,885.69	5,184.21	5,465.47	5,731.81	6,012.34	6,271.27	6,564.19	6,834.38
4,879.70	5,195.63	5,525.52	5,828.43	6,129.41	6,443.83	6,732.67	7,039.87	7,334.14
(267.77)	(309.94)	(341.31)	(362.96)	(397.60)	(431.49)	(461.40)	(475.68)	(499.77)
-5.5%	-6.0%	-6.2%	-6.2%	-6.5%	-6.7%	-6.9%	-6.8%	-6.8%

Copy formulae above each week. Actual Data entered in the 'Kg Weekly OxyContin' v

21-Jun-13	28-Jun-13	5-Jul-13	12-Jul-13	19-Jul-13	26-Jul-13	2-Aug-13	9-Aug-13	16-Aug-13
272.2	276.0	274.7	275.7	273.9	272.3	271.9	269.4	
300.0	300.9	312.1	312.6	312.5	305.7	306.6	304.6	309.8
(27.80)	(24.93)	(37.37)	(36.93)	(38.65)	(33.43)	(34.75)	(35.29)	
-9.3%	-8.3%	-12.0%	-11.8%	-12.4%	-10.9%	-11.3%	-11.6%	
7,106.58	7,382.53	7,657.22	7,932.91	8,206.77	8,479.06	8,750.96	9,020.31	
7,634.14	7,935.02	8,247.09	8,559.71	8,872.22	9,177.94	9,484.58	9,789.23	
(527.56)	(552.49)	(589.86)	(626.80)	(665.45)	(698.88)	(733.62)	(768.92)	
-6.9%	-7.0%	-7.2%	-7.3%	-7.5%	-7.6%	-7.7%	-7.9%	

vorksheet

23-Aug-13	30-Aug-13	6-Sep-13	13-Sep-13	20-Sep-13	27-Sep-13	4-Oct-13	11-Oct-13	18-Oct-13
305.7	305.8	298.1	307.4	303.3	303.9	312.4	304.4	305.4

25-Oct-13	1-Nov-13	8-Nov-13	15-Nov-13	22-Nov-13	29-Nov-13	6-Dec-13	13-Dec-13	20-Dec-13
304.6	295.0	305.5	299.9	270.7	304.7	312.2	296.0	309.5

27-Dec-13

257.7

Total Branded OxyContin

"= needs to be

Gross Up	0.55%	1.0055

notes: in Feb 2013, we changed to reporting from retail pharmacy only
the weekly budget is based on the agreed upon full year total, tl

	4-Jan-13	11-Jan-13	18-Jan-13	25-Jan-13
Actual Weekly TRx	112,524	120,276	118,988	108,221
Grossed Up Weekly TRx	113,143	120,938	119,642	108,816
YTD Grossed Up Weekly TRx	113,143	234,080	353,723	462,539
Budget TRx	113,143	120,938	119,642	108,816
YTD Budget Total	113,143	234,080	353,723	462,539
Weekly Difference	-	-	-	-
YTD Total Difference	-	-	-	-
Weekly % Difference	0.0%	0.0%	0.0%	0.0%

New Numbers	
2013 TRx Goal	5,804,885
YTD Rolling Grossed Up Weekly TRx	3,673,028
Difference	2,131,857
Remaining Weeks	20
Revised 2012 Weekly TRx Goal	106,593

Goal to date	3,647,494
Actual to date (grossed up)	3,673,028
YTD Difference	0.7%

: updated

to reporting retail pharmacies, mail order and LTC. The gross up simply reflects the recent difference
hen phased

1-Feb-13	8-Feb-13	15-Feb-13	22-Feb-13	1-Mar-13	8-Mar-13	15-Mar-13
115,072	121,640	117,664	109,872	120,657	123,202	116,106
115,705	122,309	118,311	110,476	121,321	123,880	116,745
578,244	700,553	818,864	929,340	1,050,661	1,174,541	1,291,285
115,705	122,309	118,311	110,476	121,321	123,880	116,745
578,244	700,553	818,864	929,340	1,050,661	1,174,541	1,291,285
-	-	-	-	-	-	-
-	-	-	-	-	-	-
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

between weekly and monthly Rx's over a 12 month period

22-Mar-13	29-Mar-13	5-Apr-13	12-Apr-13	19-Apr-13	26-Apr-13	3-May-13
111,519	110,562	116,985	113,283	109,820	111,523	119,075
112,132	111,170	117,628	113,906	110,424	112,136	119,730
1,403,418	1,514,588	1,632,216	1,746,122	1,856,546	1,968,683	2,088,412
112,132	111,170	117,628	113,906	110,424	112,136	119,730
1,403,418	1,514,588	1,632,216	1,746,122	1,856,546	1,968,683	2,088,412
-	-	-	-	-	-	-
-	-	-	-	-	-	-
0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

10-May-13	17-May-13	24-May-13	31-May-13	7-Jun-13	14-Jun-13	21-Jun-13
114,849	110,628	115,142	105,510	119,269	111,927	112,247
115,481	111,236	115,775	106,090	119,925	112,543	112,864
2,203,893	2,315,130	2,430,905	2,536,995	2,656,920	2,769,463	2,882,327
115,481	111,236	115,775	106,090	113,641	110,019	111,197
2,203,893	2,315,130	2,430,905	2,536,995	2,650,636	2,760,655	2,871,852
-	-	-	-	6,284	2,524	1,667
-	-	-	-	6,284	8,808	10,475
0.0%	0.0%	0.0%	0.0%	5.5%	2.3%	1.5%

28-Jun-13	5-Jul-13	12-Jul-13	19-Jul-13	26-Jul-13	2-Aug-13	9-Aug-13
112,343	111,143	114,323	113,158	111,365	112,367	111,677
112,961	111,754	114,952	113,780	111,978	112,985	112,291
2,995,288	3,107,042	3,221,994	3,335,774	3,447,752	3,560,737	3,673,028
111,683	110,357	112,925	112,693	110,624	109,007	108,353
2,983,535	3,093,892	3,206,818	3,319,511	3,430,134	3,539,141	3,647,494
1,278	1,397	2,026	1,087	1,354	3,978	3,939
11,753	13,150	15,176	16,264	17,618	21,596	25,534
1.1%	1.3%	1.8%	1.0%	1.2%	3.6%	3.6%

16-Aug-13	23-Aug-13	30-Aug-13	6-Sep-13	13-Sep-13	20-Sep-13	27-Sep-13
110,539	109,629	112,377	106,938	110,837	109,896	110,853

4-Oct-13	11-Oct-13	18-Oct-13	25-Oct-13	1-Nov-13	8-Nov-13	15-Nov-13
109,244	106,624	106,930	106,476	104,207	108,110	106,621

22-Nov-13	29-Nov-13	6-Dec-13	13-Dec-13	20-Dec-13	27-Dec-13
97,776	111,298	112,208	108,667	111,625	96,536


OxyContin Actual TRx vs. Mi
130,000
125,000
120,000
115,000
110,000
105,000
100,000
95,000
TRxs
4-Jan-13
11-Jan-13
18-Jan-13
25-Jan-13
1-Feb-13
8-Feb-13
15-Feb-13
22-Feb-13
1-Mar-13
8-Mar-13
15-Mar-13
22-Mar-13
29-Mar-13
5-Apr-13
12-Apr-13
19-Apr-13
Mid-Year Forecast Update


d-Year Update Forecast
pr-13
3-May-13
10-May-13
17-May-13
24-May-13
31-May-13
7-Jun-13
14-Jun-13
21-Jun-13
28-Jun-13
5-Jul-13
12-Jul-13
19-Jul-13
26-Jul-13
2-Aug-13
9-Aug-13
OxyContin TRx

OxyContin Weekly TRx - Original Formulation and Reformulation

Source: IMS Health NPA

Retail Pharmacies Only

Numbers Are Absolute

Strength	NDC	Week Ending	4-Jun-10	11-Jun-10	18-Jun-10	25-Jun-10
Total OER (brand + generics)						
10MG				22,367	22,497	22,666
15MG				2,215	2,154	2,190
20MG				36,046	35,706	36,021
30MG				8,692	9,079	8,951
40MG				33,524	33,569	34,255
60MG				8,767	8,954	8,756
80MG				29,397	29,228	29,572
Total				141,008	141,187	142,411
Oxycodone ER (generics)						
10MG				6,950	6,845	6,809
20MG				11,002	11,080	11,114
40MG				6,216	6,126	6,119
80MG				3,905	3,838	3,814
Total				28,073	27,889	27,856
Original OxyContin						
10MG	59011010010	TAB SA 12HR 10MG	14,577	15,417	15,652	15,857
15MG	59011081510	TAB SA 12HR 15MG	2,092	2,215	2,154	2,190
20MG	59011010310	TAB SA 12HR 20MG	24,314	25,044	24,626	24,907
30MG	59011083010	TAB SA 12HR 30MG	8,367	8,692	9,079	8,951
40MG	59011010510	TAB SA 12HR 40MG	27,682	27,308	27,443	28,136
60MG	59011086010	TAB SA 12HR 60MG	8,599	8,767	8,954	8,756
80MG	59011010710	TAB SA 12HR 80MG	24,914	25,492	25,390	25,758
Total			110,545	112,935	113,298	114,555
Reformulated OxyContin						
10MG	59011041010	TAB SA 12HR 10MG 100 0410-10 NF				
15MG	59011041510	TAB SA 12HR 15MG 100 0415-10 NF				
20MG	59011042010	TAB SA 12HR 20MG 100 0420-10 NF				
30MG	59011043010	TAB SA 12HR 30MG 100 0430-10 NF				
40MG	59011044010	TAB SA 12HR 40MG 100 0440-10 NF				
60MG	59011046010	TAB SA 12HR 60MG 100 0460-10 NF				
80MG	59011048010	TAB SA 12HR 80MG 100 0480-10 NF				
Total			-	-	-	-
Total Branded OxyContin						
10MG			14,577	15,417	15,652	15,857
15MG			2,092	2,215	2,154	2,190

20MG	24,314	25,044	24,626	24,907
30MG	8,367	8,692	9,079	8,951
40MG	27,682	27,308	27,443	28,136
60MG	8,599	8,767	8,954	8,756
80MG	24,914	25,492	25,390	25,758
Total	110,545	112,935	113,298	114,555

1 Weekly Growth of Total Branded OxyContin TRx

10MG	1.5%	1.3%
15MG	-2.8%	1.7%
20MG	-1.7%	1.1%
30MG	4.5%	-1.4%
40MG	0.5%	2.5%
60MG	2.1%	-2.2%
80MG	-0.4%	1.4%
Total	0.3%	1.1%

TRx Distribution by Strength for Total Branded OxyContin

10MG	13.7%	13.8%	13.8%
15MG	2.0%	1.9%	1.9%
20MG	22.2%	21.7%	21.7%
30MG	7.7%	8.0%	7.8%
40MG	24.2%	24.2%	24.6%
60MG	7.8%	7.9%	7.6%
80MG	22.6%	22.4%	22.5%
Total	100.0%	100.0%	100.0%

Weekly Total Prescriptions

2-Jul-10	9-Jul-10	16-Jul-10	23-Jul-10	30-Jul-10	6-Aug-10	13-Aug-10	20-Aug-10	27-Aug-10
24,158	20,973	22,969	22,960	22,532	22,515	22,651	22,613	22,473
2,364	2,193	2,284	2,308	2,280	2,326	2,276	2,213	2,322
38,932	33,905	36,256	36,508	35,824	36,261	35,634	36,541	35,785
9,701	8,686	9,341	9,201	9,066	9,244	9,478	9,519	9,145
37,408	32,071	33,737	34,402	33,455	34,392	32,965	34,230	33,535
9,571	8,699	9,169	9,091	8,870	9,341	9,228	9,354	9,189
31,615	28,074	29,924	30,061	29,034	30,577	30,319	30,398	29,070
153,749	134,601	143,680	144,531	141,061	144,656	142,551	144,868	141,519
7,290	6,169	6,804	6,779	6,519	6,476	6,421	6,354	6,279
11,562	10,129	10,579	10,865	10,449	10,614	10,580	10,150	9,216
6,624	5,701	6,072	6,241	5,973	6,307	6,044	6,291	6,012
4,210	3,754	4,030	3,934	3,949	4,044	4,058	4,087	4,035
29,686	25,753	27,485	27,819	26,890	27,441	27,103	26,882	25,542
16,868	14,804	16,165	16,181	16,013	16,037	16,204	15,751	14,610
2,364	2,193	2,284	2,308	2,280	2,325	2,269	2,092	2,051
27,370	23,776	25,677	25,643	25,374	25,646	25,006	25,527	23,270
9,701	8,686	9,341	9,201	9,066	9,243	9,463	9,254	8,381
30,784	26,370	27,665	28,161	27,482	28,082	26,829	26,466	23,102
9,571	8,699	9,169	9,091	8,870	9,340	9,201	8,982	7,908
27,405	24,320	25,894	26,127	25,083	26,528	26,166	23,600	18,678
124,063	108,848	116,195	116,712	114,168	117,201	115,138	111,672	98,000
					2	26	508	1,584
					1	7	121	271
				1	1	48	864	3,299
					1	15	265	764
					3	92	1,473	4,421
					1	27	372	1,281
				2	5	95	2,711	6,357
-	-	-	-	3	14	310	6,314	17,977
16,868	14,804	16,165	16,181	16,013	16,039	16,230	16,259	16,194
2,364	2,193	2,284	2,308	2,280	2,326	2,276	2,213	2,322

27,370	23,776	25,677	25,643	25,375	25,647	25,054	26,391	26,569
9,701	8,686	9,341	9,201	9,066	9,244	9,478	9,519	9,145
30,784	26,370	27,665	28,161	27,482	28,085	26,921	27,939	27,523
9,571	8,699	9,169	9,091	8,870	9,341	9,228	9,354	9,189
27,405	24,320	25,894	26,127	25,085	26,533	26,261	26,311	25,035
124,063	108,848	116,195	116,712	114,171	117,215	115,448	117,986	115,977

6.4%	-12.2%	9.2%	0.1%	-1.0%	0.2%	1.2%	0.2%	-0.4%
7.9%	-7.2%	4.1%	1.1%	-1.2%	2.0%	-2.1%	-2.8%	4.9%
9.9%	-13.1%	8.0%	-0.1%	-1.0%	1.1%	-2.3%	5.3%	0.7%
8.4%	-10.5%	7.5%	-1.5%	-1.5%	2.0%	2.5%	0.4%	-3.9%
9.4%	-14.3%	4.9%	1.8%	-2.4%	2.2%	-4.1%	3.8%	-1.5%
9.3%	-9.1%	5.4%	-0.9%	-2.4%	5.3%	-1.2%	1.4%	-1.8%
6.4%	-11.3%	6.5%	0.9%	-4.0%	5.8%	-1.0%	0.2%	-4.8%
8.3%	-12.3%	6.7%	0.4%	-2.2%	2.7%	-1.5%	2.2%	-1.7%

13.6%	13.6%	13.9%	13.9%	14.0%	13.7%	14.1%	13.8%	14.0%
1.9%	2.0%	2.0%	2.0%	2.0%	2.0%	2.0%	1.9%	2.0%
22.1%	21.8%	22.1%	22.0%	22.2%	21.9%	21.7%	22.4%	22.9%
7.8%	8.0%	8.0%	7.9%	7.9%	7.9%	8.2%	8.1%	7.9%
24.8%	24.2%	23.8%	24.1%	24.1%	24.0%	23.3%	23.7%	23.7%
7.7%	8.0%	7.9%	7.8%	7.8%	8.0%	8.0%	7.9%	7.9%
22.1%	22.3%	22.3%	22.4%	22.0%	22.6%	22.7%	22.3%	21.6%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

3-Sep-10	10-Sep-10	17-Sep-10	24-Sep-10	1-Oct-10	8-Oct-10	15-Oct-10	22-Oct-10	29-Oct-10
23,538	20,825	23,321	22,943	23,218	22,993	22,827	22,771	22,415
2,581	2,252	2,456	2,311	2,553	2,467	2,418	2,429	2,382
37,815	32,953	36,857	35,692	37,173	35,128	35,294	34,678	34,505
9,984	8,856	9,898	9,364	9,693	9,453	9,628	9,483	9,200
35,737	30,934	33,762	32,509	33,460	31,714	31,957	31,661	30,784
9,923	9,089	9,510	9,237	9,659	9,209	9,207	8,951	8,753
30,082	26,029	28,055	26,103	26,565	25,345	25,492	24,913	24,417
149,660	130,938	143,859	138,159	142,321	136,309	136,823	134,886	132,456
6,509	5,622	6,225	6,361	6,290	6,133	5,595	4,918	4,110
8,647	6,848	8,153	8,295	7,920	6,893	6,118	5,641	4,857
6,545	5,769	6,467	6,603	6,986	6,944	7,302	7,000	6,284
4,531	4,291	4,752	5,063	5,565	5,681	6,232	6,461	6,506
26,232	22,530	25,597	26,322	26,761	25,651	25,247	24,020	21,757
13,547	10,675	10,233	8,374	7,346	6,171	5,454	4,971	4,250
2,191	1,721	1,740	1,527	1,538	1,389	1,238	1,171	1,023
21,599	16,247	14,434	10,835	9,416	7,477	6,170	5,319	4,355
8,322	6,730	6,329	4,929	4,514	3,839	3,287	2,751	2,412
20,664	14,908	12,789	9,812	8,328	6,550	5,332	4,401	3,692
7,705	6,061	5,461	4,395	3,952	3,182	2,762	2,331	1,931
15,716	11,132	9,872	7,096	6,011	4,608	3,859	3,215	2,570
89,744	67,474	60,858	46,968	41,105	33,216	28,102	24,159	20,233
3,482	4,528	6,863	8,208	9,582	10,689	11,778	12,882	14,055
390	531	716	784	1,015	1,078	1,180	1,258	1,359
7,569	9,858	14,270	16,562	19,837	20,758	23,006	23,718	25,293
1,662	2,126	3,569	4,435	5,179	5,614	6,341	6,732	6,788
8,528	10,257	14,506	16,094	18,146	18,220	19,323	20,260	20,808
2,218	3,028	4,049	4,842	5,707	6,027	6,445	6,620	6,822
9,835	10,606	13,431	13,944	14,989	15,056	15,401	15,237	15,341
33,684	40,934	57,404	64,869	74,455	77,442	83,474	86,707	90,466
17,029	15,203	17,096	16,582	16,928	16,860	17,232	17,853	18,305
2,581	2,252	2,456	2,311	2,553	2,467	2,418	2,429	2,382

29,168	26,105	28,704	27,397	29,253	28,235	29,176	29,037	29,648
9,984	8,856	9,898	9,364	9,693	9,453	9,628	9,483	9,200
29,192	25,165	27,295	25,906	26,474	24,770	24,655	24,661	24,500
9,923	9,089	9,510	9,237	9,659	9,209	9,207	8,951	8,753
25,551	21,738	23,303	21,040	21,000	19,664	19,260	18,452	17,911
123,428	108,408	118,262	111,837	115,560	110,658	111,576	110,866	110,699

5.2%	-10.7%	12.5%	-3.0%	2.1%	-0.4%	2.2%	3.6%	2.5%
11.2%	-12.7%	9.1%	-5.9%	10.5%	-3.4%	-2.0%	0.5%	-1.9%
9.8%	-10.5%	10.0%	-4.6%	6.8%	-3.5%	3.3%	-0.5%	2.1%
9.2%	-11.3%	11.8%	-5.4%	3.5%	-2.5%	1.9%	-1.5%	-3.0%
6.1%	-13.8%	8.5%	-5.1%	2.2%	-6.4%	-0.5%	0.0%	-0.7%
8.0%	-8.4%	4.6%	-2.9%	4.6%	-4.7%	0.0%	-2.8%	-2.2%
2.1%	-14.9%	7.2%	-9.7%	-0.2%	-6.4%	-2.1%	-4.2%	-2.9%
6.4%	-12.2%	9.1%	-5.4%	3.3%	-4.2%	0.8%	-0.6%	-0.2%

13.8%	14.0%	14.5%	14.8%	14.6%	15.2%	15.4%	16.1%	16.5%
2.1%	2.1%	2.1%	2.1%	2.2%	2.2%	2.2%	2.2%	2.2%
23.6%	24.1%	24.3%	24.5%	25.3%	25.5%	26.1%	26.2%	26.8%
8.1%	8.2%	8.4%	8.4%	8.4%	8.5%	8.6%	8.6%	8.3%
23.7%	23.2%	23.1%	23.2%	22.9%	22.4%	22.1%	22.2%	22.1%
8.0%	8.4%	8.0%	8.3%	8.4%	8.3%	8.3%	8.1%	7.9%
20.7%	20.1%	19.7%	18.8%	18.2%	17.8%	17.3%	16.6%	16.2%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

5-Nov-10	12-Nov-10	19-Nov-10	26-Nov-10	3-Dec-10	10-Dec-10	17-Dec-10	24-Dec-10	31-Dec-10
22,850	22,537	23,456	19,438	23,538	22,620	23,239	22,281	18,352
2,538	2,505	2,442	2,180	2,711	2,481	2,466	2,315	2,113
35,192	33,996	35,000	30,049	37,108	33,914	34,504	33,339	27,995
9,309	9,345	9,616	8,188	10,352	9,478	9,677	9,077	8,127
30,872	29,854	30,760	26,900	32,627	29,183	29,911	28,487	25,317
8,910	8,747	9,083	7,864	9,531	8,739	8,654	8,473	7,413
24,207	23,942	24,768	21,371	25,838	23,879	23,877	22,109	20,085
133,878	130,926	135,125	115,990	141,705	130,294	132,328	126,081	109,402
3,480	2,988	2,880	2,263	2,483	2,085	1,567	1,353	1,045
4,685	4,241	4,201	3,346	4,138	3,466	3,567	3,236	2,797
5,231	3,938	3,373	2,588	2,697	2,109	1,916	2,817	3,490
6,633	6,763	7,133	6,367	7,561	6,739	6,010	5,089	4,005
20,029	17,930	17,587	14,564	16,879	14,399	13,060	12,495	11,337
4,041	3,464	3,150	2,411	2,752	2,332	1,717	1,930	1,517
912	904	810	683	736	670	488	517	458
3,886	3,118	2,900	2,407	2,578	2,234	1,728	1,784	1,333
2,214	1,964	1,771	1,335	1,408	1,201	1,122	1,190	1,004
3,323	2,914	2,704	2,070	2,391	1,947	1,591	1,449	1,205
1,770	1,554	1,566	1,109	1,301	1,054	870	890	720
2,079	1,848	1,742	1,317	1,515	1,417	1,101	1,014	975
18,225	15,766	14,643	11,332	12,681	10,855	8,617	8,774	7,212
15,329	16,085	17,426	14,764	18,303	18,203	19,955	18,998	15,790
1,626	1,601	1,632	1,497	1,975	1,811	1,978	1,798	1,655
26,621	26,637	27,899	24,296	30,392	28,214	29,209	28,319	23,865
7,095	7,381	7,845	6,853	8,944	8,277	8,555	7,887	7,123
22,318	23,002	24,683	22,242	27,539	25,127	26,404	24,221	20,622
7,140	7,193	7,517	6,755	8,230	7,685	7,784	7,583	6,693
15,495	15,331	15,893	13,687	16,762	15,723	16,766	16,006	15,105
95,624	97,230	102,895	90,094	112,145	105,040	110,651	104,812	90,853
19,370	19,549	20,576	17,175	21,055	20,535	21,672	20,928	17,307
2,538	2,505	2,442	2,180	2,711	2,481	2,466	2,315	2,113

30,507	29,755	30,799	26,703	32,970	30,448	30,937	30,103	25,198
9,309	9,345	9,616	8,188	10,352	9,478	9,677	9,077	8,127
25,641	25,916	27,387	24,312	29,930	27,074	27,995	25,670	21,827
8,910	8,747	9,083	7,864	9,531	8,739	8,654	8,473	7,413
17,574	17,179	17,635	15,004	18,277	17,140	17,867	17,020	16,080
113,849	112,996	117,538	101,426	124,826	115,895	119,268	113,586	98,065

5.8%	0.9%	5.3%	-16.5%	22.6%	-2.5%	5.5%	-3.4%	-17.3%
6.5%	-1.3%	-2.5%	-10.7%	24.4%	-8.5%	-0.6%	-6.1%	-8.7%
2.9%	-2.5%	3.5%	-13.3%	23.5%	-7.6%	1.6%	-2.7%	-16.3%
1.2%	0.4%	2.9%	-14.9%	26.4%	-8.4%	2.1%	-6.2%	-10.5%
4.7%	1.1%	5.7%	-11.2%	23.1%	-9.5%	3.4%	-8.3%	-15.0%
1.8%	-1.8%	3.8%	-13.4%	21.2%	-8.3%	-1.0%	-2.1%	-12.5%
-1.9%	-2.2%	2.7%	-14.9%	21.8%	-6.2%	4.2%	-4.7%	-5.5%
2.8%	-0.7%	4.0%	-13.7%	23.1%	-7.2%	2.9%	-4.8%	-13.7%

17.0%	17.3%	17.5%	16.9%	16.9%	17.7%	18.2%	18.4%	17.6%
2.2%	2.2%	2.1%	2.1%	2.2%	2.1%	2.1%	2.0%	2.2%
26.8%	26.3%	26.2%	26.3%	26.4%	26.3%	25.9%	26.5%	25.7%
8.2%	8.3%	8.2%	8.1%	8.3%	8.2%	8.1%	8.0%	8.3%
22.5%	22.9%	23.3%	24.0%	24.0%	23.4%	23.5%	22.6%	22.3%
7.8%	7.7%	7.7%	7.8%	7.6%	7.5%	7.3%	7.5%	7.6%
15.4%	15.2%	15.0%	14.8%	14.6%	14.8%	15.0%	15.0%	16.4%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

7-Jan-11	14-Jan-11	21-Jan-11	28-Jan-11	4-Feb-11	11-Feb-11	18-Feb-11	25-Feb-11	4-Mar-11
22,404	21,599	21,655	20,631	21,487	21,641	21,137	20,378	23,229
2,590	2,391	2,348	2,361	2,397	2,462	2,471	2,309	2,702
34,434	32,962	32,331	30,654	32,355	33,036	31,922	30,055	35,637
9,871	9,526	9,164	8,689	9,428	9,369	9,184	8,654	10,448
29,970	28,701	27,923	26,325	28,379	28,346	27,402	26,111	31,060
8,931	8,536	8,390	7,715	8,531	8,467	8,473	7,744	9,440
23,157	22,060	20,698	19,593	21,340	20,931	19,578	18,754	22,514
131,357	125,775	122,509	115,968	123,917	124,252	120,167	114,005	135,030
1,076	902	911	851	808	696	648	590	612
3,487	3,178	3,092	2,854	2,934	2,724	2,311	1,851	1,660
3,887	4,174	4,254	3,818	3,766	3,541	2,994	2,639	2,628
3,897	3,035	2,283	1,518	1,178	991	683	487	456
12,347	11,289	10,540	9,041	8,686	7,952	6,636	5,567	5,356
1,841	1,678	1,630	1,475	1,582	1,579	1,467	1,304	1,444
606	522	543	512	504	560	479	493	530
1,680	1,616	1,454	1,391	1,395	1,452	1,305	1,233	1,407
1,170	1,048	1,037	994	1,020	977	925	865	1,008
1,417	1,335	1,157	1,058	1,200	1,143	1,029	920	1,086
823	811	809	673	674	687	711	601	720
1,219	1,078	1,083	993	1,125	948	889	810	899
8,756	8,088	7,713	7,096	7,500	7,346	6,805	6,226	7,094
19,487	19,019	19,114	18,305	19,097	19,366	19,022	18,484	21,173
1,984	1,869	1,805	1,849	1,893	1,902	1,992	1,816	2,172
29,267	28,168	27,785	26,409	28,026	28,860	28,306	26,971	32,570
8,701	8,478	8,127	7,695	8,408	8,392	8,259	7,789	9,440
24,666	23,192	22,512	21,449	23,413	23,662	23,379	22,552	27,346
8,108	7,725	7,581	7,042	7,857	7,780	7,762	7,143	8,720
18,041	17,947	17,332	17,082	19,037	18,992	18,006	17,457	21,159
110,254	106,398	104,256	99,831	107,731	108,954	106,726	102,212	122,580
21,328	20,697	20,744	19,780	20,679	20,945	20,489	19,788	22,617
2,590	2,391	2,348	2,361	2,397	2,462	2,471	2,309	2,702

30,947	29,784	29,239	27,800	29,421	30,312	29,611	28,204	33,977
9,871	9,526	9,164	8,689	9,428	9,369	9,184	8,654	10,448
26,083	24,527	23,669	22,507	24,613	24,805	24,408	23,472	28,432
8,931	8,536	8,390	7,715	8,531	8,467	8,473	7,744	9,440
19,260	19,025	18,415	18,075	20,162	19,940	18,895	18,267	22,058
119,010	114,486	111,969	106,927	115,231	116,300	113,531	108,438	129,674

23.2%	-3.0%	0.2%	-4.6%	4.5%	1.3%	-2.2%	-3.4%	14.3%
22.6%	-7.7%	-1.8%	0.6%	1.5%	2.7%	0.4%	-6.6%	17.0%
22.8%	-3.8%	-1.8%	-4.9%	5.8%	3.0%	-2.3%	-4.8%	20.5%
21.5%	-3.5%	-3.8%	-5.2%	8.5%	-0.6%	-2.0%	-5.8%	20.7%
19.5%	-6.0%	-3.5%	-4.9%	9.4%	0.8%	-1.6%	-3.8%	21.1%
20.5%	-4.4%	-1.7%	-8.0%	10.6%	-0.8%	0.1%	-8.6%	21.9%
19.8%	-1.2%	-3.2%	-1.8%	11.5%	-1.1%	-5.2%	-3.3%	20.8%
21.4%	-3.8%	-2.2%	-4.5%	7.8%	0.9%	-2.4%	-4.5%	19.6%

17.9%	18.1%	18.5%	18.5%	17.9%	18.0%	18.0%	18.2%	17.4%
2.2%	2.1%	2.1%	2.2%	2.1%	2.1%	2.2%	2.1%	2.1%
26.0%	26.0%	26.1%	26.0%	25.5%	26.1%	26.1%	26.0%	26.2%
8.3%	8.3%	8.2%	8.1%	8.2%	8.1%	8.1%	8.0%	8.1%
21.9%	21.4%	21.1%	21.0%	21.4%	21.3%	21.5%	21.6%	21.9%
7.5%	7.5%	7.5%	7.2%	7.4%	7.3%	7.5%	7.1%	7.3%
16.2%	16.6%	16.4%	16.9%	17.5%	17.1%	16.6%	16.8%	17.0%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

11-Mar-11	18-Mar-11	25-Mar-11	1-Apr-11	8-Apr-11	15-Apr-11	22-Apr-11	29-Apr-11	6-May-11
21,235	20,322	20,259	20,077	20,994	20,462	19,783	19,873	21,283
2,519	2,322	2,442	2,416	2,555	2,492	2,440	2,480	2,587
31,337	29,748	29,199	30,213	30,942	29,481	29,004	29,421	31,742
9,146	8,875	8,523	9,024	9,256	9,085	8,599	8,830	9,662
26,567	25,810	25,280	26,156	26,639	25,334	24,847	25,361	27,355
8,313	7,993	7,734	8,028	8,467	8,203	7,729	8,023	8,874
19,723	18,413	17,850	18,975	19,274	17,659	17,130	18,106	19,600
118,840	113,483	111,287	114,889	118,127	112,716	109,532	112,094	121,103
546	440	430	383	379	396	362	332	323
1,294	1,013	810	702	637	545	482	420	402
2,046	1,903	1,831	1,735	1,773	1,730	1,652	1,672	1,749
350	285	235	197	177	184	159	88	83
4,236	3,641	3,306	3,017	2,966	2,855	2,655	2,512	2,557
991	1,010	941	852	862	806	720	658	686
414	368	388	378	352	388	354	316	330
949	897	814	763	731	638	586	555	605
669	624	565	611	647	595	488	454	465
749	718	742	686	607	542	504	461	482
495	465	433	430	377	378	387	308	383
681	546	528	537	490	379	411	344	365
4,948	4,628	4,411	4,257	4,066	3,726	3,450	3,096	3,316
19,698	18,872	18,888	18,842	19,753	19,260	18,701	18,883	20,274
2,105	1,954	2,054	2,038	2,203	2,104	2,086	2,164	2,257
29,094	27,838	27,575	28,748	29,574	28,298	27,936	28,446	30,735
8,477	8,251	7,958	8,413	8,609	8,490	8,111	8,376	9,197
23,772	23,189	22,707	23,735	24,259	23,062	22,691	23,228	25,124
7,818	7,528	7,301	7,598	8,090	7,825	7,342	7,715	8,491
18,692	17,582	17,087	18,241	18,607	17,096	16,560	17,674	19,152
109,656	105,214	103,570	107,615	111,095	106,135	103,427	106,486	115,230
20,689	19,882	19,829	19,694	20,615	20,066	19,421	19,541	20,960
2,519	2,322	2,442	2,416	2,555	2,492	2,440	2,480	2,587

30,043	28,735	28,389	29,511	30,305	28,936	28,522	29,001	31,340
9,146	8,875	8,523	9,024	9,256	9,085	8,599	8,830	9,662
24,521	23,907	23,449	24,421	24,866	23,604	23,195	23,689	25,606
8,313	7,993	7,734	8,028	8,467	8,203	7,729	8,023	8,874
19,373	18,128	17,615	18,778	19,097	17,475	16,971	18,018	19,517
114,604	109,842	107,981	111,872	115,161	109,861	106,877	109,582	118,546

-8.5%	-3.9%	-0.3%	-0.7%	4.7%	-2.7%	-3.2%	0.6%	7.3%
-6.8%	-7.8%	5.2%	-1.1%	5.8%	-2.5%	-2.1%	1.6%	4.3%
-11.6%	-4.4%	-1.2%	4.0%	2.7%	-4.5%	-1.4%	1.7%	8.1%
-12.5%	-3.0%	-4.0%	5.9%	2.6%	-1.8%	-5.3%	2.7%	9.4%
-13.8%	-2.5%	-1.9%	4.1%	1.8%	-5.1%	-1.7%	2.1%	8.1%
-11.9%	-3.8%	-3.2%	3.8%	5.5%	-3.1%	-5.8%	3.8%	10.6%
-12.2%	-6.4%	-2.8%	6.6%	1.7%	-8.5%	-2.9%	6.2%	8.3%
-11.6%	-4.2%	-1.7%	3.6%	2.9%	-4.6%	-2.7%	2.5%	8.2%

18.1%	18.1%	18.4%	17.6%	17.9%	18.3%	18.2%	17.8%	17.7%
2.2%	2.1%	2.3%	2.2%	2.2%	2.3%	2.3%	2.3%	2.2%
26.2%	26.2%	26.3%	26.4%	26.3%	26.3%	26.7%	26.5%	26.4%
8.0%	8.1%	7.9%	8.1%	8.0%	8.3%	8.0%	8.1%	8.2%
21.4%	21.8%	21.7%	21.8%	21.6%	21.5%	21.7%	21.6%	21.6%
7.3%	7.3%	7.2%	7.2%	7.4%	7.5%	7.2%	7.3%	7.5%
16.9%	16.5%	16.3%	16.8%	16.6%	15.9%	15.9%	16.4%	16.5%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

13-May-11	20-May-11	27-May-11	3-Jun-11	10-Jun-11	17-Jun-11	24-Jun-11	1-Jul-11	8-Jul-11
19,945	20,035	20,679	18,713	20,161	19,944	19,897	21,040	18,187
2,536	2,446	2,564	2,333	2,585	2,485	2,473	2,680	2,419
29,273	28,675	29,834	28,258	29,188	28,918	28,805	31,285	27,058
8,984	8,836	9,188	8,779	8,993	9,002	9,037	9,671	8,573
24,931	24,596	25,742	24,609	24,794	24,359	24,832	26,202	23,329
7,878	7,858	8,324	7,943	8,134	7,781	8,079	8,710	7,614
17,455	17,117	18,250	17,563	17,575	17,126	17,619	18,978	16,346
111,002	109,563	114,581	108,198	111,430	109,615	110,742	118,566	103,526
331	288	300	244	223	245	219	221	214
371	344	339	308	293	277	256	275	238
1,653	1,549	1,674	1,571	1,640	1,576	1,641	1,753	1,454
82	64	64	44	69	45	55	52	58
2,437	2,245	2,377	2,167	2,225	2,143	2,171	2,301	1,964
575	526	449	435	394	375	360	389	294
264	261	237	200	235	212	204	225	176
429	417	365	351	312	342	281	280	268
404	296	301	275	261	277	251	239	243
330	311	289	239	240	227	216	180	201
241	238	223	224	183	164	162	170	148
260	227	202	212	179	152	143	162	111
2,503	2,276	2,066	1,936	1,804	1,749	1,617	1,645	1,441
19,039	19,221	19,930	18,034	19,544	19,324	19,318	20,430	17,679
2,272	2,185	2,327	2,133	2,350	2,273	2,269	2,455	2,243
28,473	27,914	29,130	27,599	28,583	28,299	28,268	30,730	26,552
8,580	8,540	8,887	8,504	8,732	8,725	8,786	9,432	8,330
22,948	22,736	23,779	22,799	22,914	22,556	22,975	24,269	21,674
7,637	7,620	8,101	7,719	7,951	7,617	7,917	8,540	7,466
17,113	16,826	17,984	17,307	17,327	16,929	17,421	18,764	16,177
106,062	105,042	110,138	104,095	107,401	105,723	106,954	114,620	100,121
19,614	19,747	20,379	18,469	19,938	19,699	19,678	20,819	17,973
2,536	2,446	2,564	2,333	2,585	2,485	2,473	2,680	2,419

28,902	28,331	29,495	27,950	28,895	28,641	28,549	31,010	26,820
8,984	8,836	9,188	8,779	8,993	9,002	9,037	9,671	8,573
23,278	23,047	24,068	23,038	23,154	22,783	23,191	24,449	21,875
7,878	7,858	8,324	7,943	8,134	7,781	8,079	8,710	7,614
17,373	17,053	18,186	17,519	17,506	17,081	17,564	18,926	16,288
108,565	107,318	112,204	106,031	109,205	107,472	108,571	116,265	101,562

-6.4%	0.7%	3.2%	-9.4%	8.0%	-1.2%	-0.1%	5.8%	-13.7%
-2.0%	-3.5%	4.8%	-9.0%	10.8%	-3.9%	-0.5%	8.4%	-9.7%
-7.8%	-2.0%	4.1%	-5.2%	3.4%	-0.9%	-0.3%	8.6%	-13.5%
-7.0%	-1.6%	4.0%	-4.5%	2.4%	0.1%	0.4%	7.0%	-11.4%
-9.1%	-1.0%	4.4%	-4.3%	0.5%	-1.6%	1.8%	5.4%	-10.5%
-11.2%	-0.3%	5.9%	-4.6%	2.4%	-4.3%	3.8%	7.8%	-12.6%
-11.0%	-1.8%	6.6%	-3.7%	-0.1%	-2.4%	2.8%	7.8%	-13.9%
-8.4%	-1.1%	4.6%	-5.5%	3.0%	-1.6%	1.0%	7.1%	-12.6%

18.1%	18.4%	18.2%	17.4%	18.3%	18.3%	18.1%	17.9%	17.7%
2.3%	2.3%	2.3%	2.2%	2.4%	2.3%	2.3%	2.3%	2.4%
26.6%	26.4%	26.3%	26.4%	26.5%	26.6%	26.3%	26.7%	26.4%
8.3%	8.2%	8.2%	8.3%	8.2%	8.4%	8.3%	8.3%	8.4%
21.4%	21.5%	21.5%	21.7%	21.2%	21.2%	21.4%	21.0%	21.5%
7.3%	7.3%	7.4%	7.5%	7.4%	7.2%	7.4%	7.5%	7.5%
16.0%	15.9%	16.2%	16.5%	16.0%	15.9%	16.2%	16.3%	16.0%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

15-Jul-11	22-Jul-11	29-Jul-11	5-Aug-11	12-Aug-11	19-Aug-11	26-Aug-11	2-Sep-11	9-Sep-11
19,818	19,418	19,934	19,463	19,225	19,392	19,624	19,991	17,575
2,590	2,560	2,443	2,551	2,582	2,603	2,630	2,514	2,461
28,881	28,705	28,190	28,326	27,997	28,212	28,194	28,872	26,186
9,155	8,915	8,933	9,129	8,812	9,094	9,138	9,043	8,509
24,153	24,096	24,035	23,858	23,308	23,616	23,815	23,983	21,866
8,084	7,931	8,030	7,983	7,901	8,007	8,093	8,183	7,423
17,117	17,330	17,376	16,796	16,700	17,028	17,075	17,143	15,891
109,798	108,955	108,941	108,106	106,525	107,952	108,569	109,729	99,911
231	168	174	178	156	138	136	142	118
267	209	235	172	178	187	184	188	187
1,402	1,022	708	468	366	282	248	212	119
39	49	44	33	26	35	30	40	23
1,939	1,448	1,161	851	726	642	598	582	447
335	359	362	309	282	290	258	274	223
179	159	171	157	153	182	161	142	136
271	242	232	214	190	205	163	164	168
211	166	170	195	179	156	140	141	163
158	174	154	154	149	110	149	120	114
131	148	139	153	135	129	127	116	114
105	121	126	116	105	107	116	96	89
1,390	1,369	1,354	1,298	1,193	1,179	1,114	1,053	1,007
19,252	18,891	19,398	18,976	18,787	18,964	19,230	19,575	17,234
2,411	2,401	2,272	2,394	2,429	2,421	2,469	2,372	2,325
28,343	28,254	27,723	27,940	27,629	27,820	27,847	28,520	25,831
8,944	8,749	8,763	8,934	8,633	8,938	8,998	8,902	8,346
22,593	22,900	23,173	23,236	22,793	23,224	23,418	23,651	21,633
7,953	7,783	7,891	7,830	7,766	7,878	7,966	8,067	7,309
16,973	17,160	17,206	16,647	16,569	16,886	16,929	17,007	15,779
106,469	106,138	106,426	105,957	104,606	106,131	106,857	108,094	98,457
19,587	19,250	19,760	19,285	19,069	19,254	19,488	19,849	17,457
2,590	2,560	2,443	2,551	2,582	2,603	2,630	2,514	2,461

28,614	28,496	27,955	28,154	27,819	28,025	28,010	28,684	25,999
9,155	8,915	8,933	9,129	8,812	9,094	9,138	9,043	8,509
22,751	23,074	23,327	23,390	22,942	23,334	23,567	23,771	21,747
8,084	7,931	8,030	7,983	7,901	8,007	8,093	8,183	7,423
17,078	17,281	17,332	16,763	16,674	16,993	17,045	17,103	15,868
107,859	107,507	107,780	107,255	105,799	107,310	107,971	109,147	99,464

9.0%	-1.7%	2.6%	-2.4%	-1.1%	1.0%	1.2%	1.9%	-12.1%
7.1%	-1.2%	-4.6%	4.4%	1.2%	0.8%	1.0%	-4.4%	-2.1%
6.7%	-0.4%	-1.9%	0.7%	-1.2%	0.7%	-0.1%	2.4%	-9.4%
6.8%	-2.6%	0.2%	2.2%	-3.5%	3.2%	0.5%	-1.0%	-5.9%
4.0%	1.4%	1.1%	0.3%	-1.9%	1.7%	1.0%	0.9%	-8.5%
6.2%	-1.9%	1.2%	-0.6%	-1.0%	1.3%	1.1%	1.1%	-9.3%
4.9%	1.2%	0.3%	-3.3%	-0.5%	1.9%	0.3%	0.3%	-7.2%
6.2%	-0.3%	0.3%	-0.5%	-1.4%	1.4%	0.6%	1.1%	-8.9%

18.2%	17.9%	18.3%	18.0%	18.0%	17.9%	18.0%	18.2%	17.6%
2.4%	2.4%	2.3%	2.4%	2.4%	2.4%	2.4%	2.3%	2.5%
26.5%	26.5%	25.9%	26.2%	26.3%	26.1%	25.9%	26.3%	26.1%
8.5%	8.3%	8.3%	8.5%	8.3%	8.5%	8.5%	8.3%	8.6%
21.1%	21.5%	21.6%	21.8%	21.7%	21.7%	21.8%	21.8%	21.9%
7.5%	7.4%	7.5%	7.4%	7.5%	7.5%	7.5%	7.5%	7.5%
15.8%	16.1%	16.1%	15.6%	15.8%	15.8%	15.8%	15.7%	16.0%
100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%